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1. INTRODUCTION 
1.1 Epigenetics  
Conrad Waddington, who introduced the term epigenetics in the early 1940s [1], defined 
epigenetics as ‘‘the branch of biology which studies the causal interactions between genes 
and their products which bring the phenotype into being.’’ In the original sense of this 
definition, epigenetics referred to all molecular pathways modulating the expression of a 
genotype into a particular phenotype. Over the following years, the meaning of the word has 
gradually narrowed, due to drastic progress of genetics [1-3]. By contrast, Arthur Riggs and 
colleagues defined epigenetics as “the study of mitotically and/or meiotically heritable 
changes in gene function that cannot be explained by changes in DNA sequence” [4]. Given 
that there are several existing definitions of epigenetics, the following could be a unifying 
definition of epigenetic events: the structural adaptation of chromosomal regions so as to 
register, signal or perpetuate altered activity states. This definition is inclusive of 
chromosomal marks, because transient modifications associated with both DNA repair or cell-
cycle phases and stable changes maintained across multiple cell generations qualify. It focuses 
on chromosomes and genes, implicitly excluding potential three-dimensional architectural 
templating of membrane systems and prions, except when these impinge on chromosome 
function. Also included is the exciting possibility that epigenetic processes are buffers of 
genetic variation, pending an epigenetic (or mutational) change of state that leads an identical 
combination of genes to produce a different developmental outcome [5]. 
In the eukaryotic nucleus, DNA is compacted in a structure defined as chromatin, whose 
basic unit is the nucleosome. Each nucleosome is formed by protein called histone which in 
turn surrounded by about 145–147 pairs of DNA bases. Histone is an octamer constituted by 
four pairs of proteins, called H3, H4, H2A and H2B. The very long molecules of DNA are firstly 
“supercoiled” and then packaged on to histones, allowing to their compression into a single 
cell [6-7]. Eukaryotic chromatin is in equilibrium between two distinct higher-order 
structures: heterochromatin is a more condensed structure, transcriptionally silent, and in 
regions surrounding centromeres and telomeres; euchromatin is a less condensed structure 
and transcriptionally competent [8-9]. This feature accomplishes that, starting to the same 
DNA sequence, cells may differentiate in very different ways. The bidirectional conversion 
between euchromatin and heterochromatin is determined by epigenetic regulation. Over-all, 
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three main mechanisms of epigenetic regulation have been identified. Two of them, including 
DNA methylation and histone covalent modification, influence the type of chromatin, 
whereas the third is based on the expression of micro-RNAs [10-11]. The most intensely 
studied epigenetic modification is DNA methylation[12]; however, the most diverse modifi-
cations are those that occur on histone proteins [13-14]. In addition to DNA and histone 
modification, chromatin structure and function are regulated by chromatin remodeling 
complexes (for example, SWI/SNF and NuRD families), non-coding RNAs (for example, HOX 
transcript antisense RNA (HOTAIR) and HOXA distal transcript antisense RNA (HOTTIP)) and 
mutations in histone proteins themselves [15-16]. 
These mechanisms together alter the local structural dynamics of chromatin to regulate 
the functioning of the genome, mostly by regulating its accessibility and compactness. All 
together, these mechanisms govern the chromatin architecture and gene function in various 
cell types, developmental and disease states [10, 14, 17-20]. Disruption in the proper 
maintenance of these heritable epigenetic mechanisms can result in activation or inhibition 
of various critical cell signaling pathways thus leading to various disease states [21-22]. 
Importantly, the epigenetic state of a cell is malleable; it evolves in an ordered manner during 
the cellular differentiation and development of an organism, and epigenetic changes are 
responsible for cellular plasticity that enables cellular reprogramming and response to the 
environment. Because epigenetic mechanisms are responsible for the integration of 
environmental cues at the cellular level, they have important roles in diseases related to diet, 
lifestyle, early life experience and environmental exposure to toxins [23-24]. Thus, epigenetics 
is of therapeutic relevance in multiple diseases such as cancer, inflammation, metabolic 
disease and neurological disorder, as well as in infectious diseases [25-27]. 
Epigenetic regulators can be divided into distinct groups based on broad functions: 
epigenetic writers lay down epigenetic marks on DNA or histones; these marks are removed 
by epigenetic erasers and recognized by epigenetic readers (Fig. 1.1). The enzymatic nature 
of epigenetic writers and erasers has facilitated the generation of pharmacological inhibitors 
for many of these enzymes, some of which are clinically approved [15-16]. Inhibitors of epi-
genetic readers are also in development [16, 28]. These inhibitors show potent anticancer 
efficacy as well as activity in a range of other disease states. The most successful and long-
standing inhibitors of epigenetic processes are the US Food and Drug Administration (FDA)-
approved DNA-demethylating agents azacitidine (also known as 5-azacytidine (Vidaza; 
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Celgene)) and decitabine (also known as 5-aza-2ʹ-deoxycytidine (Dacogen; Eisai)), which are 
used to treat myelodysplastic syndromes (MDS) and a range of other malignancies [29-30]. 
Other inhibitors of epigenetic writers, such as the histone methyltransferases DOT1L [31-32] 
and EZH2 [33-34], have exciting potential for cancer treatment, whereas protein arginine 
methyltransferase (PRMT) inhibitors show promise for cancer and immune-mediated 
diseases [35-36]. 
 
Fig. 1.1: Simplified framework of the various components and mechanisms of the epigenetic machinery. A 
histone octamer is shown as orange cylinder, and DNA wrapped around the octamer is shown as green ribbon. 
Chemical modifications to histone surfaces and tails are depicted as filled circles, and modifications to DNA are 
depicted as filled diamonds [37]. 
1.2 DNA Methylation 
DNA methylation is a common mechanism of epigenetic regulation in eukaryotic 
organisms ranging from fungi to mammals. DNA methylation is a heritable epigenetic mark 
involving the covalent transfer of a methyl group to the C-5 position of the cytosine ring of 
DNA by DNA methyltransferases (DNMTs) [38].  In humans, DNA methylation is a stable 
epigenetic mark that occurs at the C5 position of cytosines, mainly in a CpG dinucleotide 
context, but also in non-CpG regions of stem cells[39-40]. More than 50% of genes are 
associated with CpG islands in their promoter regions. Generally, low levels or a lack of DNA 
methylation in the promoter region is correlated with an “on” configuration of chromatin that 
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favors the interaction of DNA with transcription complexes leading to the activation of gene 
expression. By contrast, methylation of CpG islands in gene promoters is correlated with an 
“off” configuration of chromatin that leads to gene silencing [41-42]. DNA methylation can 
maintain differential gene expression patterns in a tissue-specific and developmental-stage-
specific manner. The roles of DNA methylation in gene bodies and other regions started to be 
characterized in the last years [41]. DNA methylation is a highly effective mechanism for 
silencing of gene expression in vertebrates and plants, either by interfering with the binding 
of transcription factors, or by attracting methylated DNA-binding proteins (MBDs), able to 
recruit other proteins and histone modifying enzymes, which leads to formation of a closed 
chromatin configuration and silencing of gene expression [43-44]. Indeed, most DNA 
methylation is essential for normal development, and it plays a very important role in a 
number of key processes including genomic imprinting, X-chromosome inactivation, and 
suppression of repetitive element transcription and transposition and, when dysregulated, 
contributes to diseases like cancer [38, 45]. Noteworthy, DNA methylation patterns are 
altered in the progression of cancer. Both the hypomethylation and hypermethylation of 
different regions of the genome play a crucial role in tumorigenesis. During the development 
of tumors, a genome-wide demethylation occurs and this can promote genomic instability 
possibly by activating silenced retrotransposons [46]. On the other hand, focal 
hypermethylation of CpG islands has been intensively studied in cancer. Nearly all types of 
cancers have transcriptional inactivation of tumor suppressor genes due to DNA 
hypermethylation [12]. However, the exact mechanism responsible for the appearance of 
DNA methylation in a given promoter is not fully understood.  
DNA methylation is regulated by a family of DNMTs: DNMT1, DNMT2, DNMT3A, 
DNMT3B, and DNMT3L [47-49]. DNMT1 preferentially methylates hemimethylated DNA in 
vitro and is localized to replication foci during S phase. As such, it is the proposed maintenance 
methyltransferase responsible for copying DNA methylation patterns to the daughter strands 
during DNA replication [50].  DNMT2 is a methyltransferase homolog that methylates 
cytosine-38 in the anticodon loop of aspartic acid transfer RNA instead of DNA [51]. DNMT3A 
and DNMT3B, in contrast to DNMT1, have preference for unmethylated CpG dinucleotides 
and perform de novo methylation during development. Possessing homology to DNMT3A and 
DNMT3B, DNMT3L assists the de novo methyltransferases by increasing their ability to bind 
to the methyl group donor, S-adenosyl-L-methionine (SAM), and stimulating their activity in 
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vivo [52], although DNMT3L has no catalytic activity itself. Cooperation among different 
DNMTs is also required in methylating some regions of the genome, particularly repetitive 
elements. As previously mentioned, it has been widely believed that DNMT1 acts mainly as a 
“maintenance” methyltransferase during DNA synthesis and that DNMT3A and DNMT3B act 
as “de novo” enzymes in development. However, mounting evidence indicates that DNMT1 
may also be required for de novo methylation of genomic DNA [53] and that DNMT3A and 
DNMT3B contribute to maintenance methylation during replication [54]. 
A mechanistic proposal for the DNA methylation at the cytosine C5 position in CpG 
nucleotide islands catalysed by DNMT is shown in Fig. 1.2. The formation of a reactive 
enamine intermediate by the addition of a cysteine residue of the DNMT binding pocket to 
cytosine C6 position following base-flipping [55-56], assisted by the protonation at C3 by a 
glutamic acid, is followed by the transfer of the methyl group of cofactor SAM to and a β-
elimination on the 5-methyl-6-Cys-S-5,6-dihydrocytosine intermediate [57].  
 
Fig. 1.2: Mechanism of cytosine methylation at C5 catalysed by DNMT, with SAM as electrophile 
[57]. 
 
1.3 Histone Modification and Chromatin Remodeling  
Eukaryotic cells organize their genetic material into a DNA-protein complex, called 
chromatin where its assembly limits the accessibility of genomic sequences, and thus it 
creates inherent barriers for nuclear events such as transcription, DNA replication, and DNA 
repair. Consequently, chromatin structure must be dynamic or fluid, and local changes in 
chromatin structure are utilized to provide the cell with profoundly effective methods for fine-
tuning DNA metabolism. Not too surprisingly, disruption of mechanisms that control 
chromatin dynamics can lead to aberrant gene expression, improper or nonexistent DNA 
repair, chromosomal translocations, inappropriate proliferation, developmental errors, 
oncogenesis, or even cell death [58]. 
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Nucleosomes are efficient DNA-packaging units (Fig. 1.3). The fundamental protein unit 
of the nucleosome is the histone dimer, a simple α-helical domain possessing a highly basic, 
curved surface that closely matches the phosphate backbone of bent duplex DNA. Two copies 
each of histone heterodimer, H3/H4 and H2A/H2B, form a histone octamer that is wrapped 
with approximately 146 bp of duplex DNA in a left-handed spiral [59-60]. Nucleosomes are 
assembled into long, linear arrays in which each nucleosome is connected by 10–70 bp of 
linker DNA, with the length varying between species and cell types. The high affinity of the 
histone octamer for DNA ensures that nucleosome assembly is a significant barrier for 
enzymes requiring DNA access, and the folding or compaction of nucleosomal arrays can lead 
to additional constraints on nuclear processes [61].  
 
Fig. 1.3: Structure of nucleosome. a) Each nucleosome comprises an octamer of histone molecules, which 
consists of an H32–H42 tetramer and two H2A–H2B dimers. The amino (N) termini of histones project out of the 
nucleosome core and can be epigenetically modified. b) Crystal structure of the nucleosome depicting the 
interaction of DNA with histones. c) Many sites in the N terminus can be targets for epigenetic tagging [62]. 
Consequently, in addition to DNA sequence, which influences both preferred nucleosome 
positioning and unwrapping characteristics [63-66], two distinct mechanisms further 
modulate nucleosome stability and dynamics. One mechanism involves chemically altering 
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the histones themselves, which changes the energy landscape of histone–DNA interactions 
and therefore greatly increases the dynamic range of DNA accessibility. These chemical 
changes can be in the form of post-translational modifications (PTMs) that can modulate 
chromatin folding [67-68], and guide the binding of regulatory proteins [69-70]. Non-allelic 
variants of the core histones, such as H2A.Z or H3.3, can also be incorporated into 
nucleosomes, and these variant nucleosomes can have altered stability and/or present novel 
opportunities for PTMs [71-72].  
The second, and perhaps most potent mechanism, is the use of ATP-dependent 
chromatin remodeling enzymes that can lead to a discernible change in histone–DNA 
contacts. Such changes in contacts can result from the repositioning (sliding) of nucleosomes 
on DNA, the removal of part or all of the histone octamer from DNA, an induced change in 
the accessibility of the DNA in chromatin to proteins such as transcription factors or 
nucleases, and the exchange of histone variants for core histones [73]. Indeed, several 
chromatin remodeling enzymes use the energy of ATP hydrolysis to catalyze the deposition 
or removal of histone variants, and thus they play an integral role in regulating their 
chromosomal distributions. There are four subfamilies of ATP-dependent chromatin 
remodeling enzymes: SWI/SNF, INO80, ISWI, and CHD [58, 73-74]. Each family is defined by a 
characteristic ATPase subunit that is related to the DEAD/H superfamily of DNA helicases, but 
they also possess unique motifs that mediate binding to nucleosomes and individual complex 
subunits.  
In conjunction with histone variants, PTMs not only alter intrinsic dynamics of 
nucleosomes but also provide chemical signposts to help guide cellular factors to particular 
locations in the genome. Through recruitment of cellular factors that bind to PTM-marked 
histones, termed the “histone code,” PTMs play an essential role in defining and maintaining 
functionally distinct regions of the genome [75-80]. Histone chaperones and chromatin 
remodels bind to and sense PTMs as well, and in many cases the specificity of their activities 
can be traced to PTM-dependent interactions [81-87]. The majority of histone PTMs occur 
within the 10–30 amino acid N-terminal domains of each of the histones (often called the 
histone “tails”). These domains extend from the nucleosomal surface, and although they do 
not directly contribute to the organization of nucleosomal DNA, the N-terminal tails provide 
interaction surfaces for a host of nucleosome binding proteins, and are essential for 
chromatin higher order folding [61, 69]. Histone modifications also occur within the globular 
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domains that organize nucleosomal DNA, and given the remarkable number of histone 
modifications, it may well be that every solvent-exposed histone residue might be a target for 
modification. Histone PTMs that can be dynamically added and removed enzymatically, with 
the best-studied modifications including acetylation, methylation, phosphorylation, 
ubiquitylation, and ADP-ribosylation (Fig. 1.4) [75-76, 80]. These marks, plus other more 
recently appreciated modifications such as crotonylation, succinylation, and malonylation 
[88], have the potential to alter histone–DNA and histone–histone interactions and thus 
provide a means for transiently targeting changes in nucleosome dynamics [89-
91]. Surprisingly, very few histone marks appear to affect chromatin structure dramatically by 
themselves [69], with the large majority of histone modifications influencing either the 
binding or activity of other regulatory factors, such as ATP-dependent chromatin remodelling 
enzymes. 
 
 
Fig. 1.4: Histone modifying enzymes. The histone octamer is assembled from a histone H3:H4 tetramer and 
two H2A:H2B dimers. The histone tails of all four core histones are subject to a variety of post-translational 
modifications, including methylation (Me), acetylation (Ac), phosphorylation (P), and ubiquitination (Ub). These 
modifications are controlled by enzymes such as: histone methyltransferases (HMTs) (dark blue), HDMs (purple), 
HATs (dark green), HDACs (pink), kinases (orange), and ubiquitin-conjugating enzymes (dark red) [92]. 
 
 
9 
 
 
2. HISTONE POSTTRANSLATIONAL MODIFICATIONS (PTMs) 
2.1 Histone Methylation 
Methylation of histones was first described in 1964 [93]. Direct evidence linking 
methylation and transcription was only found some 35 years later, when the histone H3 
arginine-specific histone methyltransferase (HMT) CARM1 was shown to interact and 
cooperate with the steroid-hormone-receptor coactivator GRIP-1 in transcriptional activation 
[94]. Histone methylation occurs on all basic residues: arginines, lysines and histidines. Lysines 
can be mono-, di- or trimethylated on their ε-amine group [93, 95], arginines can be 
monomethylated, symmetrically dimethylated or asymmetrically dimethylated on their 
guanidinyl group, and histidines have been reported to be monomethylated, although this 
methylation appears to be rare and has not been further characterized [96-97]. Initial studies 
of histone modifications have indicated that histones H3 (lysines 4, 9 and 27) and H4 (lysine 
20) are frequently preferentially methylated [98]. Whereas, Arginine methylation takes place 
within the tails of histone H3 at R2, R17, R26 and histone H4 at R3. Furthermore, the N-
terminus of H1 is methylated at lysine residues [99] and the methylation of nonhistone 
proteins has been documented as well [100-101]. However, many other basic residues beside 
the histone proteins H1, H2A, H2B, H3 and H4 have also recently been identified as 
methylated by mass spectrometry and quantitative proteomic analyses. The number of 
targetable histone lysine residues and the degree of methylation on each methylation site 
give rise to a highly complex repertoire of potential functional outputs. Histone methylation 
marks do not working in isolation but rather in cooperation with other histone modifications 
[102]. While some lysine methylation marks are preferentially associated with euchromatin 
and hence gene activation (like H3K4, H3K36, and H3K79) or with heterochromatin and gene 
silencing (H3K9, H3K27, and H4K20) [103], more often the final effect on chromatin is 
influenced by the interplay of several histone modifications together (“histone crosstalk”) 
[104]. An aberrant covalent histone modification profile, leading to a dysregulated expression 
of oncogenes and tumor suppressor genes, is often associated with cancer [102]. Fraga et al. 
demonstrated, for example, that the reduction of Lys16 acetylation and Lys20 trimethylation 
at histone 4 constitutes a typical “cancer signature” [105]. Furthermore, aberrant histone 
methylation has been related not only with cancer but also with mental retardation and aging 
[106-108]. 
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Histone methylation is a stable epigenetic mark that does not alter the overall charge of 
the histone tails. However, with increasing methylation [109] comes an increase in basicity, 
hydrophobicity, and an influence on the affinity for anionic molecules like DNA [110-111]. 
HMTs display remarkable specificity in the level of methylation they catalyze, and the latest 
findings suggest that this could have functional significance in transcription [112]. 
Similar to other histone modifications, histone methylation can modulate histone 
interaction with DNA and chromatin associated proteins, which results in an alteration of 
nucleosomal structures and functions, and ultimately contributes to different biological 
processes [113]. Two super-families of enzyme control histone lysine methylation states: 
lysine methyltransferases (KMTs) and demethylases (KDMs). 
2.1.1 Histone Methyltransferases 
Histone lysine methyltransferases (termed protein lysine methyltransferases, PKMTs, 
because of their histone and non-histone substrates) and histone arginine methyltransferases 
(termed protein arginine methyltransferases, PRMTs) [114] catalyze the transfer of a methyl 
group from S-adenosyl-L-methionine (Ado-Met) to N-terminal histone lysines (producing 
mono, di-, and trimethylate) and arginines (producing mono- or dimethylate in a symmetric 
or asymmetric manner), respectively, with release of S-adenosyl-L-homocysteine (Ado-Hyc) 
(Fig. 2.1). A range of 60−96 HMTs have been identified in the human genome through 
phylogenetic analysis, though not all putative HMTs have been shown to methylate histones 
[23, 114]. There are two different families of lysine methyltransferases divided on the basis 
of their catalytic domain sequence: the DOT1-like proteins and the SET domain-containing 
proteins. The acronym SET came from the Drosophila polycomb proteins in which this domain 
was originally found, namely Suppressor of variegation 3–9 (Su(var)3–9), Enhancer of zeste 
(E(z)), and Trithorax (Trx) [115-117]. 
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Fig. 2.1: (top) Mechanism of methylation of histone lysine residues catalyzed by KMTs and (bottom) of 
arginine residues catalyzed by PRMTs [57]. 
To date, over 300 proteins have been identified that contain SET domains[118], and 
which can be grouped into four major classes: SET1, SET2, SUV39 and RIZ-SET. Their 
classification is based foremost on sequence similarity between the SET domains and 
secondarily on their relationship to SET domains in the yeast S. cerevisiae [119-120]. 
Furthermore, each enzyme family shows other common structural features, such as bromo-, 
chromo-, PRE-SET- and POST-SET domains; it appears that all of them have the same substrate 
specificity [119, 121-122]. 
The SET methyltransferase represents the catalytic domain, while the accessory proteins 
control the selectivity and the activity of the complex. The SET1 family is characterized by the 
presence of the SET domain usually followed by a post-SET domain, even if the two most 
studied members of this family, EZH1 and EZH2, do not harbor this region. The members of 
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the SET2 class have a SET domain that is always between a post-SET and an AWS domain, rich 
in cysteines. In this family, we find the nuclear receptor binding SET domain-containing 
proteins NSD1-3, the SETD2 and the SMYD family proteins. The SUV39 family members all 
present a pre-SET domain, essential for enzymatic activity [115]. SUV39H1, SUV39H2, G9a, 
GLP, ESET, and CLLL8 belong to this class. Finally, the RIZ family members, bearing the SET 
domain at the amino terminus, are RIZ1, BLIMP1, and PFM1. To date, no known RIZ proteins 
possess methyltransferase activity. There are examples of SET domain HKMTs that 
monomethylate only (SET7/9) and that mono-, di-, and trimethylate (G9a, EZH2) histone 
lysines. PKMT-catalyzed trimethylation has been found to proceed by both processive (G9a) 
and distributive (EZH2) biochemical mechanisms [123-125].  
In 2002, the first non-SET HKMT was identified, termed Dot1. It exhibits specificity for H3-
K79 [116]. For this reason, HKMTs should not be classified by sequence homology, but instead 
on the basis of epigenetic criteria regarding their histone specificity. At this point it is not 
known how different HKMTs control their catalysis of mono-, di-, and trimethylation, and in 
which way this varied substitution pattern correlates with transcription [126]. 
Mammalian PRMTs methylate the terminal guanidino side chain of Arg to one of three 
species: (1) monomethyl arginine, (2) asymmetric dimethylarginine, and (3) symmetric 
dimethylarginine (Fig. 2.1) [127-128]. There are nine mammalian PRMTs, all of which catalyze 
the formation of monomethyl arginine. Among these, type I PRMTs also catalyze the 
formation of asymmetric dimethylarginine (PRMT1−4, -6, and -8), and type II PRMTs also 
catalyze the formation of symmetric dimethylarginine (PRMT5) [128-129]. PRMT7 catalyzes 
only monomethyl arginine formation, and PRMT9 is active but has not yet been characterized. 
Enzyme and structural studies indicate that PRMT-catalyzed reactions proceed via an ordered 
sequential bi-bi kinetic mechanism with Ado-Met, as the methyl donor, binding followed by 
binding of the arginine-containing protein [130]. Similar to that of PKMTs, PRMT-catalyzed 
methyl transfer likely proceeds through an SN2 mechanism, and data indicate that the 
reaction is processive from arginine to dimethylarginine (Fig. 2.1) [114, 131]. 
2.1.2 Histone Demethylases 
For many years after the discovery and characterization of histone methylation, it was 
proposed that this PTM is highly stable [111, 132] and that only nonenzymatic mechanisms, 
such as histone protein exchange, are responsible for histone demethylation [133-134]. Only 
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a decade ago was this disproven by Shi and colleagues with the first report of a histone 
demethylase, lysine-specific demethylase 1 (LSD1) [115].  
Up to date, two classes of KDM have been described: the amine-oxidase type lysine-
specific demethylases 1 and 2 (LSD1 and 2; also known as KDM1A and B, respectively) and the 
JumonjiC (JMJC) domain-containing histone demethylases (Table 2.1). The latter consist of a 
group which contains over 30 members and can be divided, based on the JMJC-domain 
homology, into seven subfamilies (KDM2-8) [115, 135-136]. These two classes of 
demethylases possess different catalytic mechanism. LSD1 and LSD2 are flavin adenine 
dinucleotide (FAD)-dependent amine oxidases that catalyze a two-electron oxidation of 
methylated lysine, generating FADH2 and H2O2, to form an imine that reduces upon addition 
of water to form demethylated lysine and formaldehyde (Fig. 2.2). The catalytic mechanism 
relies on a lone electron pair on the lysine ε-nitrogen atom, and for this reason the LSD 
enzymes can demethylate mono- and dimethylated lysines but not trimethylated lysines 
[137]. Whereas the Jumonjii domain-containing demethylases are iron and α- ketoglutarate 
(2-oxoglutarate (2-OG))-dependent enzymes and are able to remove methyl groups from all 
three methyl lysine states, with concomitant production of succinate, carbon dioxide, and the 
demethylated lysine and formaldehyde (Fig. 2.3) [136, 138]. The target specificity of KDMs is 
regulated by their participation in different complexes. KDMs are implicated in different 
diseases, such as leukemia, prostate and breast cancer, esophageal squamous carcinoma, and 
as mental retardation [102, 139-140]. 
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Fig. 2.2: Outline of the demethylation mechanisms for the KDM1 (LSD). The KDM1 enzymes (KDM1A and 
KDM1B) are members of the amine oxidase superfamily that couple oxidation of the methyl group to reduction 
of the co-substrate flavin adenine dinucleotide (FAD), likely via transfer of hydride. The resultant iminium ion 
intermediate is unstable and reacts with water to give the demethylated product and formaldehyde. The 
reduced FAD is reoxidized by molecular oxygen, forming hydrogen peroxide. The inset shows a view from a 
crystal structure of KDM1A (PDB 2UXN).  
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Fig. 2.3: Outline of the demethylation mechanisms for the JmjC KDM. JmjC KDM catalysis proceeds via 
oxidative decarboxylation of 2-oxoglutarate to give succinate, carbon dioxide and a Fe(IV) = O species, which 
catalyzes methyl group oxidation to give a hemiaminal which fragments to give the demethylated product and 
formaldehyde. The inset shows a view from a crystal structure of KDM4A complexed with H3K9me3, N-
oxalylglycine substituting for 2-oxoglutarate, and nickel for iron (PDB 2OQ6). 
 
Table 2.1: Classification of histone demethylases 
Histone 
demethylase 
Other 
names 
Histone 
Substrates Phenotype 
Association with human 
disease 
LSD1 
KDM1A, 
AOF2, 
BHC110 
H3K4me2/1 
H3K9me2/1 
Embryonic 
lethality around 
E5.5 
Overexpression in prostate 
cancer, undifferentiated 
malignant neuroblastoma, 
oestrogen-receptor-negative 
breast cancer, bladder 
cancer, lung and colorectal 
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carcinoma and 
silencing/downregulation in 
breast cancer 
LSD2 KDM1B, AOF1 H3K4me2/1 
Maternal effect 
lethality 
Amplification and 
overexpression in urothelial 
carcinoma 
JMJD5 KDM8 H3K36me2 
Embryonic 
lethality around 
E11 
N.D. 
JMJD6 N.D. H3R2, H4R3 
Perinatal 
lethality and 
various 
developmental 
defects 
Overexpression in chronic 
pancreatitis 
FBXL11 KDM2A, JHDM1A H3K36me2/1 N.D. N.D. 
FBXL10 KDM2B, JHDM1B 
H3K36me2/1 
H3K4me3 
Partial peri- or 
postnatal 
lethality, neural 
tube closure 
defects, 
exencephaly 
and reduced 
sperm count 
Overexpression in various 
leukaemias and bladder 
carcinoma 
KIAA1718 KDM7A, JHDM1D 
H3K9me2/1 
H3K27me2/1 N.D. N.D. 
PHF2 JHDM1E H3K9me2 N.D. 
Mutation or 
silencing/downregulation in 
breast carcinoma and head 
and neck squamous cell 
carcinoma 
PHF8 JHDM1F H3K9me2/1 H4K20me1 N.D. 
Mutation and deletion 
associated with X-linked 
mental retardation and cleft 
lip/palate 
JMJD1A 
KDM3A, 
JHDM2A, 
TSGA 
H3K9me2/me1 
Male infertility 
and adult onset 
obesity 
Overexpression in malignant 
colorectal cancer, 
metastasized prostate 
adenocarcinoma, renal cell 
carcinoma and 
hepatocellular carcinoma 
UTX KDM6A H3K27me2, H3K27me3 
Neural tube 
defects at E9.5, 
female 
embryonic 
lethality at 
E10.5, partial 
male embryonic 
lethality, defects 
in cardiac 
development 
Mutation in multiple tumour 
types including multiple 
myeloma, oesophageal 
squamus cell carcinoma, 
renal clear cell carcinoma, 
transitional cell carcinoma, 
chronic myelomonocytic 
leukaemia, overexpression in 
breast cancer and deletion in 
Kabuki syndrome 
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and increased 
tumour 
formation 
JMJD3 KDM6B H3K27me3/me2 
Perinatal 
lethality and 
premature lung 
development 
Overexpression in various 
cancers including lung and 
liver carcinomas and several 
haematological 
malignancies, in neutrophils 
of patients with ANCA 
vasculitis and in primary 
Hodgkin's lymphoma 
JMJD2A KDM4A, JHDM3A 
H3K9me3/2 
H3K36me3/2 
H1.4K26me3/2 
Altered 
response to 
cardiac stress 
Silencing/downregulation in 
bladder cancer and 
overexpression in breast 
cancer 
JMJD2B KDM4B, JHDM3B 
H3K9me3/me2 
H3K36 me3/me2 
H1.4K26, me3/me2 
N.D. 
Overexpression in malignant 
peripheral nerve sheath 
tumour 
JMJD2C 
KDM4C, 
JHDM3C, 
GASC1 
H3K9me3/me2 
H3K36me3/me2 
H1.4K26me3/me2 
N.D. 
Amplification in oesophageal 
cancer, breast cancer, 
medulloblastoma and 
translocation in lymphoma 
RBP2 KDM5A, JARID1A, H3K4me3/2 
Aberrant 
behaviour when 
held by the tail 
and 
haematological 
abnormalities 
Silencing/downregulation or 
deletion in melanoma, 
translocation in acute 
leukaemia and mutation in 
ankylosing spondylitis 
JARID1B KDM5B, PLU1 H3K4me3/2 
Embryonic 
lethality before 
E7.5 
Overexpression in bladder 
cancer, prostate cancer and 
breast cancer 
JARID1C KDM5C, SMCX H3K4me3/2 
Neurulation and 
cardiac looping 
defects 
Mutation in mental 
retardation, in autism and in 
renal carcinoma 
JARID1D KDM5D, SMCY H3K4me3/2 N.D. Deletion in prostate cancer 
JARID2   
Embryonic 
lethality before 
E15.5 
Mutation associated with 
non-syndromic cleft lip, 
spina bifida and congenital 
heart defects 
NO66 N.D. H3K4me3/2 H3K36me3/2 N.D. 
Overexpression in non-small 
cell lung cancer 
2.1.2.1 Lysine Specific Demethylase-1 (LSD1) 
Human lysine demethylase 1 (KDM1 or LSD1) was originally identified as a component of 
a transcriptional corepressor complex that also contained the REST corepressor (CoREST) and 
HDAC1/2. This transcriptional corepressor complex could be recruited to RE1 element-
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containing gene promoters by REST and repressed the transcription of neuron-specific genes 
in nonneuronal cells [141-144]. 
Analysis of the LSD1 structure has led to significantly greater insight into its function. 
Overall, the structure of LSD1 consists of an N-terminal SWIRM domain [145], and an amine 
oxidase domain split into two halves, consisting of a substrate-binding half and an FAD-
binding half, which come together to form a globular domain (Fig. 2.4). The active site of the 
enzyme is located in between these two halves. Two long, antiparallel α-helices divide and 
project away from the globular halves of the amine oxidase active site. This so-called tower 
domain serves as the binding interface between LSD1 and its protein cofactor, CoREST, and 
distinguishes it from other amine oxidases [146-147]. The Tower domain of LSD1 is essential 
for the interaction with other proteins, such as a transcriptional corepressor protein (CoREST) 
and histone deacetylase (HDAC) 1 or 2, together with them it forms a stable core subcomplex 
recruited by many chromatin remodeling multiprotein complexes [148]. 
 
Fig. 2.4: LSD1 structure interacting with CoREST (PDB code 2UXN). The SWIRM domain is represented as 
cyan protein surface. AOL domain is represented as orange cartoon, while the tower domain is represented as 
salmon cartoon. FAD is shown as black sticks while the substrate is represented as blue surface. CoREST is 
represented as yellow cartoon, while SANT2 domain is shown as purple cartoon. There is a schematic 
representation of the LSD1 domains according to residues enumeration at the bottom [148-149]. 
In corepressor complexes, LSD1 binds to the C-terminal portion of CoREST, forming a 
biochemically stable complex that renders LSD1 less prone to proteasomal degradation [150-
151]. In addition to its function as an adaptor, CoREST binding is required for LSD1 to catalyze 
H3K4 demethylation on intact nucleosomal particles [150, 152]. Although nucleosomal 
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substrates are refractory to recombinant LSD1, addition of recombinant CoREST endows 
nucleosomal demethylation by LSD1, indicating that the primary function of CoREST is to 
enable LSD1 demethylation of nucleosomal substrates [150, 152]. Consistently, mutations 
that inhibit the ability of CoREST to bind to DNA inhibit the ability of the complex to 
demethylate nucleosomes [147]. 
Without these binding proteins LSD1 is able to demethylate H3K4me1/me2 in peptide or 
bulk histones but not in nucleosomes. The crystal structure of the LSD1-CoREST-histone 
peptide ternary complex reveals that the peptide binds to the amine oxidase domain [153] 
adopting a folded conformation that enables the binding site to accommodate the relatively 
long stretch of the N-terminal H3 tail (Fig. 2.4). The H3-histone N-terminal tail peptide binding 
of LSD1 performs as an allosteric modulator by repressing the turning of the amine oxidase 
(AO) domain regarding the tower domain [154-155]. 
Modulation of LSD1 specificity can also be altered by association with other specific 
cofactors. Metzger et al.  demonstrated that LSD1 can change specificity from H3K4 to H3K9 
when it is associated with the androgen receptor. This presents a strategy by which LSD1 can 
enhance its substrate repertoire by associating with different regulatory proteins [156-157]. 
The structural basis of this protein cofactor-dependent switch in LSD1 substrate specificity is 
not known. 
Indeed, as well as site of action, the protein complex partners LSD1 takes have a major 
influence on its downstream effects on gene expression. In vitro LSD1 is able to directly 
demethylate isolated histones but not when they are organized in the context of intact 
nucleosomes, as they exist in vivo [137]. Interactions with various protein complexes via the 
Tower domain release its catalytic activity, but also dictate the genetic loci at which this 
activity can occur. LSD1 has most commonly been found in association with transcription-
repressive complexes, such as the CoREST-containing chromatin regulatory complex, which 
itself associates with certain HDACs and other proteins with transcription-repressive activity. 
Its core component, RCOR1, has been found to be critical in allowing LSD1 to demethylate 
histone lysines on nucleosome complexes. Yang et al. showed that this complex interacts in a 
bidentate manner, with recognition of the H3 tail by a shallow groove on the surface of LSD1 
[147], and interactions with DNA on the chromatin via a SANT2 domain bound to the Tower 
domain of LSD1 [158]. This additional interaction has been observed both to increase the 
catalytic rate and decrease proteasomal degradation of LSD1, thereby permitting CoREST to 
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direct its demethylation of H3K4 and so act to repress gene expression [151]. LSD1 has also 
been found in association with other repressive complexes, including the NuRD and the CtBP 
chromatin modifying complexes [159-160]. 
In contrast, LSD1 is also found in complexes that activate transcription, most notably 
through interaction with the androgen and estrogen receptors, in which context its substrate 
specificity and demethylase activity is alternatively directed against H3K9, resulting in 
activated gene expression [156]. 
Several data have shown that LSD1 is highly expressed in different types of cancer, 
including bladder and colorectal cancer, oestrogen-receptor-negative breast cancer and 
prostate cancer[161-163]. Recent demonstrations have suggested that inhibiting LSD1 
activity may have therapeutic potential in cancer; examples include the finding that LSD1 is 
required for the maintenance of acute myeloid leukaemia (AML)-containing MLL trans-
locations [164], and that its inhibition can reactivate the all-trans retinoic acid (ATRA) 
differentiation pathway in AML [165]. In addition to providing genetic evidence for a role of 
LSD1 in a mouse model of MLL–AF9-induced leukaemia, Harris et al. showed that the 
monoamine oxidase (MAO) inhibitor tranylcypromine (also known as 
trans-2-phenylcyclopropylamine; 2-PCPA) significantly inhibited the colony-forming ability of 
AML cells [164]. This proof-of-concept study was further extended using two analogues of 
tranylcypromine that have been reported to be more potent and more selective inhibitors of 
LSD1 [164]. These tranylcypromine analogues exhibited 23- and 57-fold higher biological 
potencies than tranylcypromine in a similar setting, thus underlining the feasibility of LSD1 
inhibition for the treatment of AML. 
There are very few reports that link histone demethylases to diseases other than cancer. 
LSD1 is involved in the ‘hyperglycemic memory’ of cells, a series of mechanisms that causes 
negative effects of hyperglycemia to persist for an extended period of time after return to 
normoglycemia. LSD1 shows enhanced recruitment to monomethylated H3K9 in 
hyperglycemic cells and thus contributes to an increased expression of pro-inflammatory 
genes such as NFκB. The expression of these genes is elevated in mice during and after periods 
of transient hyperglycemia [166-167]. 
2.1.2.2 Lysine Specific Demethylase-2 (LSD2) 
In 2009, the second FAD-dependent demethylase, AOF1/LSD2/KDM1B, was identified in 
mammals [135]. Similar to LSD1, LSD2 contains a conserved SWIRM domain required for its 
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catalytic activity and specifically demethylates H3K4me1 and H3K4me2; nevertheless, its 
repressing activity seems to be unrelated to the demethylase function [168]. LSD2 shared less 
than 31% sequence similarity with LSD1. Different from LSD1, LSD2 lacks the Tower domain 
and thus it is not able to bind CoREST (Fig. 2.5); it forms active complexes with euchromatic 
histone methyltransferases such as G9a and NSD3 as well as cellular factors involved in 
transcription elongation rather than with HDACs, and it is localized at the gene body level 
rather than at the promoters [169]. With respect to LSD1, LSD2 has a more restricted 
expression pattern, it being abundant essentially in growing oocytes and being required for de 
novo DNA methylation of some imprinted genes [170]. Thus, considering the involvement of 
both the 2 flavin-containing amino oxidases LSD1 and LSD2 with DNMTs and de novo DNA 
methylation, it seems feasible that a real functional link between DNA methylation and 
histone demethylation would exist. LSD2 has been reported to promote H3K9me2 in addition 
to H3K4me2 demethylation, leading to control of stimulus-induced recruitment of NF-κB to 
the MDC and IL12B promoters and activation of these inflammatory genes [171]. 
 
Fig. 2.5: Lysine-specific demethylase 1 (LSD1) and LSD2 have an amine oxidase-like (AOL) domain shared 
by a large family of oxidases, and uniquely among these they also have the chromatin factor-associated SWIRM 
(SWI3, RSC8 and Moira) domain. The Tower domain of LSD1 and the zinc finger (ZFs) domain of LSD2 distinguish 
the two proteins from each other. PDB ID for LSD1: 2H94; PDB ID for LSD2: 4GU1. 
2.1.2.3 JmjC Histone Demethylase 
The JmjC domain-containing KDMs (KDM2-7 subfamilies; JmjC KDMs) represent the 
larger KDM class, comprising about 20 human enzymes which are grouped into five 
subfamilies (KDM2/7, KDM3, KDM4, KDM5, and KDM6) [172]. These enzymes belong to a 
much larger enzyme superfamily, the 2-OG oxygenases, whose members (about 70-80 genes 
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in the human genome) catalyse a diverse range of oxidation reactions, using 2-OG, molecular 
oxygen, and Fe2+ as co-substrates/co-factors [173].  In particular, the 2-OG-dependent 
histone lysine demethylases are members of the Jumonji family of 2-OG oxygenases, which 
have common structural features (e.g., with respect to 2-OG binding residues) and comprise 
nonhistone modifying enzymes such as factor inhibiting HIF (FIH) [174]. The name Jumonji, 
Japanese for ‘cruciform’, originates from the first reported Jmj family study [175], which 
detailed the formation of a cross-like shape upon neural groove development in jmj knockout 
mice. Among the 30 JmjC domain-containing proteins identified so far within the human 
genome, about 20 have been published to demethylate specific lysines in the histone proteins 
[176-177]. 
The enzymatic mechanism involves two cofactors, Fe(II) and 2-oxoglutarate, which are 
bound in the JMJC domain; they react with dioxygen to form a highly reactive oxo-ferryl 
(Fe(IV)=O) intermediate that hydroxylates the Nε-methyl groups of the methylated lysine 
substrate. The resulting, hemiaminal intermediate, is highly reactive and spontaneously gives 
formaldehyde and lysine residue lacking one methyl group, while oxidative decarboxylation 
α-ketoglutarate gives succinate and CO2 (Fig. 2.3) [173, 178-179]. Unlike LSD1, the 
hydroxylation-based mechanism of the JmjC KDMs does not require a protonatable lysine ε-
amine group, enabling these enzymes to demethylate all 3 lysine methylation states (tri-, di- 
and monomethylation) at H3K4, H3K9, H3K27, and H3K36, as well as H1K26 [180].  
Six different subfamilies (JMJD1s, JMJD2s, JARID1s, UTX/Y-JMJD3, PHFs, and FBXLs) of 
JmjC histone demethylases have been identified, which have different histone sequence and 
methylation state selectivity [180-181]. For instance, KDMs of the JmjC domain-containing 2 
(JMJD2) subfamily are selective for the demethylation of the tri- and di-Nε-methylation states 
of specific lysines on histone H3, whereas other subfamilies (e.g., the PHF and FBXL 
subfamilies) are selective for the di- and mono-Nε-methylated states and do not accept the 
trimethylated state [182]. 
The JmjC domain is a double-stranded β-helical (DSBH) fold also called the jelly-roll fold 
or double Greek motif. The DSBH fold is composed of eight β-strands that form a β-sandwich 
structure comprised of two four-stranded antiparallel β-sheets. The active center is buried in 
the interior of the JmjC domain, where Fe2+ is coordinated by three conserved residues 
(HxE/DxH iron binding motif comprising one aspartyl/glutamyl and two histidyl residues) and 
further stabilized by the 2OG cofactor (Fig. 2.6). The substrate is bound unusual by hydrogen 
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bonds, which is formed between one methyl group of methylated lysine and the oxygen 
atoms from active-site residues [172, 182-185]. In addition to the core structure of the JmjC 
domain, most JmjC-dependent demethylases contain auxiliary functional domains that 
maintain the overall structural stability and contribute to substrate recognition, recruitment 
and catalysis. These auxiliary domains include PHD, Tudor, CXXC, FBOX, ARID, LRR, JmjN, and 
Zn2+ finger domains, which are likely to contribute to substrate selectivity [172, 186-188]. For 
example, the JmjN domain, which is formed by three short helices and two β-strands, is 
essential for the demethylation activity of JHDM3/JMJD2 [189].  
 
Fig. 2.6: The Overall Structures of c-JMJD2A with and without α-KG. (A) The structure of c-JMJD2A in the 
presence of Fe2+ and Zn. The domains include the JmjN domain (residues 14 to 56, green), the long β hairpin 
(residues 65 to 94, red), the mixed structural motif (residues 95 to 171, gray), the JmjC domain (residues 171 to 
293, light blue), and the C-terminal domain (residues 294 to 350, pink). The Fe and Zn ions are coloured brown 
and purple, respectively. (B) The structure of c-JMJD2A with Fe2+ and α-KG. The colour coding is the same as in 
(A). α-KG is coloured yellow with the oxygen atoms shown in red. Residues involved in α-KG binding and Fe 
chelating are labelled.  
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Despite the functional characterization of many JmjC histone demethylases being still at 
a relatively early stage, recent evidence suggests for these enzymes many important 
biological roles ranging from the regulation of cellular differentiation and development to the 
control of neuronal function. Notably, dysregulation of JmjC demethylases can lead to 
aberrant histone methylation states and is associated with a number of diseases, including 
cancer and neurological disorders such as autism and X-linked mental retardation [190-192] 
(Table 2.1). An additional mechanism by which KDMs are overexpressed in various cancers is 
via their induction under hypoxic conditions. Inadequate or inefficient vascularization of 
rapidly growing tumors results in reduced oxygen tension, which activates the hypoxia-
inducible factor (HIF) transcription factor [102].  
2.2 Histone Acetylation 
One of the most widely studied histone PTM is acetylation [193]. Histones are covalently 
modified at the ε-amino group of lysines by histone acetyltransferases (HATs), thereby 
neutralizing the positive charge and thus interfering with the histone−DNA interaction 
essential for nucleosome stability [194]. Since Allfrey’s discovery of histone acetylation in 
1964 [195], it is now understood that the interplay of acetylation and deacetylation of 
chromatin plays a critical role in transcription [193]. The transfer or removal of acetyl groups 
to ε-amino group of lysine residues is mediated by two classes of enzymes. HATs catalyze the 
covalent attachment of acetyl groups to lysine residues of histones and other proteins by 
using acetyl-coenzyme A (acetyl-CoA) as a cofactor. Histone deacetylases (HDACs) conversely 
catalyze the amide hydrolysis of acetylated lysine. The attachment of acetyl groups to lysine 
residues goes along with two functional consequences. First, the positive charge of 
physiologically protonated ε-amino groups is abolished, resulting in altered electrostatic as 
well as steric properties of the affected protein region. Second, acetylation serves as a mark 
for distinct “reader” domains, which comprise specialized tertiary structures in proteins that 
undergo a selective interaction with acetylated lysines [196-197]. Key to this process is the 
ability of “readers” to recognize specific PTMs that ultimately determine the functional 
outcome of the PTM[77, 198]. Three readers (bromodomain [199-200], double PHD finger 
[201-202], and pleckstrin homology domain) [203] that recognize acetylated lysine (KAc) have 
been identified and the bromodomain is the most thoroughly characterized of the three 
[204]. 
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 ε-N-acetylation of lysine residues on the amino-terminal tails of histones has been 
generally associated with open chromatin architecture as well as transcriptional activation 
[205]. Upon acetylation, local affinity of the modified histone protein to negatively charged 
DNA is decreased, resulting in a less condensed chromatin structure and in exposure of 
promoter sites. As a consequence of the increased accessibility, the DNA globally becomes 
more prone to access of the transcriptional machinery [131]. In addition, transcription factors 
and other regulatory elements are recruited in a modification-specific manner to the relaxed 
promoter locus by interaction of specialized reader domains with acetyl lysine moieties [197, 
206]. Thus, HATs and histone acetylation are functionally linked with the control of 
transcription activation, replication, and DNA damage repair [207]. 
2.2.1 Histone Acetyltransferases (HATs)  
HATs catalyze the acetylation of lysine residues, which has been accepted as an 
important epigenetic marker. Acetylation occurs on both histone and nonhistone proteins, 
with an estimated 2,000–4,000 acetylated proteins and 15,000 acetylation sites in animal 
tissues [208]. HATs catalyze the transfer of acetyl groups to lysine residues using acetyl-CoA 
as donor. Fig. 2.7 depicts the transfer of the acetyl group to the lysine ε-amino residues in 
histones on a ternary complex with the lysine substrate bound to a hydrophobic pocket 
located close to the acetyl group of the acetyl-CoA binding site, which is one of the 
mechanisms proposed based on crystal structures [209]. 
 
Fig. 2.7: Mechanism of acetyl transfer in the ternary complex containing the HAT, acetyl-CoA (insert), and 
a fragment of H3 [209] 
Since the isolation of the Gcn5 HAT from Tetrahymena by Allis and coworkers [210], and 
the identification of HAT1 by Sternglanz and coworkers [211] and Gottschling and coworkers 
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[212] just more than a decade ago, many other HATs have been identified from yeast to man. 
Some of these HATs (e.g., PCAF and HAT1) show sequence conservation with Gcn5 within 
their catalytic domain, leading to their classification as Gcn5-related histone N-
acetyltransferases (GNATs) [213]. Many other HATs, like CBP/p300, Rtt109, and the MYST 
proteins have extremely limited sequence conservation. Based on this sequence divergence 
within the HAT domain, HATs can be grouped into at least five different subfamilies (Table 
2.2). This includes HAT1 (named histone acetyltransferase 1 as the founding member of the 
superfamily or KAT1) [214], Gcn5/PCAF (named for its founding member yeast Gcn5 and its 
human ortholog, PCAF, or KAT2a/KAT2B according to the alternative nomenclature), MYST 
(named for the founding members MOZ, Ybf2/ Sas3, Sas2, and TIP60, or KAT5), p300/CBP 
(named for the two human paralogs p300 and CBP, or KAT3B/KAT3A), and Rtt109 (named for 
its initial identification as a regulator of Ty1 transposition gene product 109, also referred to 
as KAT11). Although the Gcn5/PCAF, HAT1, and MYST subfamilies have homologs from yeast 
to man, p300/CBP is metazoan specific, and Rtt109 is fungal specific [206]. Although other 
nuclear HAT subfamilies have been identified, such as the steroid receptor coactivators 
(ACTR/AIB1, SRC1) [215], TAF250 [216], ATF-2 [217], and CLOCK [218], their HAT activities 
have not been studied as extensively as the five major HAT classes. 
Table 2.2: The five major HAT families. 
Major HAT 
subfamilies 
Prominent 
members Key structural and biochemical properties 
HAT1 yHat1 
Member of the GNAT family, 
Amino- and carboxy-terminal segments used for histone 
substrate binding, 
Requires the yHat2 regulatory subunit for maximal catalytic 
activity 
Gcn5/PCAF 
yGcn5 
hGCN5 
hPCAF 
Member of the GNAT family, 
Uses a ternary complex catalytic mechanism, 
Amino- and carboxy-terminal segments used for histone 
substrate binding 
MYST 
yEsa1 
ySas2 
ySas3 
hMOZ 
dMof 
hMOF 
hTIP60 
hHBO1 
Uses a ping-pong catalytic mechanism, 
Requires autoacetylation of a specific lysine at the active site 
for cognate histone acetylation 
p300/CBP hp300 hCBP 
Metazoan-specific, but shows structural homology with 
yRtt109 
Uses a ternary Theorell–Chance (hit-and-run) catalytic 
 
 
27 
 
mechanism, 
Contains a substrate-binding loop that participates in AcCoA 
and lysine, binding 
Contains an autoacetylation loop that requires lysine 
autoacetylation for maximal catalytic activity 
Rtt109 yR11109 
Fungal-specific, but shows structural homology with p300 
Contains a substrate-binding loop that participates in AcCoA 
and probably also lysine binding, 
Requires autoacetylation of a lysine residue near the active site 
for maximal catalytic activity, 
Requires one of two histone chaperone cofactors (Asf1 or 
Vps75) for maximal catalytic activity and histone substrate 
specificity 
y, yeast; h, human; GNAT, Gcn5-related N-acetyltransferase. 
HATs mediate many different biological processes including cell-cycle progression, 
dosage compensation, repair of DNA damage, and hormone signaling. Aberrant HAT function 
is correlated with several human diseases including solid tumors, leukemias, inflammatory 
lung disease, viral infection, diabetes, fungal infection, and drug addiction [219-220]. 
Deregulated HAT activity is particularly linked to cancer formation and progression [23, 221-
223]. Certain types of leukemia are characterized by the occurrence of fusion proteins with 
increased HAT activity [224]. Furthermore, lysine acetylation of the oncogenic fusion protein 
AML1-ETO by the HAT p300 has been demonstrated in patient blasts using western blotting 
and is required for leukemic transformation in mouse models as shown by mutation studies. 
In addition, the p300 inhibitor C646 increased survival in a mouse model of leukemia [225]. An 
impaired acetylation equilibrium is also observed in several solid tumors [221, 226] including 
prostate [227-228], colon [229] and breast [230] cancers with evidences for both HATs and 
deacetylases as potential drug targets. The activities of HATs and HDACs are also changed in 
asthma and chronic obstructive pulmonary disease because bronchial biopsies and alveolar 
macrophages from asthmatic patients show increased HAT and reduced HDAC activity [231]. 
p300-mediated acetylation of the HIV-1 viral protein, integrase, increases its activity in 
integrating the HIV-1 virus into the human genome [232]. The leading diabetes drug, 
Metformin, was shown to act through p300/CBP inhibition, and heterozygous CBP knockout 
mice are noticeably lean with increased insulin sensitivity [233]. The Rt109 HAT was also 
reported to be required for the pathogenesis of Candida albicans, the most prevalent cause 
of hospital-acquired fungal infections [234]. Studies in drug addiction and the related disease 
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of depression using animal models have also uncovered interesting correlations between 
stages of drug addiction and histone acetylation status [220]. 
2.2.2 Histone Deacetylases 
HDACs catalyse the removal of acetyl groups from the amino-terminal lysine residues of 
histone and non-histone proteins, such as transcription factors (TFs), hormone receptors, 
signaling proteins, chaperones, and DNA damage response proteins [235-238]. There are 18 
different mammalian HDACs which are categorized into 2 families and 4 classes. First 
identified zinc dependent Rpd3/Hda1 family (class I, II, and IV) is referred as ‘classical’ HDACs, 
while the NAD+-dependent sirtuin family or Sir2 proteins (SIRT1–7) are divided into class III 
HDACs [13, 236, 239-240]. HDAC1, 2, 3, and 8 belong to class I and are localized in the nucleus, 
presenting similarity to the yeast Rpd3 [236]. Class II HDACs [241] are present in both the 
cytoplasm and nucleus, and they shuttle between these compartments [242-245]. Class II 
HDACs (grouped for homology to Hda1 in yeast) are divided into two subclasses: class IIa 
(HDAC4, 5, 7, and 9) and class IIb (HDAC6, 10). Class IV HDACs includes one member (HDAC11) 
[246-247], which can be considered a “hybrid” sharing similarities to both class I and II HDACs. 
Sirtuins, related to Sir2 in yeast [248], have also been categorized as class III HDACs [249] (Fig. 
2.8, lower part) and grouped as SIRT1-7 [250]. These enzymes display an NAD function that is 
associated to a nuclear, mitochondrial, and cytoplasmic localization [251-252].  
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Fig. 2.8: HDAC and SIRT classification. Enzymes are divided into classes and sub-classes; subcellular 
localization and tissue distribution is reported for each member.  
 
2.2.2.1 HDACs 
HDACs are heterogeneous in length, varying from 347 amino acids for the shortest 
(HDAC11) to 1215 amino acids for the longest (HDAC6) (Fig. 2.8) [235, 253]. All HDACs have a 
highly conserved deacetylase domain. Based on the ligand-bound crystal structures, the 
mechanism of deacetylation (Fig. 2.9) was recognized to involve the activation of the 
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acetamide carbonyl group by the Zn2+ ion and its hydrolysis with formation of a tetrahedral 
intermediate facilitated by a “charge-relay” system. Several variants of the deacetylation 
mechanism have been proposed [254-257]. Upon activation, the N-acetyl group is attacked 
by a water molecule, producing an N- 3 free lysine and acetic acid. The major residues 
differences are found at the entry of the active site. The most recent computations support 
the involvement of two charge-relay systems, the recognition of the H142/D176 dyad as the 
general base of the reaction, the stabilization of the intermediate by Y306, and the inhibitory 
effect of K+. 
 
Fig. 2.9: Simplified mechanism for HDAC-8 catalyzed deacetylation reactions [257] 
Histone deacetylation gives a tag for epigenetic repression and plays an important role 
in transcriptional regulation, cell cycle progression and developmental events. The classical 
HDACs are emerging targets for metabolic disease [258], cancer [259], and 
neurodegeneration [260]. HDACs are also involved in inflammation and infection. Class I 
HDACs have a role in innate immunity through inflammatory cytokine production and class 
IIa HDACs are involved in adaptive immunity through the regulation of antigen presentation 
[16].  
2.2.2.2 HDAC Inhibitors 
HDAC inhibitors (HDACi) have set a paradigm to reverse abnormal epigenetic changes 
related to cancer. HDACi are mostly studied as anticancer agents, but there is a growing body 
of literature ascribing these enzymes to play a crucial role in other diseases such as 
neurological disorders, inflammatory processes and infectious diseases [261-264]. With 
emphasis on their structural diversity, the different classes of HDAC inhibitors include 
hydroxamic acids, benzamides, short chain fatty acids, macrocyclic peptides and others. 
These Zn2+ dependent HDAC inhibitors share three pharmacophoric motifs, a cap group or a 
surface recognition unit (usually a hydrophobic and aromatic group interacting with the rim 
of the binding pocket), a Zn2+ binding domain (ZBD) or chelating group (hydroxamic acid, 
carboxylic acid or benzamide groups), that coordinates with Zn2+ ion and a saturated or 
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unsaturated linker with linear or cyclic structure, joining the cap group to the ZBD (Fig. 2.10). 
Alterations in any or all three motifs have variably affected the potency and selectivity of the 
HDAC inhibitors [265-270].  
 
Fig. 2.10: Approved HDAC inhibitors in clinical trials with their pharmacophores. The cap, linker and the 
Zn2+ binding group are represented in blue, green and red, respectively [263]. 
In 2006, the hydroxamic acid SAHA (suberoylanilide hydroxamic acid, INN: Vorinostat, 
Fig. 2.10) was the first KDAC inhibitor that was approved for the treatment of cutaneous T-
cell lymphoma (CTCL) [271]. Romidepsin, belinostat, and chidamide followed with similar 
indications (Fig. 2.10). While romidepsin is approved for the treatment of CTCL and peripheral 
T-cell lymphoma (PTCL) [272], the use of belinostat and chidamide is restricted to PTCL [273-
274]. Panobinostat (Fig. 2.10) is approved for the treatment of multiplemyeloma [275]. 
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Currently, there are numerous HDACi under clinical development (Table 2.3), which can be 
divided into three groups based on their specificity: (1) nonselective HDACi, such as 
vorinostat, belinostat, and panobinostat; (2) selective HDACi, such as class I HDACi 
(romidepsin and entinostat) and HDAC6 inhibitor (ricolinostat); and (3) multipharmacological 
HDACi, such as CUDC-101 and CUDC-907 [276]. 
Table 2.3: HDAC inhibitors currently under clinical investigations 
HDACi Specificity Cancer types Clinical trial Ref 
Hydroxamic acid 
Vorinostat (SAHA) Classes I, II, and IV CTCL 
FDA approved 
in 2006  [277] 
Belinostat 
(Beleodaq/PXD101) 
Classes I, II, and 
IV PTCL 
FDA approved 
in 2014 [278] 
Panobinostat (LBH-589) Classes I, II, and IV MM 
FDA approved 
in 2015 [279] 
Resminostat (4SC-201) Classes I and II 
Advanced colorectal 
and hepatocellular 
carcinoma; HL 
Phase II trial [280-281] 
Givinostat (ITF2357) Classes I and II CLL; MM; HL Phase II trial [282-283] 
Pracinostat (SB939) Classes I, II, and IV AML Phase II trial [284] 
Abexinostat (PCI-24781) Classes I and II 
Metastatic solid 
tumors; HL; non-HL; 
CLL 
Phase I trial [285-286] 
Quisinostat (JNJ-
26481585) 
Class I and II 
HDACs 
Advanced solid tumor; 
lymphoma; CTCL 
Phase I and II 
trial [287] 
MPT0E028 HDAC1, 2, 6 Advanced solid tumor Phase I trial [288] 
CHR-3996 Class I Solid tumor Phase I trial [289] 
CUDC-101 
Classes I and II 
HDAC, EGFR, 
HER2 
Solid tumor Phase I trial [290] 
CUDC-907 Classes I and II HDAC, PI3K 
MM; lymphoma; solid 
tumor Phase I trial [291] 
Benzamides 
Entinostat (MS-275) Class I 
Solid and 
hematological 
malignancies 
Phase I and II 
trial [292] 
Mocetinostat 
(MGCD0103) Class I and IV 
Solid and 
hematological 
malignancies 
Phase I and II 
trial [293] 
Tacedinaline (CI-994) Class I MM; lung and pancreatic cancer 
Phase II and III 
trial [294] 
Ricolinostat (ACY-1215) HDAC6 MM; lymphoma Phase I and II trial [295] 
Chidamide (CS055/HBI-
8000) 
HDAC1, 2, 3, 
and 10 PTCL 
Chinese FDA 
approved in 
2015 
[273, 296] 
Cyclic peptides 
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Romidepsin 
(Depsipeptide/FK228) Class I CTCL; PTCL 
FDA approved 
in 2009 and 
2011 
[297] 
Aliphatic fatty acids 
Valproic acid (VPA) Class I and II 
Solid and 
hematological 
malignancies 
Phase I and II 
trial [298] 
Phenylbutyrate Classes I and II 
Solid and 
hematological 
malignancies 
Phase I and II 
trial [299] 
AR-42 Class I and IIb AML Phase I trial [300] 
Pivanex (AN-9) Classes I and II NSCLC; myeloma; CLL Phase II trial [301] 
2.2.2.3 Sirtuins 
Sirtuins, also referred to as Sir2-like proteins, were discovered in the late 1970s by Klar 
et al. when studying the yeast gene Sir2 (silent information regulator 2) [302]. Initial 
investigations on the catalytic activity suggested Sir2 to be primarily a mono-ADP-
ribosyltransferase [303]. It took a while until the NAD+-dependent deacetylase activity of Sir2 
was elucidated by Imai et al. in the year 2000 [304]. Today, more than 200 members of the 
sirtuin family were identified in bacteria, plants, invertebrates, and vertebrates [305]. In 
prokaryotes, usually one or two sirtuin isotypes can be found, whereas eukaryotic genomes 
encode several sirtuin isotypes. The hallmark of this enzyme family is a domain of 
approximately 260 amino acids with a high degree of sequence homology across the species 
[249]. In mammals, the sirtuin family comprises seven proteins (SIRT1-SIRT7), which vary in 
tissue specificity, subcellular localization, enzymatic activity and targets. Sirtuins carry a 
conserved catalytic domain consisting of about 275 residues. Based on phylogenetic analysis 
mammalian Sirtuins are grouped into four different classes (I-IV) [306-308]. SIRT1, SIRT2 and 
SIRT3 belong to class I along with most eukaryotic Sirtuins such as Sir2.1 from Drosophila 
melanogaster and the founding member yeast Sir2, HST1 and 2 from yeast. SIRT4 belongs to 
class II, SIRT5 to class III, and SIRT6 and SIRT7 are placed in class IV. Additionally, a novel class 
(“U”) has been created to include sirtuins with unique features, such as gram-positive bacteria 
and Termoga maritime sirtuins [308-310]. 
The subcellular localization of the sirtuin isotypes as well as their different slice variants 
(isoforms) is actively regulated by their C- and N-termini, which can contain specific 
localization sequences. For example, Sirt1 and Sirt2 were shown to be able to shuttle between 
nucleoplasm and cytoplasm in a cell cycle and cell-type-dependent manner [311-312]. 
Nevertheless, Sirt1 is a primarily nuclear deacetylase, while Sirt2 is the most important 
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cytosolic sirtuin isotype. The mitochondrial sirtuins are Sirt3–5. However, the existence of a 
long, unprocessed isoform of Sirt3 (lSirt3) in the nucleus was reported as well [313-314]. After 
its mitochondrial uptake lSirt3 is cleaved by the mitochondrial matrix processing peptidase 
(MPP) to sSirt3, which is shorter by 16 kDa [315]. Sirt6 is an exclusively nuclear isotype. The 
localization of Sirt7 was reported to be restricted to the nucleolus. Recently, a cytosolic 
isoform of Sirt7 (lSirt7, 47.5 kDa) was identified, which is slightly longer than the known 
nucleolar isoform (sSirt7, 45 kDa) [316]. SIRTs can catalyze both deacetylation and ADP-
ribosylation [251]. Their best characterized activity is NAD+-dependent lysine deacetylation, 
but recent studies demonstrated that some SIRTs also remove other acyl groups such as 
succinyl, malonyl, glutaryl, and long-chain fatty acyl groups [307, 317] (Table 2.4). Moreover, 
SIRT4 and SIRT6 possess ADP-ribosyltransferase activity, yet its biological relevance remains 
to be fully established [303, 318-320]. Together, all these enzymatic activities are essential 
for mammalian sirtuins to modulate a variety of physiological processes, such as 
transcriptional regulation, genomic stability, cellular responses to stress, metabolism, 
inflammation, aging and cancer [321-322]. 
Table 2.4: Characterization of seven mammalian sirtuins 
HDAC 
III 
Sirtui
n 
Localization Substrates Catalytic 
activity 
Function Phathology 
Class I SIRT1 Cytosol, 
nucleus 
PGC1α, 
eNOS, 
FOXO, 
MyoD, NF-
kB, H3K9ac, 
H1K26ac, 
H4K16ac 
NAD+-
dependent 
protein 
deacetylation 
Cell survival, 
insulin, 
signaling, 
inflammation, 
metabolism 
regulation 
oxidative stress 
response, 
lifespan 
regulation. 
Neurodegenerat
ive diseases.       
Cancer: AML, 
colon, prostate, 
ovarian, glioma, 
breast, 
melanoma, lung 
adenocarcinom
a. 
SIRT2 Cytosol, 
nucleus 
H3K56ac, 
H4K16ac, α-
tubulin, 
Foxo3a, 
p53, G6PD, 
MYC 
NAD+-
dependent 
protein 
deacetylation 
Cell cycle 
regulation, 
nervous system 
development. 
Neurodegenerat
ive diseases. 
Cancer: brain 
tissue, glioma. 
SIRT3 Mitochondria
, nucleus 
AceC2, 
ShdhA, 
SOD2, 
PDMC1a, 
IDH2, 
GOT2, 
FoxO3a 
NAD+-
dependent 
protein 
deacetylation 
Regulation of 
mitochondrial 
energetic 
metabolism. 
 
Neurodegenerat
ive diseases. 
Cancer: B-CLL, 
mantle cell 
lymphoma, CLL, 
breast, gastric. 
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Class II SIRT4 Mitochondria GDH, MCD Mono- ADP-
ribosyltransfera
se, NAD+-
dependent 
protein 
deacetylation 
Regulation of 
mitochondrial 
energetic 
metabolism/ 
lipid 
metabolism, 
insulin 
secretion. 
 
Cancer: breast, 
colorectal. 
Class 
III 
SIRT5 Mitochondria Histone H4, 
CPS1, cyt c 
NAD+-
dependent 
Malonyl, 
succinyl, 
glutaryl 
deacetylase 
Urea cycle 
regulation, 
apoptosis. 
 
Cancer: 
pancreatic, 
breast, non-
small cell lung 
carcinoma. 
Class 
IV 
SIRT6 Nucleus H3K9ac 
H3K56ac, 
PARP1 
NAD+-
dependent 
protein 
deacetylation, 
Mono- ADP-
ribosyltransfera
se, long-chain 
fatty acyl 
deacetylase 
Genome 
stability, DNA 
repair, 
nutrient-
dependent 
metabolism 
regulation. 
Cancer: breast, 
colon 
SIRT7 Nucleoli RNA pol I, 
p53, 
histone 
H3K18ac 
NAD+-
dependent 
protein 
deacylation 
Regulation of 
rRNA 
transcription, 
cell cycle 
regulation. 
Cancer: liver, 
testis, spleen, 
thyroid, breast. 
 
 
All sirtuins share a conserved catalytic core of ∼275 amino acids that is flanked by N- and 
C-terminal extensions. The extensions are variable in length and sequence, and they have 
been reported to play various roles such as ensuring a proper cellular localization, regulating 
the oligomerization state, and/or exerting autoregulation mechanisms [315, 323-324]. 
Whereas other HDAC families activate a water molecule for the hydrolysis reaction by using 
a zinc cofactor, the unique Sirtuin mechanism is based on the use of NAD+ as a co-substrate. 
Catalytic mechanisms of nucleophilic substitution SN1-type [325-326] or SN2-type [327-329] 
deacetylation by NAD+-dependent class III deacetylases or sirtuins [330] have been proposed 
with formation of an O-alkylamidate intermediate as shown in Fig. 2.11. A highly dissociative 
and concerted displacement of nicotinamide has been proposed as first step of the 
mechanism of deacetylation. The transition state shows a significant oxocarbenium ion 
character, but the cleavage appears to be facilitated by the nucleophilic assistance of the 
acetylated lysine, as shown by dynamics simulations [331]. Once the nicotinamide has been 
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released it can rebind in the C-pocket and react with the intermediate to reform NAD+. In this 
step Phe33 appears to play a role as gatekeeper in the nicotinamide exchange reaction in 
which it helps to shield the O-alkylamidate intermediate from free nicotinamide. After the 
formation of 1′-O-alkylamidate intermediate, the 2′-hydroxyl group of the ribose is activated 
by a conserved His116 to afford 1′, 2′-cyclic intermediate. Then a protonated histidine can act 
as acid, protonates the amino-acetal and led the deacetylated substrate release. Finally, an 
activated water molecule attacks the cyclic intermediate to furnish 2′-O-acetyl-ADP ribose 
(might be in equilibrium with its corresponding 3′ isomer) [328, 332]. 
 
Fig. 2.11: Mechanism of deacetylation of acetylated lysine catalyzed by sirtuins [258, 325-326, 331]. 
2.2.2.4 Sirtuin Inhibitors 
The potential involvement of sirtuins in the pathogenesis of several diseases has driven 
research groups worldwide to develop small-molecule modulators of sirtuin activity. To 
identify novel sirtuin modulators various approaches have been applied, for example, high-
throughput screening, focused library screening, fragment-based screening, or computer-
based screening in combination with in vitro modulation tests. Despite the little structural 
information toward sirtuin modulation, the use of in silico methods has resulted in the 
identification of several promising sirtuin modulators. However, in contrast to the small-
molecule inhibitors of the Zn2+-dependent KDACs, which are already established drugs in the 
treatment of certain cancers, the clinical potential of sirtuin inhibitors is mostly unknown. Up 
to date, only one sirtuin inhibitor, selisistat, reached clinical trials [333-335]. One reason for 
this is certainly that until recently, most of the developed inhibitors lack either potency, 
isotype selectivity, or suitable physicochemical properties. In the last few years, however, 
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several promising inhibitor classes have been developed that fulfill these requirements. Most 
studies that were launched to discover sirtuin inhibitors focused on the isotypes Sirt1–3 and 
mainly on the inhibition of their deacetylase activity. Very recently, first studies were 
published concerning the pharmacological inhibition of isotypes Sirt4–7 as well as the acyl 
selectivity of sirtuin inhibition. Nonetheless, several small-molecule [336-342] and peptide-
based [343-358] Sirtuin inhibitors have been reported in the literature. 
2.3 Histone Phosphorylation  
Phosphorylation of histones, which is highly dynamic, takes place on serines, threonines 
and tyrosines, predominantly, but not exclusively, in the N-terminal histone tails [76]. The 
levels of the modification are controlled by kinases and phosphatases that add and remove 
the modification, respectively [359]. All of the identified histone kinases transfer a phosphate 
group from ATP to the hydroxyl group of the target amino-acid side chain. In doing so, the 
modification adds significant negative charge to the histone that undoubtedly influences the 
chromatin structure [360].  
Histone phosphorylation controls many important cellular processes, including 
transcription, apoptosis, DNA repair, and chromosome condensation  [14, 361-363]. In most 
cases, phosphorylation of serine and threonine residues of the histone tails appears to be 
involved in chromatin condensation during mitosis and meiosis; for example, C-terminal 
phosphorylation of Thr119 in histone H2A is linked to regulation of chromatin structure and 
function during mitosis [362], and H3 Ser10 (H3S10) phosphorylation is related to chromatin 
compaction during mitosis. Yet H3S10 phosphorylation has also been shown to play a role in 
transcriptional activation of NF-κB pathway genes and immediate early genes like c-jun and 
c-fos [14]. With regard to DNA repair, phosphorylation of histone H2AX at Ser139 (γ-H2AX) 
has been identified as one of the early events after a DNA double-strand break that helps 
recruit DNA damage repair proteins to the site [364].  
2.4 Histone Ubiquitylation  
Ubiquitin (Ub) is a highly conserved protein of 76 amino acids. Its name reflects the broad 
presence of Ub in all eukaryotic cells [365]. The covalent attachment of Ub to other proteins 
was observed 30 years ago with histones [366]. The exact purpose of this modification is still 
under investigation. In most cases, ubiquitinylation serves as a mark for the proteolytic, ATP-
dependent degradation of proteins by the proteasome [367]. In this process, several Ub units 
are transferred to the target protein by a succession of three enzymatic steps [368]. 
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Histone H2A is the first protein identified to be modified by ubiquitin in cells [369]. We 
know now H2A and H2B are two of the most abundant ubiquitinated proteins in the nucleus. 
The dominant form of ubiquitinated histones are monoubiquitinated H2A (H2Aub) and H2B 
(H2Bub). A single molecule of ubiquitin is added to the highly-conserved lysine residues: Lys-
119 for H2A, and Lys-123 in yeast or Lys-120 in vertebrate for H2B [370-372]. Usually histone 
modifications result in relatively small molecular changes to amino-acid side chains. In 
contrast, ubiquitylation results in a much larger covalent modification. Ubiquitin itself is a 76-
amino acid polypeptide that is attached to histone lysines via the sequential action of three 
enzymes: ubiquitin-activating enzymes, ubiquitin-conjugating enzymes and ubiquitin ligases 
[373]. Even though ubiquitylation is such a large modification, it is still a highly dynamic one. 
The modification is removed via the action of isopeptidases called de-ubiquitinating enzyme 
(DUBs) and this activity is important for both gene activity and silencing [76].  
In addition to H2A & H2B, core histones H3, H4, and linker histone H1 have also been 
reported to be modified by ubiquitin. For example, H3 & H4 were polyubiquitinated in vivo by 
CUL4–DDB–RBX1 ubiquitin ligase complex after UV irradiation[374-375]. But the biological 
function of these modifications has not been well elucidated. Besides monoubiquitination, 
histone H2A and H2B can be modified by ubiquitin chains [376-377]. Ubiquitination of 
mammalian H2B occurs at K120 and is predominantly regulated by ubiquitin-conjugating 
enzyme E2A (UBE2A or RAD6A) and the RNF20/RNF40 ubiquitin ligase complex [378]. Altered 
expression of UBE2A and RNF20/RNF40 may contributes to the development and progression 
of various tumor types. Recent study shown that the ubiquitination of H2B is involved in DNA 
double strand break (DSB) repair [371, 379]. Furthermore, cells in which either RNF20 or 
RNF40 were independently or simultaneously silenced exhibited significant increases in DSBs 
which strongly links H2Bub1 to DNA DSB repair [380].  
2.5 Histone ADP-ribosylation 
Histones are known to be mono- and poly-ADP ribosylated on glutamate and arginine 
residues, but relatively little is known concerning the function of this modification. What we 
do know is that once again the modification is reversible. For example, poly-ADP-ribosylation 
of histones is performed by the poly-ADP-ribose polymerase (PARP) family of enzymes and 
reversed by the PARP family of enzymes. These enzymes function together to control the 
levels of poly-ADP ribosylated histones that have been correlated with a relatively relaxed 
chromatin state [381]. Presumably, this is a consequence, at least in part, of the negative 
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charge that the modification confers to the histone. In addition, though, it has been reported 
that the activation of PARP-1 leads to elevated levels of core histone acetylation [382]. 
Moreover, PARP-1-mediated ribosylation of the H3K4me3 demethylase KDM5B inhibits the 
demethylase and excludes it from chromatin, while simultaneously excluding H1, thereby 
making target promoters more accessible [383]. Histone mono-ADP-ribosylation is performed 
by the mono-ADP-ribosyltransferases and has been detected on all 4 core histones, as well as 
on the linker histone H1. Notably, these modifications significantly increase upon DNA 
damage implicating the pathway in the DNA damage response [381].  
The inclusion of PARP-1 into the group of chromatin modifying enzymes is justified by 
some similarities to HATs, for example [384]. PARP-1 affects various DNA-based processes like 
transcription, replication, and DNA repair; it also participates directly in the assembly of 
transcription complexes at enhancers and promoters [385]. In addition, the PAR modification 
is part of a synergism that is typical for the histone code: nucleosomes can be modified 
simultaneously by acetyl groups and PAR residues [386]. 
2.6 Histone SUMOylation  
The abbreviation SUMO (small ubiquitin-like modifier) designates a group of small 
proteins that are related to Ub through secondary and tertiary structure elements [387]. Their 
mechanism of attachment to target proteins is also similar to that of Ub. A SUMO-activating 
enzyme E1 (SAE1/SAE2) binds SUMO with concomitant ATP hydrolysis as a reactive thioester, 
which is trans-esterified to the SUMO-conjugating enzyme E2 (Ubc9). The last step is likely to 
be the transfer of the SUMO group from E2 to the e-amino function of a lysine residue by the 
action of a ligase E3 [388]. 
Sumoylation is a modification related to ubiquitylation [388], and involves the covalent 
attachment of small ubiquitin-like modifier molecules to histone lysines via the action of 
ubiquitin-activating, conjugating and ligases enzymes. Sumoylation has been detected on all 
four core histones and seems to function by antagonizing acetylation and ubiquitylation that 
might otherwise occur on the same lysine side chain [389-390]. Consequently, it has mainly 
been associated with repressive functions, but more work is clearly needed to elucidate the 
molecular mechanism(s) through which sumoylation exerts its effect on chromatin. 
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3. EPIGENETIC TARGETS IN MALARIA AND NEGLECTED TROPICAL DISEASES 
3.1 Overview of Malaria and Neglected Tropical Diseases 
Neglected tropical diseases (NTDs) are defined by WHO as ‘a diverse group of 
communicable diseases that prevail in tropical and subtropical conditions;’ the official WHO 
list of NTDs is currently comprised of 17 infectious diseases [391]. NTDs, which though 
treatable and/or preventable, remain a leading cause of morbidity and mortality among the 
world’s poorest populations. These diseases further fuel a vicious cycle because they are also 
big contributors to regression of child development and human productivity [392]. Alongside 
malaria, these diseases predominantly affect populations living in poverty, under poor living 
conditions and in close proximity with the vectors of disease-causing agents. Their effects are 
far-reaching and devastating: over 1 billion people in 149 countries suffer from one or more 
NTDs with millions of others at risk, and the economic repercussions of these diseases can be 
just as damaging as their health effects [391-392]. These diseases contribute significantly to 
child mortality in the developing world and greatly undermine economic development. In 
2010, NTDs and malaria were estimated to be the cause of 1.321 million deaths globally, an 
increase of 9.2% from 1990 and representing 2.5% of all deaths that year [393]. The 
socioeconomic impact of the NTDs is not trivial. It is projected that 57 million disability 
adjusted life-years (DALYs) are lost every year due to these diseases, a figure widely believed 
to be an underestimate [394]. Additionally, diseases such as the trypanosomiases, which are 
zoonoses, also affect livestock, contributing to reduced livestock productivity in infected 
populations and thereby aggravating the economic impact by decreasing agricultural output 
[391]. 
Although most, if not all, of the NTDs including malaria can be managed clinically through 
fairly inexpensive chemotherapeutic and public health interventions, major contributors to 
their continued prevalence include increasing drug resistance, a limited range of available 
drug options, and in the case of diseases such as trypanosomiasis and leishmaniasis, the high 
cost and very significant toxicity of current recommended drug regimens. Most important is 
the fact that these diseases mainly afflict patients from the poorest populations in the world 
where costs of healthcare remain largely beyond the reach of many [392].  
Altogether, in the absence, with the only exception of RTS,S/AS01 for malaria [395], of 
approved vaccines targeted to the human parasitic diseases, anti-parasitic drugs, together 
with focused public health measures, continue to be crucial to addressing the growing health 
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and economic burdens caused by these diseases. Unfortunately, where the drugs are 
available, they are old, have unknown mechanisms of action, and quite often have limited 
efficacy and poor safety profiles. Moreover, the pandemic drug resistance, that has been 
observed following the treatment of all major parasitic pathologies, put the currently 
available drugs under an increasing threat of failure. Therefore, huge research efforts are now 
underway to develop new drugs to treat parasitic diseases and to overcome the growing 
problem of drug resistance. One extremely promising strategy to face these problems is 
represented by the so called “piggyback” approach that, focusing on drug targets and 
associated drug compounds that have been already validated for other human diseases, try 
to apply them to new indications such as parasitic diseases. Although this “drug repurposing” 
strategy is quite attractive, since it has the potential to accelerate the drug development 
process due to lower costs, reduced risk and decreased time to market due to availability of 
preclinical data, the parasite selectivity remains one of the major obstacles to overcome in 
moving such compounds into clinical trials as potential novel anti-parasitic drugs [396-397]. 
By using the “piggyback” approach, small molecule epigenetic modulators, which have 
been originally targeted for cancer use or other diseases, are now being investigated to target 
a range of parasitic diseases [397]. This approach holds great promise and can in part mitigate 
the relative lack of investment in efforts to improve the control and treatment of those 
malaria and neglected parasitic diseases. 
3.2 Malaria Epidemiology and Therapeutics  
The word ‘Malaria’ originates from the Italian word mala aria, meaning ‘bad air’ which 
justly reflects how this deadly disease had instilled fear from people in the medieval time 
[398]. Malaria is a devastating infectious disease that is characterized by intermittent high 
fevers and, in the case of cerebral malaria, neurological complications such as brain injury and 
coma. Found in tropical regions throughout sub-Saharan Africa, Southeast Asia, the Pacific 
Islands, India, and Central and South America, malaria parasites threaten the lives of 3.3 
billion and cause 600,000 deaths and there are approximately 200 million clinical cases of 
infection each year. Africa is still the leading region in terms of malaria burden. This region 
accounts for majority (80%) of the malaria cases as well as malaria-associated deaths (90%) 
globally [264, 396]. While pregnant women and children are particularly vulnerable to the 
threat of malaria, severe disease is also a threat for naïve travelers to malaria endemic regions 
and immunocompromised people [399]. It is caused by protozoan parasites of the genus 
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Plasmodium, which are transmitted to humans by the bites of female Anopheles mosquitoes. 
Four of the more than 100 Plasmodium species infect humans and cause distinct disease 
patterns: P. falciparum (malaria tropical), P. vivax, P. ovale (both malaria tertiana), and P. 
malariae (malaria quartana). P. falciparum and P. vivax account for 95% of all malaria 
infections. P. falciparum is found throughout tropical Africa, Asia, and Latin America. Nearly 
all severe and fatal cases are caused by P. falciparum. P. vivax is more common in India and 
South America, but is also found worldwide in tropical and some temperate zones. P. ovale is 
mainly confined to tropical West Africa, while the occurrence of P. malariae is worldwide, 
although its distribution is patchy [400-401]. 
Indeed, a strong relationship exists between poverty and malaria. This relationship is 
evident in the fact that most malaria endemic countries are also among the poorest countries 
of the world. Poverty contributes to the malaria burden as it has the ability to affect integral 
aspects of malaria treatment-seeking behaviors [402], including access to preventive 
measures and treatment—in relation to affordability, acceptability and availability—[403], 
and adherence to treatment. 
Presently, there have been renewed efforts in the global malaria control with several 
organizations and non-endemic countries increasingly getting involved in the fight against 
malaria [404-405]. These efforts have resulted in reduction in the global malaria burden over 
the last decade [406]. The current achievement is mostly attributed to the increase in malaria 
research funding, and scale-up of interventions against malaria, including insecticides-treated 
nets (ITNs), indoor residual spraying (IRS), rapid diagnostic testing (RDT), and importantly, the 
use of artemisinin-based combination therapy (ACT) [407]. There has been significant 
improvement in access, availability and affordability of ACT in malaria endemic regions [406]. 
While substantial funds have been invested in producing a malarial vaccine, to date poor 
efficacy has been achieved for those that have been trialed clinically, including the leading 
candidate RTS,S [408-409]. This means that mosquito control and chemotherapy are the main 
strategies for the prevention and treatment of this disease. ACTs have been adopted as first 
line treatment for uncomplicated malaria in most endemic countries, while chloroquine is 
now only used in some countries in the Americas due to widespread drug resistance [396]. In 
relation to previously used anti-malarial drugs, artemisinin drugs are very effective in parasite 
clearance and can relief the malaria symptoms faster [410-411]. Unfortunately, the 
development of resistance to ACT (which has been confirmed in five countries of Southeast 
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Asia: Cambodia, Lao PDR, Myanmar, Thailand and Viet Nam] [412-415] poses a major threat 
to its efficacy and use as first-line treatment. This also threatens the sustainability of the 
present success in malaria control [416]. 
Similar to the artemisinin class drugs, the development of resistance to most of the 
previously used anti-malarial drugs (such as chloroquine, sulfadoxine-pyrimethamine, 
mefloquine) originated from South East Asia. Nevertheless, the burden and effects of 
resistance are usually borne more by the African region that accounts for most of the global 
malaria cases. Considering the quick and widespread of previous cases of resistance to anti-
malarial drugs from the SEA to Africa, the African region stands at risk of spread of artemisinin 
resistance [417-418]. Regrettably, only one drug, primaquine, can completely eliminate P. 
vivax and P. ovale and thus provide a radical cure. P. vivax and P. ovale infections are 
challenging to treat because they form dormant liver stages (hypnozoites) that are refractory 
to most drugs. Primaquine, an 8- aminoquinoline, requires repeated dosing (up to 15 days) 
and is toxic to individuals with glucose-6-phosphate dehydrogenase deficiency [419] a 
common condition in malaria endemic regions. This limits the use of primaquine by the 
billions of people at risk for P. vivax infection in Central and Southeast Asia, and in Central 
and South America [420]. Therefore, new drugs with activity against all stages of the parasite 
life cycle and with new mechanisms of action are needed to help fulfill the ultimate goal of 
elimination. This is pushing research efforts into development and discovery of new 
antimalarial drugs endowed with new mechanisms of action on novel targets in the parasite.  
3.3 Malaria Life Cycle 
Malaria parasites have a complex life cycle that use a multi-stage developmental program 
to transition between their mammalian host and mosquito vector: while replicative stages in 
the host are strictly haploid and intracellular, cell division in the vector occurs in an 
extracellular milieu, within a cyst-like structure. Each developmental stage (Fig. 3.1) has a 
distinct morphology and physiology that is determined by its gene expression profile, as 
revealed by stage-specific transcriptomic and proteomic analyses of human and rodent 
malaria parasites [421-427]. Human infection starts with the bite of an infected 
female Anopheles mosquito, resulting in the transfer of sporozoites, motile cell forms that 
enter the bloodstream soon after the insect's bite, that quickly migrate to the liver [428-433]. 
Inside liver cells (hepatocytes), these sporozoites multiply extensively over a period of 
approximately two weeks and are then released into the vasculature in the form of thousands 
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of merozoites to infect red blood cells. P. vivax and P. ovale can remain dormant in the liver 
as hypnozoites, but can re-emerge and begin a blood-stage infection month to years after 
initial infection (relapsing malaria). During this intra-erythrocytic developmental cycle (IDC), 
the parasite progresses through three distinct stages, termed ring, trophozoite, and schizont. 
The ring stage is characterized by remodeling of the host cell to establish the supply of 
hemoglobin as an energy source, as well as to ensure evasion of the human immune system. 
During the trophozoite stage, the parasite becomes highly transcriptionally and metabolically 
active, in preparation for cell division. Finally, the parasite multiplies into 16–32 daughter 
parasites using a process of asexual replication called schizogony. During schizogony, the 
nucleus undergoes multiple rounds of division, which is followed by cytokinesis to subdivide 
the multinucleated parasite into identical daughter cells. Approximately 48 h after invasion 
of the red blood cell, these daughter parasites burst out of the host cell, ready to invade new 
red blood cells [432-433].  
 In a process that is not completely understood, a small fraction of the haploid asexual 
parasites differentiate into male and females gametocytes within the red blood cell [434]. It 
is possible that secreted parasite factors induce this differentiation [435-436]. These 
asymptomatic, non-replicating forms can persist for weeks and are responsible for malaria 
transmission. The uptake of mature gametocytes by a feeding mosquito followed by sexual 
replication in the mosquito midgut [437] and further develop into the salivary gland 
sporozoites that can be transmitted to a new human host. 
The asexual replication cycle is responsible for symptomatic disease and for the 
complications that are associated with severe malaria, such as anemia due to rupturing of red 
blood cells. In addition, severe disease can result from cytoadherence, the attachment of P. 
falciparum-infected erythrocytes to the smallest blood vessels, preventing clearance by the 
spleen and causing organ dysfunction. This cytoadherence is mediated by a family of parasite 
virulence proteins that are expressed on the erythrocyte surface: Plasmodium falciparum 
Erythrocyte Membrane Protein 1 (PfEMP1) [438-440]. Each P. falciparum parasite has 
approximately 60 different PfEMP1 variants encoded by var genes, only one of which is 
expressed at any time. Switching var gene expression enables the parasite to escape from 
host immune responses [441-442]. This process of antigenic variation is one example of the 
excellent adaptation of the parasite to survive in the human host. For these reasons, this 
parasite species and this stage of the parasite life cycle have been most extensively studied. 
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Consequently, most of our knowledge concerning epigenetic regulation of gene expression in 
the parasite is restricted to the P. falciparum IDC, while little is known about epigenetic 
profiles in sporozoites, the liver stage, the mosquito stages, or in other Plasmodium species.  
 
Fig. 3.1: Life cycle of malaria [431]. 
3.4 The Epidemiology and Distribution of Human Schistosomiasis 
Schistosomiasis is one of the major neglected parasitic diseases which still represents a 
serious public health problem in tropical regions of the world [443-444]; where infections are 
mediated through contact with infected fresh water snails that serve as intermediate vectors 
between human hosts. However, recently S. haematobium was reported in the 
Mediterranean area, particularly in the island of Corsica, a French territory  [445-447]. This 
finding, together with a decade of native cases around Europe, raised concerns regarding the 
presence of schistosomiasis in Europe. Three epidemiological conditions were argued [446] 
to be of special relevance in further assessing the risk of schistosomiasis in Mediterranean 
Europe: (i) this area is ecologically favorable to snails of the genus Bulinus which are the 
intermediate hosts of human  and animal schistosomes [448], (ii) climate warming creates 
favorable conditions for local transmission of Schistosoma spp. [449], and (iii) movement of 
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people which brings infected individuals from endemic regions to the European region 
allowing, given the conditions, the establishment of transmission chains in these areas. 
The disease is endemic in 76 countries globally; mainly in South America, southeast Asia, 
but mostly Africa where more than 90% of the estimated 41 000 deaths and approximately 
1.7 million DALYs lost occur every year. It is also estimated that the disease has a prevalence 
of 230 million cases annually worldwide [450]. It also affects almost 259 million people 
worldwide [451] causing an annual death toll of 280,000 [452] and millions of people suffering 
from long-term morbidity due to chronic schistosomiasis. Eight species of Schistosoma have 
been reported infecting humans (Table 3.1). Definitive vertebrate host species, other than 
human, may contribute to Schistosoma epidemiology and persistence in nature (Table 3.1). 
Table 3.1: The eight species of schistosome reported in humans [453].  
Schistosoma 
species 
Distribution  Natural definitive host species (excluding 
humans)  
Human public 
health 
importance  
S. mansoni  Africa, Middle East,  
South America,  
Caribbean  
Non-human primates (including  
apes), rodents, insectivores,  
artiodactylids  
(waterbuck),  
procyonids (raccoon)  
High  
S. haematobium  Africa, Middle East  Non-human primates (not apes)  High  
S. intercalatum  Central Africa  
(D.R. Congo only)  
Possibly rodents  Low  
S. guineensis  West Africa  
(Lower Guinea)  
Possibly rodents  Low  
S. mattheei  Southern Africa  Non-human primates (not apes), 
artiodactylids (cattle, antelope)  
Low  
S. japonicum  East Asia (China,  
Philippines,  
Indonesia)  
Non-human primates, artiodactylids 
(water buffalos in particular),  
carnivores, rodents, perissodactylids 
(horses)  
High  
S. mekongi  SE Asia (Vietnam,  
Cambodia, Laos,  
Thailand)  
Carnivores (dogs), artiodactylids (pigs)  Moderate  
S. malayensis  Malayan penisular  Rodents (van Mueller’s rat)  Low  
3.5 Schistosoma mansoni Life Cycle  
Schistosomiasis is caused by the platyhelminth worms of the genus Schistosoma, 
trematodes that live in the bloodstream of humans and animals. Three species (Schistosoma 
mansoni, Schistosoma haematobium and Schistosoma japonicum) account for the majority of 
human infections [454]. Schistosomes are digenean parasites that successively infect fresh 
water snails (the intermediate host) and the vertebrate definitive host. They reproduce both 
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asexually (within the snail host) and sexually (vertebrate host) and their life-cycle includes 
four distinct morphological forms and separate sexes at the adult worm stage (Fig. 3.2) [455]. 
Cercariae break out of the snail tissues into the water, swimming actively till dying or 
penetrating the unbroken skin of humans or animals, the definitive host, where they lose their 
bifurcated tail and become schistosomula. During the first 24 h after infection, nearly 90% of 
S. mansoni and S. haematobium schistosomula are present only in the blood-free, lymph-free 
epidermis. Majority of schistosomula are found in the dermis only after 48 h, and they appear 
to reach the dermal vessels around 72 h after infection [456-458]. Once in the blood 
capillaries, the schistosomula are carried passively by the blood flow till reaching the right 
heart and then the lungs. Depending on the species, schistosomula stay inside the pulmonary 
capillaries from 3 to 16 days, where they change into much longer and slender organisms, 
such a shape that enables them to traverse the thin pulmonary capillaries to the left heart 
and the systemic circulation [459].  
Following this period, schistosomula migrate from the lungs to the hepatic portal system 
via the blood stream and transform into adult worms. Male and female worms pair in the 
hepatic portal system and migrate to the mesenteric veins (except S. haematobium, which 
migrates to the urogenital system) to lay nearly 300 eggs per day. These eggs either pass into 
the gut lumen to be voided in the faeces and continue the life cycle or pass through the 
mesenteric veins and lodge in the liver, where they can cause granulomatous changes and 
fibrosis, both of which are key contributors to schistosomiasis [456, 460]. The morbidity 
associated with schistosomiasis results from the immunologic reactions to egg-derived 
antigens, beside the mechanical and toxic irritation caused by eggs trapped in the wall of 
blood vessels. Some of the most common pathological changes seen in chronic 
schistosomiasis infections include bleeding into the intestine or urinary system, liver and 
spleen enlargement, and periportal fibrosis [460-462].  
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Fig. 3.2: Lifecycle of Schistosoma [392]. 
3.6 Control of Schistosomiasis, the Lack of Alternative Therapeutics 
Despite its introduction in the mid-1970s, praziquantel still remains the only drug of 
choice for the treatment of schistosomiasis [463-464]. Praziquantel is a low-cost and highly 
effective antischistosomial agent, which is active against all Schistosoma species, albeit its 
exact mechanism of action is still not fully understood [465-466]. It is adminstered orally as a 
single dose, showing no notable side effects [467]. The long-term use of praziquentel as a sole 
antischistosomal treatment alongside its implementation in mass drug administration 
campaigns has raised deep concerns over the potential for emergence of drug-
resistance[465-466, 468-470]. Indeed, incidences of a reduced efficacy of praziquantel against 
some Schistosoma species [471-473] and the induction of drug-resistance in laboratrory 
strains [474-476] have already been reported. Evidently, a diminished efficacy of praziquantel 
would have a serious impact on the ongoing efforts to combat the disease, highlighting the 
need to develop new antischistosomal agents. 
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4. MALARIA EPIGENETICS  
4.1 Epigenetic Mechanisms as Drug Targets for P. falciparum 
Throughout the Plasmodium lifecycle, regulation of gene expression is orchestrated by a 
variety of mechanisms, including epigenetic, transcriptional, posttranscriptional, and 
translational control of gene expression. Owing to the absence of most canonical eukaryotic 
transcription factors in the Plasmodium genome [477], epigenetic control has long been 
recognized to play an important role in gene expression regulation. 
The epigenome of P. falciparum mainly consists of histone PTMs, histone variants, 
chromatin remodelers, histone modifying enzymes and non-coding RNAs (ncRNAs) [429, 431, 
478-485]. DNA methylation, although not well characterized in P. falciparum and which 
previously could not be detected [486], has recently been identified [487-488]. Still, the 
overall epigenetic makeup of Plasmodium is unique and differs from other eukaryotic 
organisms in many ways. Unlike the other eukaryotes, the Plasmodium epigenome is mainly 
euchromatic [489-490] and lacks the linker histone H1 [491]. Absence of a functional RNA 
interference system [492] also suggests an involvement of alternative regulators of epigenetic 
processes compared with other eukaryotes.  
In malaria parasites, epigenetic regulation of gene expression has been extensively 
studied only in Plasmodium falciparum. For many years, studying epigenetics in this parasite 
was almost synonymous to studying the regulation of var genes, which are important for 
antigenic variation and virulence [493]. However, recent findings have revealed a more 
general role for epigenetics in malaria parasite biology, including processes as diverse as 
erythrocyte invasion, solute transport, or formation of sexual forms necessary for human-to-
mosquito transmission. The contribution of epigenetic regulation of gene expression to these 
processes stems from the clonally variant expression of some of the genes involved. Silencing 
of clonally variant genes, which is a process truly controlled at the epigenetic level [494], 
generally depends on histone modifications that result in reversible formation of repressive 
chromatin structures (heterochromatin), but several additional layers of regulation operate 
specifically on particular gene families such as var genes. 
In Plasmodium, the epigenetic mechanism of regulation of gene expression can be 
divided broadly into three distinct areas based on parasite development [495]. 
Firstly, during asexual intra-erythrocytic developmental stages where differential gene 
expression occurs which are responsible for all clinical symptoms of malaria. Plasmodium 
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falciparum shows unusual mode of gene expression during its 48 h developmental process 
within the erythrocyte, implying tight and integrated genome-wide regulation of transcription 
[496-498]. Recently, a battery of proteins like Api-AP2, HP1, histone deacetylases, and histone 
methylases have been shown to be involved in gene regulation [499-501]. Two nucleosome 
assembly proteins, PfNapS and PfNapL, have been also identified [502] and PfNapS was shown 
to be essential for the parasite’s survival [503].These observations suggest the role of 
epigenetic mechanism in transcriptional regulation in Plasmodium. 
Secondly, epigenetics likely play role during sexual and morphological differentiation for 
the rest of the life cycle. The blood stage parasites differentiate in to gametocytes. These 
gametocytes mate to form ookinetes followed by formation of sporozoites in the mosquito, 
leading to the subsequent transmission and development in the human hepatocytes before 
the release of the merozoites in the asexual erythrocytic cycle. Distinct transcriptional 
profiling has been reported in gametocytes, ookinetes, oocyst sporozoites, salivary gland 
sporozoites hepatocyte stage and erythrocyte stage [424, 504-508]. All these observations 
may suggest epigenetic control over life cycle transition and stage differentiation. The AP2 
transcription factor, pfap2-g, located on chromosome 12, is one of the master regulators of 
gametocyte differentiation [509-510][. In asexual parasites, the locus containing pfap2-g is 
localized to the nuclear periphery and silenced by H3K9me3 and PfHP1 (Fig. 4.1C) [489, 
511]. In vitro studies show that downregulation of PfHDA2 activates pfap2-g and induces the 
formation of gametocytes [512]. Similarly, depletion of PfHP1 activates pfap2-g and increases 
the rate of gametocyte production [513]. These results raised the idea that sexual conversion 
is regulated at the epigenetic level, a view that was later corroborated by studies in which 
specific epigenetic factors were depleted [512-513]. The ortholog of pfap2-g in the distantly 
related murine malaria parasite P. berghei, pbap2-g, also plays a key role in gametocyte 
formation [510]. This observation suggests that ap2-g is a conserved regulator of sexual 
conversion in malaria parasites; whether or not epigenetic control of the process is a 
conserved feature in all Plasmodium species awaits experimental confirmation. 
Moreover, invasion proteins present in P. falciparum, responsible for new erythrocyte 
invasion are also regulated epigenetically. Invasion of a new erythrocyte by the malaria 
parasite involves binding of parasite ligands to specific recognition surface receptors on the 
red blood cell [514]. Eba, rhoph1/clag, acbp, and PfRH are among some of the gene families 
involved in the invasion process, but are not essential for parasite survival. The genes in these 
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families are thought to be partially regulated through epigenetic mechanisms and show 
differential expression patters in different parasite lines, as they can be in either active or 
inactive states (Fig. 4.1B) [515]. According to a more recent study exploring the parasite-
specific bromodomain protein PfBDP1 using in vitro culture, invasion genes are regulated in 
a more ‘classical’ manner by transcription factors interacting with specific promoters [516]. 
In schizonts, an enrichment of PfBDP1 was observed at the transcription start sites of invasion 
genes. PfBDP1 was shown to positively regulate transcription of invasion genes by binding to 
acetylated histone H3. Additionally, conditional knockdown of PfBDP1 resulted in erythrocyte 
invasion defects and parasite growth inhibition, further confirming the essentiality of this 
bromodomain protein for the coordinated expression of invasion genes in P. falciparum. 
Thirdly and most importantly, epigenetic control is involved in the mutually exclusive 
expression of individual var genes involved in the virulence processes such as cytoadherence 
and variant erythrocyte invasion. The best characterized family of antigen coding gene is the 
var family in P. falciparum. This gene family encodes ~ 60 variants of PfEMP1, expressed on 
infected erythrocytes. PfEMP1 is responsible for the attachment of the infected erythrocytes 
with the vascular endothelial cells thereby preventing the clearance from the circulatory 
system. Most of the var genes are generally silenced, with only one or a few being expressed 
at any given time [495, 497, 517-520]. Silent var genes are clustered to one or more repressive 
regions at the nuclear periphery, marked by H3K9me3 and PfHP1 (Fig. 4.1A) [489-490, 511, 
521-524]. Absence of PfHP1 in the parasite has also been shown to result in loss of 
monoallelic var gene expression as well as result in parasite growth arrest [513], which 
indicates that PfHP1 plays an essential role in maintaining repressive heterochromatin. The 
variegated expression of these genes has been shown to correlate with alterations in histone 
modifications and these chromatin states can be epigenetically inherited [489, 525-526]. 
HDACs, in particular NAD+-dependent class III HDAC proteins PfSIR2A and PfSIR2B and class II 
HDAC protein PfHDA2, play a role in regulating the repressive clusters containing 
silent var genes, as manipulated parasite lines lacking these proteins show loss of 
monoallelic var gene expression [489, 512, 527-528]. PfSET2 is an HKMT that specifically 
marks var genes, and the disruption of PfSET2 results in the de-repression of the 
silenced var gene cluster(s) [529-530]. The active var gene, transcribed at the ring stage, is 
distinguished by the presence of H3K4me3 and H3K9ac marks and resides in a region of the 
nucleus away from the repressive heterochromatin cluster(s) [489, 526-527]. At the later 
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trophozoite and schizont stages, the active var gene is controlled by the HKMT PfSET10, which 
is suggested to play a role in maintaining epigenetic memory of var gene expression [531]. 
Recent evidence suggests that sense and anti-sense long ncRNAs can also regulate var gene 
expression [532-534]. Collectively, these results highlight the relationship between proper 
chromatin assembly and regulation of antigenic variation in the parasite.  
 
 
 
Fig. 4.1: Epigenetic Regulation of Specific Genes and Gene Families in Plasmodium falciparum. (A) The 
family of var genes is controlled by clustering of silent var genes at the nuclear periphery and the deposition of 
repressive H3K9me3 marks, which recruits PfHP1 and results in the formation of heterochromatin. The single 
active var gene is isolated from all other var genes, marked by H3K4me3 and H3K9ac, and localized in a 
euchromatic environment. LncRNAs transcribed from a bidirectional promoter in the var introns also contribute 
to regulation of var gene expression. (B) Several families of invasion genes are epigenetically regulated through 
repressive and active histone marks that recruit heterochromatin marker PfHP1 and gene activator PfBDP1, 
respectively. (C) During the IDC, gametocyte-specific TF pfap2-g localizes to the nuclear periphery and is silenced 
by repressive histone marks, including H3K9me3 and PfHP1 [483]. 
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4.2 Plasmodium falciparum Chromatin Organization and Histone PTMs 
The malaria parasite chromosomes have a typical nucleosomal organization consisting of 
155 bp of DNA [535]. This is complemented by the absence of linker histone H1 [536], 
indicating ‘‘looser” chromosome packaging and/or an absence of higher order compaction of 
P. falciparum DNA. The low level of chromosome compaction likely underlines the 
transcriptionally active euchromatin that persists throughout the IDC. The four core histones 
H2A, H2B, H3, and H4, as well as four P. falciparum variant histones H2A.Z, H2Bv (or H2B.Z), 
H3.3 and H3Cen (H3 centromeric), have been identified in P. falciparum parasites [491, 537]. 
The P. falciparum H3 and H3.3 protein sequences are 94% identical. PfCenH3 protein shares 
61% amino acids identity with H3 and H3.3 (Table 4.1)  [479].  
Table 4.1: Histones and their different modifications in P. falciparum 
Sr. No. Histones Gene ID Chromosome Length 
(aa) 
PTM(s) 
1. H2A PFF0860c 11 132 N-term-ac, K3ac, K5ac 
2. H2A.Z PFC0920w 3 158 N-term-ac, K11ac,K15ac, 
K19ac, K25ac K28ac, K30ac, 
K35ac 
3. H2B PF11_0062 11 117 K112ub 
4. H2Bv Pf07_0054 7 123 N-term-ac, K3ac, K8ac, K13ac, 
K14ac, K18ac, T85ph 
5. H3 PFF0510w 6 136 K4me, K4me2, K4me3, K9ac, 
K9me, K9me3, K14ac, K14me, 
R17me, R17me2, K18ac, K23ac, 
K27ac, K36me3, K56ac, 
K79me3 
6. H3.3 PFF0865w 6 136 K4me, K4me2, K4me3, K9ac, 
K14ac, R17me, R7me2, 
K18ac, K23ac, K27ac 
7. H4 PF11_0061 11 103 N-term-ac, R3me, R3me2, 
K5me, K5ac, K8ac, K12ac, 
K12me, K16ac, R17me, K20me, 
K20me2, K20me3 
8. CenH3 Pf13_0185 13 170  
 
Epigenetics lies at the very heart of gene expression, regulating access of the 
transcriptional machinery to chromatin [482, 538] via (1) PTMs of histones, (2) nucleosome 
occupancy, and (3) global chromatin architecture. In the past decade, various histone PTMs 
have been identified throughout the Plasmodium lifecycle. Although the histones are well 
conserved amongst the eukaryotes, P. falciparum histone variants H2A.Z and H2Bv carry 
more PTMs including several unique acetylations [537]. At least 50 different histone PTMs 
(Table 4.2) have been identified in P. falciparum, including acetylations, methylations, 
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phosphorylations, ubiquitylations, and sumoylations [491, 537, 539-540]. PTMs involve 
multiple acetylation sites on H2A, H2A.Z and H2Bv, one phosphorylation site on H2Bv, one 
ubiquitination site on H2B, and many acetylation and methylation sites on H3, H3.3 and H4. 
An additional in-depth analysis revealed the presence of 14 phosphorylation sites at the N-
terminal tails of all histones in P. falciparum that are frequently adjacent to acetylation sites 
[541]. Moreover, H4 and H2A.Z were identified as small ubiquitin modifier (SUMO) substrates 
with at least six independent SUMOylation sites [542]. It is, however, important to mention 
that a majority of the parasite genome carries a large proportion of activating histone marks 
(H3K9ac and H3K4me3) compared to silencing marks (H3K9me3 and H3K36me3). This 
contrasts with what has been identified in multicellular eukaryotes [543], but validates 
further the transcriptionally permissive euchromatic state of the parasite genome. In 
mammalian genomes, H3K9ac and H3K4me3 strictly localize to active promoters [103, 544-
547], while in P. falciparum these modifications not only mark promoters and 5′ coding 
regions of genes that are highly transcribed [548-549], but are also found in intergenic regions 
and ‘silenced’ promoters [490, 537, 548].  
Repressive histone marks are mostly limited to regions of the genome harboring the 
clonally expressed variant surface antigen gene families (var, rifin, stevor, and pfmc-2tm) and 
invasion gene families (eba and clag), as well as some additional loci, such as the gametocyte-
specific transcription factor pfap2-g. These regions are organized into transcriptionally silent 
heterochromatin marked by H3K9me3 [489-490, 523, 525, 550]. In addition, silent var genes 
and to a lesser extent rifin and stevor genes carry H3K36me3 [49]. The single active var gene 
is physically separated from this repressive heterochromatin and is enriched in H3K4me3 and 
H3K9ac, in particular around its TSS [526]. 
The extensive ability of P. falciparum to evade the host’s immune system has been 
traditionally attributed to the high sequence variability and the mutually exclusive pattern of 
the var gene family expression. However, transcriptional switching is also one of the main 
factors of var-driven immune evasion of P. falciparum and it is now clear that epigenetic 
mechanisms play a central role in silencing of the var genes and possibly other 
heterochromatin-linked genes in P. falciparum. Indeed, the canonical heterochromatin 
marker, H3K9me3, helps in maintaining the silenced state of the var genes [489]. Their 
activation is then restored by replacement of H3K9me3 at their 5′flanking regions by H3K9ac 
[525-526]. Hence epigenetic memory plays a role in antigenic switching of the var genes as 
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well as other transcriptional heterogeneity amongst isogenic parasite lines [551-553]. Similar 
to var genes, factors involved in red blood cell invasion and genes implicated in nutrient 
import across the infected red blood cell plasma membrane are also regulated through 
epigenetic mechanisms; some in a mutually exclusive manner [515, 554]. There is a general 
association between heterochromatin marks and clonally variant gene expression of 
essentially all differentially expressed gene families [553, 555]. These results suggest that 
phenotypic variations of parasite populations are (at least partially) governed by H3K9me3 
linked heterochromatin. 
H3K36me3 is also enriched at the transcription start sites (TSSs) of silent var genes and 
at the coding regions of both active and repressed members [529]. Moreover, H3K36me2 
serves as another global repressive mark in P. falciparum and gene expression is regulated by 
altering the ratio of activation marks to H3K36me2 [556]. Interestingly, the highly conserved 
heterochromatic marker, H3K27me3, has not been detected in Plasmodium [537]. H4K20 
methylations also mark silent heterochromatic domains in P. falciparum and Toxoplasma 
gondii [557] but their distribution and role are still not conclusive. In particular, H4K20me3 
that is enriched at heterochromatin in most eukaryotes [558-559], has a broad chromosomal 
distribution in P. falciparum [489]. In fact, H4K20me3 marks euchromatic as well as 
heterochromatic domains but its transcription associated occupancy is restricted mainly to 
the var genes [560]. These observations tempt us to speculate that the mutually exclusive 
expression of var genes and epigenetic memory are maintained by multiple histone PTMs 
including H3K9ac, H4K20me3, H3K36me2 and possibly others. 
In addition to histone PTMs, nucleosome organization plays a critical role in gene 
expression regulation in Plasmodium. In general, heterochromatin is substantially enriched in 
nucleosomes compared with euchromatin [561] and active promoters and intergenic regions 
in Pf show markedly reduced nucleosome occupancy [562]. In addition, common transcript 
features such as TSSs, transcription termination sites, and splice donor/ acceptor sites show 
clearly distinguishable nucleosome positioning in P. falciparum [563], but previously 
described dynamic changes in nucleosome positioning [561] appeared to be mostly restricted 
to TSSs during the IDC [563]. Uniquely in Plasmodium spp., canonical histones in intergenic 
regions are replaced by histone variant H2A.Z [548], which, in concert with the apicomplexan-
specific H2B.Z, establishes a H2A.Z/H2B.Z double-variant nucleosome subtype enriched at AT-
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rich promoter regions and correlates with open chromatin and active gene transcription 
[564]. 
Table 4.2: List of putative epigenetic factors involved in controlling chromatin structure and 
epigenetic regulation in P. falciparum 
Histone methyltransferases Proposed function 
Protein name                         Gene ID (previous ID)                                               
PfSET1 PF3D7_0629700 
(PFF1440w) 
Involved in the deposition of the epigenetic mark 
H3K4me3 
PfSET2 (PfSETvs) PF3D7_1322100 
(MAL13P1.122) 
Involved in the deposition of the epigenetic mark 
H3K36me2/3, participates in var regulation 
PfSET3 (PfKMT1) PF3D7_0827800 
(PF08_0012) 
Involved in the deposition of the epigenetic mark 
H3K9me2/3 
PfSET4 PF3D7_0910000 
(PFI0485c) 
Involved in the deposition of epigenetic marks on H3K4 
PfSET5 PF3D7_1214200 
(PFL0690c) 
Involved in the deposition of unknown epigenetic marks; 
mitochondrial localization also reported  
PfSET6 PF3D7_1355300 
(PF13_0293) 
Involved in the deposition of epigenetic marks on H3K4 
PfSET7 PF3D7_1115200 
(PF11_0160) 
In vitro data suggest methylation of H3K4 and H3K9 
PfSET8 PF3D7_0403900 
(PFD0190w) 
Involved in the deposition of the epigenetic mark 
H4K20me1/2/3 
PfSET9 PF3D7_0508100 
(PFE0400w) 
Involved in the deposition of unknown epigenetic marks 
PfSET10 PF3D7_1221000 
(PFL1010c) 
Involved in the deposition of the epigenetic mark 
H3K4me3, localized to the var expression site 
Protein Arginine transferase (PRMT) 
PfRMT1 PF14_0242  
PfRMT4/PfCAR
M1  
PF08_0092  
PfRMT5   PF13_0323  
Histone demethylases  
JmjC1 PF3D7_0809900 
(MAL8P1.111) 
Involved in the removal of epigenetic marks from H3K9 
and H3K36 
JmjC2 PF3D7_0602800 
(PFF0135w) 
Involved in the removal of unknown epigenetic marks 
LSD1 PF3D7_1211600 
(PFL0575w) 
Involved in the removal of unknown epigenetic marks 
Histone acetyltransferases  
PfGCN5 PF3D7_0823300 
(PF08_0034) 
Involved in the deposition of the epigenetic marks 
H3K9ac and H3K14ac 
PfHAT1 PF3D7_0416400 
(PFD0795w) 
Probable ortholog to HAT1 in higher eukaryotes 
PfMYST PF3D7_1118600 
(PF11_0192) 
Member of the MYST family of acetyltransferases, 
proposed to acetylate H4K5, K8, K12, and K16 
Histone deacetylases  
PfSIR2A PF3D7_1328800 Involved in telomere maintenance and 
PfSIR2B (PF13_0152) 
PF3D7_1451400 
regulation of var gene expression 
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(PF14_0489) 
PfHDAC1 PF3D7_0925700 
(PFI1260c) 
Putative class I histone deacetylase, probable ortholog of 
Rpd3 from yeast 
PfHDAC2 PF3D7_1472200 
(PF14_0690) 
Putative class II histone deacetylase 
PfHDAC3 
(PfHda2) 
PF3D7_1008000 
(PF10_0078) 
Putative class II histone deacetylase, linked to var gene 
silencing and sexual differentiation 
Other 
PfBDP1 PF3D7_1033700 
(PF10_0328) 
Bromodomain protein 1, involved in the regulation of 
genes linked to erythrocyte invasion 
PfHP1 PF3D7_1220900 
(PFL1005c) 
Heterochromatin protein 1, involved in the maintenance 
of silenced regions of the genome, linked to var gene 
silencing and sexual differentiation 
Both current 3D7 ID numbers and previous numbers are provided, along with a brief, 
general description of the predicted function. Many of the listed functions are predicted 
based on computational analysis and have not been experimentally verified. Several 
additional uncharacterized putative epigenetic factors have been predicted by in silico 
analysis [565]. 
4.3 Malarial Histone-modifying Enzymes 
There are several classes of histone-modifying enzymes influencing chromatin structure 
via histone PTMs that were recently studied in P. falciparum. These include (i) modifiers of 
histone acetylation: HATs and HDAC); and (ii) modifiers of histone methylation: HMTs and 
HDMs (Table 4.2). 
4.3.1 Modifiers of histone acetylation 
4.3.1.1 Plasmodium HATs 
Histone acetylation is usually associated with transcriptionally active genomic regions 
through direct alterations of physical properties of the chromatin and/or recruitment of 
specialized protein complexes that regulate transcription directly or indirectly [566]. In 
particular, acetylation of nucleosomes around the TSSs stabilizes binding of transcription-
modulating chromatin remodeling factors at the promoter regions [567]. Histone lysine 
acetylation is catalyzed by histone acetyltransferase (HATs). At least four HATs are found in 
malaria parasite genomes: PF08_0034, PF11_0192, PFL1345c and PFD0795w [568]. 
Plasmodium falciparum GCN5 N acetyltransferase 5 (PfGCN5), a well characterized member 
of GNAT family has most homologous region within HAT domain and bromodomain in 
Plasmodium species [500]. PfGCN5 (PF08_0034), in association with its coactivator ADA2 
[569], acetylates H3K9 and H3K14 residues in P. falciparum [500, 569], implicating that its 
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active role in chromatin remodeling and regulation of transcription in P. falciparum [569]. By 
contrast, PfMYST exhibits a predilection to acetylate histone H4 at K5, K8, K12 and K16 [531]. 
Both proteins seem to be essential for asexual intraerythrocytic growth, and PfGCN5 inhibi-
tion leads to the arrest of parasite development, while PfMYST overexpression leads to the 
disruption of cell cycle regulation and DNA repair [531, 570]. 
4.3.1.2 Plasmodium HDACs 
In contrast, HDACs mediate removal of acetyl groups that generally leads to tight inter-
nucleosomal interactions limiting the access of DNA to transcription factors. The HDAC super-
family is grouped into three classes based on their phylogenetic relationship to the yeast 
orthologues. Class I (Rpd3) and class II (Hda1) have a zinc-dependent HDAC activity and act 
on intra-chromosomal domains [571], while class III HDACs (Sir2) are NAD-dependent and 
mediate gene silencing at the subtelomeres as well as the mating-type and rDNA loci [572-
573]). Five HDAC encoding genes have been identified in the Plasmodium falciparum genome. 
Three of these genes encode proteins with homology to class I (PfHDAC1) or class-II (PfHDAC2 
and 3) mammalian HDACs, while two genes are class-III HDAC homologues (PfSir2A and 
PfSir2B) [264, 397, 512, 574-576].  
PfHDAC1 is localized in the parasite nucleus, has up to  55% sequence identity to other 
eukaryotic class-I HDACs and is expressed/transcribed across multiple lifecycle stages of the 
parasite (asexual intraerythrocytic parasites, gametocytes, and sporozoites) [397, 422, 574-
575, 577]. Despite the PfHDAC1 functional roles have still to be fully characterized, the 
consequences of the HDACi treatment of P. falciparum parasites have recently begun to be 
elucidated and confirm that PfHDAC1 is involved in the post-translational modification of 
histone and non-histone Plasmodium proteins, in the consequent modulation of its gene 
expression, and seems also important for the parasites survival [550, 574-575, 578-580]. In 
silico homology modeling studies of PfHDAC1 have shown that the predicted active site tunnel 
of PfHDAC1 is highly conserved with that of human HDACs, but displays differences at its 
entrance that could explain the better in vitro growth inhibition of P. falciparum compared 
with mammalian cells that has been observed with several HDACi [264, 397, 574-575] and 
could also be more efficiently exploited by novel HDACi tailored to be selective for PfHDAC1 
over hHDACs [264, 397, 422, 574-575, 577-579]. 
The PfHDAC2 regulates virulence gene expression and frequency of gametocyte 
conversion [512]. Thus, PfHDAC2 is part of the epigenetic machinery that controls the 
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expression of var genes and of the master regulator of sexual development — the 
transcription factor PfAP2G [509, 512]. PfHdA2 is proposed to control histone PTMs within 
the heterochromatin domain as its knockdown leads to deregulation of the var genes and 
increased conversion to gametocytes. The latter event is likely caused by upregulation of the 
PfAP2-G transcription factor that resides in a heterochromatin domain and is believed to 
function as a “master regulator” of the sexual stage commitment. Both PfHDAC2 and 
PfHDAC3 are predicted to be high molecular weight proteins, that share less than 14 % amino 
acid identity to each other, and have limited sequence homology with other class II HDACs 
[422, 512, 576-577]. Recently, by the mean of knock-down experiments, PfHDAC3 has been 
reported to be essential to the asexual-stage P. falciparum parasite growth and survival, and 
to play a role in P. falciparum transcriptional control [512]. 
4.3.1.3 Plasmodium Sirtuins 
Sir2 is an NAD+-dependent HDAC (or sirtuin) that was first identified in yeast as important 
for silencing telomeric genes. Since NAD+ is a key cofactor and metabolite, Sir2 may act as a 
sensor for environmental or nutrient changes. In Plasmodium, there are two Sir2 orthologs, 
PfSir2A and PfSir2B [528] that work in concert to regulate var silencing. Plasmodium parasites 
that lack PfSir2A and B are unable to effectively silence undesired var genes, and transcript 
levels of var genes are generally elevated [528, 581]. 
PfSir2A and PfSir2B have been assigned as type III and IV sirtuins since they have 30% and 
38% sequence identity to an Archaeoglobus fulgidus class-III HDAC and group IV sirtuins, 
respectively [528, 582]. In addition to both histone deacetylase and ADP-ribosyltransferase 
activity [582-583], PfSir2A is also able to effectively remove medium and long chain fatty acyl 
groups from lysine residues [584]. PfSir2A has a role in maintaining P. falciparum telomere 
length, in establishing heterochromatin in subtelomeric genomic regions, and in the 
regulation of a subset of P. falciparum virulence genes involved in antigenic variation and 
cytoadhesion/pathogenesis [528, 550].  Recently, a new role has been reported for PfSir2A in 
modulating rRNA transcription [585]. Using a parasite line in which PfSir2A has been 
disrupted, it was observed that histones near the transcription start sites of all rRNA genes 
are hyperacetylated and that transcription of rRNA genes is upregulated, which are linked to 
higher numbers of daughter merozoites and increased parasite multiplication rate. More in 
detail, both PfSir2A and PfSir2B are involved in the mutually exclusive silencing (or expression) 
of different telomeric-associated var gene subsets, with distinct promoter types, that encode 
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for the parasite-derived P. falciparum erythrocyte membrane protein 1 (PfEMP1) molecules 
that are displayed on the erythrocyte surface [528, 550]. The resulting antigenic variation of 
PfEMP1 accounts for the ability of P. falciparum to evade the host immune surveillance during 
infection.76  Apart from virulence genes, PfSir2A also deacetylates rRNA genes and regulates 
the multiplication rate in P. falciparum [585]. Moreover, PfSir2B has been also found to have 
a role in the telomeric end protection [528]. Knock-out of the two P. falciparum Sir2 genes 
has shown that the absence of either one of them is not lethal to the parasite, and also 
established their functional redundancy in the parasite [528]. However, to the best of our 
knowledge, the effect of a simultaneous knock-out of both PfSir2 genes has not been 
examined yet. Despite both PfSir2A and PfSir2B seem to dispensable for the in vitro growth 
and development of P. falciparum [550, 576], both of them, for their crucial role in regulating 
var genes expression, are thought to be essential for the persistence parasite survival in vivo 
(or inside a host), and have been proposed as potential targets for antimalarial therapies, for 
example by interfering with infected erythrocyte cytoadhesion to host cell receptors that 
mediate severe forms of the diseases and/or by blocking the malarial parasite’s evasion from 
the host innate immune system [528, 550]. In other Plasmodium species, even though no var 
genes have been identified, other sub-telomeric gene families able to undergo antigenic 
switching have been disclosed, suggesting the possible involvement of their sirtuins (Sir2A 
and Sir2B) in the mutually exclusive silencing (or expression) of these sub-telomeric genes 
[528]. 
4.3.2 Modifiers of Histone Methylation 
Histone methylation, either in lysine or arginine residues, mediated by histone lysine 
methyltransferases (HKMT) or protein arginine methyltransferases (PRMT), is involved in both 
transcriptional activation and silencing [586]. Bioinformatics analysis of P. falciparum genome 
reveals at least ten members of histone methyltransferases (HMTs) containing a SET [Su(var), 
E(z), Trithorax] domain, characteristic of histone lysine methyl transferases and five putative 
PRMTs [587]. During the IDC, PfSET1, PfSET2, PfSET3 and PfSET8 mediate methylations at 
H3K4, H3K36, H3K9 and H4K20, respectively [557, 588]. An unusual function has been 
revealed for PfSET2, which methylates H3K36 and is associated with repressive chromatin of 
the var multigene family (in other eukaryotes, SET2 is associated with RNA polymerase II 
function) [529]. PfSET8 displays conserved activity to confer H4K20 mono-, di-, and 
trimethylation [557, 588]. The H3K9 methylase PfSET3 (PF08_0012) is encoded by an essential 
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gene and is localized to the heterochromatic nuclear periphery marked by CenH3, and 
H3K9me3-enriched genes also reside in this compartment [489, 589]. PfSET7 methylates 
H3K4 and H3K9, and localizes to distinct foci outside of the parasite nucleus in erythrocytic 
and liver stages, and throughout the cytoplasm in sporozoites  [590]. This cytoplasmic 
localization hints that pfSET7 might be acting on newly synthesized histones and/or additional 
non-histone substrates. PfSET7 is presumed to be essential for both the blood and mosquito 
stages of parasite development and thus may be amenable as a potent drug target. PfSET10, 
which methylates H3K4, colocalizes with the active var gene in post-ring stages, suggesting a 
role for PfSET10 in maintaining the active var gene in a poised state during mature stage 55. 
In contrast, Dot1, the HKMT without a SET domain, is absent in apicomplexans. The presence 
of corresponding epigenetic mark H3K79 methylation in P. falciparum is controversial as it 
was not seen by mass spectrometry [537, 588], but it has been shown to be localized to the 
nuclear periphery [591]. The SET subfamily E(z) and the corresponding mark H3K27me are 
also not reported in P. falciparum [537, 588]. Among, the PRMTs, only PfPRMT1/ PfCARM1 
has been characterized. PfPRMT1 localizes to the nucleus and cytoplasm of intraerythrocytic 
parasites and catalyzes mono- and di-methylation of R3 of histone H4, as well as non-histone 
protein substrates [587]. 
The malaria parasite genome also contains two types of histone demethylases (HDMs), 
the lysine specific demthylases (LSD1) and JmjC (jumionji C) domain containing histone 
demethylases (JHDMs). There are at least one LDS1 (PFL0575w) and two JHDMs (MAL8P1.111 
and PFF0135w) in Plasmodium [592]. Knockout of the corresponding genes showed that these 
genes are not essential in blood-stage parasites [529]. The role of histone methylation in gene 
regulation and maintenance of the subtelomeric heterochromatin needs to be explored 
further in P. falciparum. 
4.3.3 Consequences of Histone Modifications: “Histone Readers” in Malaria 
It is now clear that both heterochromatin and euchromatin carry multiple types of 
epigenetic “modules” that are characterized by distinct combinations of histone PTMs. For 
transcriptional regulation, these must be interpreted by downstream factors known as 
“histone readers” [565, 593]. Many histone PTMs exert their function by recruiting specific 
proteins called histone readers, which contain functional domains that bind to acetylated 
lysine residues (bromodomains), methylated lysine residues (chromodomains and plant 
homeodomains (PHDs)) or phosphorylated serine and threonine residues (14-3-3 proteins) 
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(Fig. 4.2) [120, 199, 429, 480, 593-594]. P. falciparum has more than 15 predicted proteins 
containing such binding domains [479, 565, 589], and two of them have been validated as 
specific histone readers: the structural protein heterochromatin protein 1 (PfHP1) and a 
14-3-3 protein. Specifically, PfGCN5 (HAT) and PfSET1 (HKMT) carry a single bromodomain, 
and PfMYST and heterochromatin protein 1 (PfHP1) possess one chromodomain. In addition 
to bromodomain, PfSET1 also possesses four PHD domains, suggesting that PfSET1 is targeting 
the euchromatic regions that are marked with histone acetylations and H3K4 methylations 
[588]. Despite the great number of potential histone PTM-binding modules in Plasmodium, 
only PfHP1 has been characterized [511, 524]. PfHP1 contains a chromodomain and a chromo-
shadow domain, which are involved in H3K9me3 binding and dimerization, respectively. 
Inducible PfHP1 depletion leads to var gene derepression and gametocyte production, 
showing that the same histone modification controls monoallelic var gene expression and 
switch to sexual commitment [513], which is similar to the dual effects mediated by the 
deacetylase PfHDAC2 [512]. PfSIP2, a member of the ApiAP2 family of transcription factors, 
is associated with PfHP1 [499, 595-596]. A parasite-specific bromodomain protein, PfBDP1, 
binds at TSSs of invasion-related genes and positively controls their expression [516]. PfBDP1 
also binds to acetylated histone H3 and another bromodomain protein, PfBDP2, suggesting a 
critical coordination during the expression of the invasion genes. PfHP1 is essential for IDC, 
and overexpression of PfHP1 leads to enhancement of variegated gene expression [511]. The 
ability of this protein to dimerize is probably responsible for aggregating nucleosomes in the 
subtelomeric regions and thus for the formation of the subtelomeric heterochromatin. 
 In addition to the canonical histone readers, P. falciparum protein Pf14-3-3I binds 
selectively to histone H3 phosphorylated on Ser28, suggesting its role in chromatin binding 
[541]. Taken together, P. falciparum contains a number of well conserved as well as unique 
chromatin binding proteins that are capable of interpreting the histone PTM modules in both 
heterochromatin and euchromatin. Given the unique character of the P. 
falciparum epigenome, it is feasible to speculate that these proteins evolved to adjust to the 
highly dynamic character of the unique histone PTM combinations.  
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Fig. 4.2: Post-translational modifications (PTMs) and their writers and readers observed in the amino-
terminal region of histone H3 of Plasmodium falciparum — including methylation (me; on lysine 4 (K4), K9 and 
K36), acetylation (ac; on K9, K14, K18 and K23) and phosphorylation (P; on serine 10 (S10), threonine 11 (T11) 
and S28) — are illustrated.  
4.4 Antimalarial Epi-drugs 
The emergence and spread of malaria drug resistance presents a worrisome situation 
impacting disease control programs. It is now becoming clear that the (possibly near) future 
of malaria control will require the introduction of new chemotherapies to overcome this 
situation. In fact, in the search for promising drugs to combat malaria, inhibitors of chromatin 
modifying factors have started to obtain attention. The first obvious targets for antimalarial 
“epidrug” development are the enzymes that add or remove acetyl or methyl groups from 
histone tails (Table 4.2). Importantly, inhibitors of this type of enzymes have been developed 
for the fight against other diseases such as cancer, providing a large number of chemical 
starting points and a wealth of knowledge that could be used for the development of malaria-
specific epigenetic inhibitors. Several compounds that were identified as inhibitors of HDACs 
or HATs in other eukaryotes inhibit P. falciparum growth, and some of them have a more 
potent effect on malaria parasites than on human cells [264, 481, 574, 583, 588, 597]. 
Inhibitors of P. falciparum KMTs have also been identified and shown to effectively kill malaria 
parasites of different species and at different stages of development [598-599]. In any case, 
new antimalarial drugs with desirable properties, such as being effective against all parasite 
stages or requiring a single dose, if available, would certainly facilitate the task. In this regard, 
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epigenetic regulators are considered a promising new class of drug targets, with some 
attractive characteristics described below. 
4.4.1 Antimalarial HAT Inhibitors 
Histone acetylation in the parasite has been shown to regulate the monoallelic 
expression of the var genes, which mediates the antigenic switching and virulence of the 
parasite [527, 550]. Variegated expression of genes essential for erythrocyte invasion in 
different parasite clones are under epigenetic control suggesting conserved epigenetic 
mechanism for transcriptional regulation in malaria parasites [515]. The H3 acetylation by 
GCN5 plays important role in the parasite gene activation and inactivation of histone 
acetylation compromises the parasite development suggesting its role for viable drug targets 
[500, 549, 569]. Parasite growth has been shown to be inhibited by PfGCN5 HAT inhibitors 
curcumin (Fig. 4.3) [570]. Reversible and noncompetitive inhibition of PfGCN5 by Anacardic 
acid (1) treatment induced hypoacetylation at H3K9 and H3K14, causing down-regulation of 
207 genes in late trophozoite state [600]. Treatment with Anacardic acid for 12 h induced 
two-fold or greater changes in the expression of ~5% of genes in P. falciparum trophozoites, 
among which 76% were downregulated [600].  Both curcumin (2) and Anacardic acid inhibited 
the growth of chloroquine resistant and susceptible strains of P. falciparum either by 
generating reactive oxygen species or by down-regulating the HAT activity of PfGCN5 which 
introduced disturbances in the regulation of transcription in the parasite [600] [570]. Embelin 
(3) (Fig. 4.3), a HAT inhibitor showed down-regulation of var gene expression with 
hypoacetylation at H3K9 around var gene promoters suggesting interplay among histone 
acetylation status, as well as subnuclear compartmentalization of different genes and their 
activation in P. falciparum [601]. Competitive methylation and acetylation marks at H3K9 in 
var 5′ flanking region is reported to epigenetically regulate mono-allelic expression pattern of 
var genes during parasite proliferation through activation or repression [602]. Kumar et al. 
elucidated, through comparative sequence and structural analysis, differences in the catalytic 
pocket of PfGCN5 which can be exploited to design selective inhibitors specific to PfGCN5 
over HsGCN5 [603]. This study reports 20 potential inhibitors of PfGCN5, in which 11 were 
found to be selective to PfGCN5 over HsGCN5. Compound C14 (4) (Fig. 4.3) was validated for 
its inhibitory action against PfGCN5 experimentally. In vitro parasite growth assay in the 
presence of C14 showed significantly lower IC50 (225 nM) than the previously known HAT 
inhibitor like Curcumin, Anacardic acid and Embelin (20 μM, 30 μM and 25 μM, respectively) 
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in P. falciparum, but, no effect in mammalian fibroblast cells was observed for C14 (up to 
20 μM). The authors suggested that C14 could be used as hit to study the effect of GCN5 
mediated acetylation in gene expression of P. falciparum.  
Therefore, the effect of these inhibitors in histone hypoacetylation and downregulation 
of developmentally regulated genes in the parasite may have great potential for parasite 
survival and growth. 
 
Fig. 4.3: HAT inhibitors potentially active against Plasmodium falciparum  
4.4.2 Antimalarial HDAC Inhibitors 
The potential utility of HDACi as antimalarial agents was first reported two decades ago 
when the cyclic tetrapeptide 5 (apicidin) was found to potentially target Plasmodium and 
other Apicomplexan parasites [604]. Since then a growing number of studies have focused on 
the antimalarial activity of HDACi belonging to various structural classes, highlighting the 
potential of these epigenetic modulators for anti-parasitic intervention. 
4.4.2.1 Cyclic Tetrapeptide HDAC Inhibitors 
In a pioneering study in 1996, Darkin-Ratray et al. disclosed that the natural cyclic 
tetrapeptide 5 (Table 4.3) is endowed with a potent in vitro activity against P. falciparum (IC50 
= 200 nM) and a panel of Apicomplexan parasites (T. gondii, Cr. parvum, N. caninum, B. 
jellisoni, E. tenella, etc.) [604]. Subsequent studies showed that 5 is able to induce substantial 
changes to the P. falciparum intra-erythrocytic developmental cycle transcriptional cascade, 
with ~ 30-60% of the genes showing altered expression [605-606], so resembling the effects 
of many HDACi, including 5 itself, on higher eukaryotic cells [607-608]. Indeed, 5 causes in situ 
hyperacetylation of P. falciparum histones [604] and inhibits the activity of recombinant 
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PfHDAC1 enzyme in the low nanomolar range (IC50  1 nM) [580]. Despite orally (2-20 mg/kg 
for 3 days) active in vivo in a lethal P. berghei mouse model of malaria [609], 5 for its poor 
bioavailability and a substantial lack of selectivity for P. falciparum-infected erythrocytes 
versus mammalian cell lines (Table 4.3) has never been considered suitable for clinical 
applications. While the structural similarities between one of the side chains of 5 called Aoda 
(2-amino-8-oxodecanoic acid) and the acetylated histone lysines enable the chelation of the 
zinc ion at the bottom of the HDAC catalytic tunnel, the other components of the cyclic 
peptide presumably do not distinguish the flanking amino acid residues that characterize the 
different entrances to the catalytic active site of the different HDAC isoforms so providing a 
possible explanation for its inability to selectively inhibit P. falciparum over human HDACs 
[604, 609]. To address the selectivity issue, many analogues of 5 were prepared over the years 
by Merck Research Laboratories by modifying either its Aoda side chain or its tryptophan 
moiety, and it was found that the replacement of tryptophan with quinolone/quinoline nuclei 
led to analogues of 5 showing 50- to 230-fold parasite selectivity over mammalian cells (e.g. 
compound 6, Table 4.3) [609-612]. Together with a series of synthetic analogues, 5 was also 
comparatively investigated for inhibitory activity against two Trypanosoma species (T. cruzi 
and T. brucei), P. falciparum and L. donovani. Both 5 and its analogues showed potent and 
nonselective activity toward T. brucei, similarly to P. falciparum, but revealed to be toxic 
against T. cruzi and L. donovani [612]. Recently, the cyclic depsipeptide 7 (romidepsin, also 
called FK228 in Table 4.3), together with the other three HDACi to date clinically approved as 
anticancer drugs (see below in the text), was assessed for its in vitro activity against drug 
sensitive (3D7) and drug resistant (Dd2) asexual P. falciparum parasites and the bloodstream 
forms of T. b brucei. Parasites [613]. Compound 7 displayed activity in the low nanomolar 
range against all parasite lines, caused hyperacetylation of both histone and non-histone 
proteins in P. falciparum, and inhibited deacetylase activity of parasite nuclear extracts and 
recombinant PfHDAC1, but unfortunately exhibited no selectivity over mammalian cells (NFF 
and HEK293) for both parasites (SI < 1) [613]. 
4.4.2.2 Short-chain Fatty Acid HDAC Inhibitors 
Short-chain fatty acid-type HDACi, such as 8 (VPA, Table 4.3), sodium butyrate, 4-
phenylbutyrate and related derivatives, despite weak inhibitors of mammalian HDACs, are 
pretty safe molecules, in one case already approved for some therapeutic indications (e.g. 8 
is still widely used as antiepileptic and mood-stabilizing drug), that are now undergoing 
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several trials for HDAC-related diseases, and could be intriguing for repurposing in parasitic 
diseases [614]. These compounds are active in vitro in the (sub)millimolar range against 
different parasites such as P. falciparum, T. gondii and S. mansoni and suffer from poor 
selectivity for parasites (especially P. falciparum) over mammalian cells [615-617]. To best of 
our knowledge, compound 8, despite its anti-parasitic activity in vitro falls within the 
therapeutic range of the compound for its primary use as mood-stabilizing drug, has still to 
be tested in vivo in animal models of any of these parasitic diseases. 
4.4.2.3 Hydroxamate-Based HDAC Inhibitors 
As in other human diseases such as cancer, HDACi bearing a hydroxamic acid warhead as 
zinc-binding group (ZBG) are the best studied anti-parasitic HDACi and have shown promising 
in vitro activity profiles against P. falciparum and other parasites. Several studies have been 
devoted to investigate the antimalarial potential of a number of natural and synthetic class-
I/II HDACi such as 9 (TSA) [618], suberoylanilide hydroxamic acid 10 (SAHA) [613], suberic 
bishydroxamate 11 (SBHA) [618], 12 (MW2796) [618] and aroyl-pyrrolylhydroxyamides 
(APHAs, e.g. 13), [619] which were among the first hydroxamate-based HDACi tested against 
several parasites, including P. falciparum (Table 4.3) [618] [397, 574-575, 580, 619-620]. 
These compounds showed inhibitory activities against P. falciparum in the range of low/sub 
micromolar (10, 12, 13, etc.) to nanomolar (9) concentrations, but almost all suffered, despite 
to a different extent, of poor selectivity versus host cells, with the only exception of 11, which 
displayed somewhat better selectivity for the parasite based on mammalian cytotoxicity data. 
More in detail, the extremely potent compound 9, despite not suitable for clinical progression 
for its lack of selectivity, has resulted a highly useful tool to understand how HDAC inhibition 
affects malarial parasite’s growth, development and gene transcription [580, 605, 621]. 
Indeed, 9 inhibited PfHDAC1 activity in the subnanomolar range (IC50  0.6 nM) [580] and, like 
5, caused hyperacetylation of P. falciparum histones and large scale genome-wide 
transcriptional changes in the parasite [605]. Compound 10, the first HDACi approved for the 
clinical treatment of cutaneous T-cell lymphoma in humans with the name of vorinostat in 
2006, is less potent than 9 against P. falciparum parasites in vitro (IC50 values in the 
submicromolar range), but displays a somewhat improved parasite selectivity (up to  200-
fold, Table 4.3) [397, 574, 620]. Despite its clinical utility for cancer, the in vivo efficacy of 10 
against Plasmodium parasites in mice models of malaria has still to be evaluated. In contrast, 
compound 11, endowed with lower 
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in vitro potency than 10 against P. falciparum, but, depending on 
the specific cell lines examined, better selectivity for the parasite versus 
mammalian cells (Table 4.3), has been examined in vivo in P. berghei-infected BALB/c mice 
(200 mg/kg, twice daily intra-peritoneally for 3 days) where it showed a cytostatic effect by 
significantly inhibiting peripheral parasitemia [618]. Despite no mice recovery was observed, 
these early data about compound 11 suggested that hydroxamate-based HDACi deserved 
further investigation as potential antimalarial agents [397, 574, 618].  
Inspired by the promising initial results, a number of HDACi with better in vitro potency 
against P. falciparum parasites than 10 or 11, and with varying improvements on selectivity, 
were identified in the subsequent years by screening compounds that, keeping intact the 
hydroxamic acid as ZBG, showed variations into the three other structural motifs of the 
general pharmacophoric model for HDAC inhibition: the CAP group that, acting as an enzyme 
surface recognition moiety, interacts at the entrance of the catalytic tunnel; the linker region 
that connecting the CAP with the ZBG fits the narrow, hydrophobic, tubular enzyme cavity; 
and the dispensable polar connection unit (CU) between the CAP and the linker [397, 574-
575, 622]. Among them, supported by in silico molecular modeling of PfHDAC1 and docking 
studies, the Fairlie’s group reported some L-cysteine-based (thioether in the linker region, e.g. 
45) and 2-aminosuberic acid (2-ASA)-based (only methylene groups in the linker region) 
hydroxamates that showed similar in vitro anti-parasitic potency (IC50s in the low nanomolar 
range) against both CQ-sensitive (3D7) and CQ-resistant (Dd2) P. falciparum strains, with the 
better selectivity generally observed for the 2-ASA compounds (Table 4.3). Among these 
latter, 15 (2-ASA-9) and 16 (2-ASA-14), in addition to cause a marked hyperacetylation of P. 
falciparum histones, showed the interesting capability to inhibit the P. falciparum growth in 
erythrocytes at both early and late stages of the parasite’s life cycle [579]. In one study, 9, 10 
and 15 were profiled for their effects on gene expression in P. falciparum parasites. Each 
compound caused genome-wide transcriptional changes (up to 2-21%), consistent with 
inhibition of HDAC activity in the parasite. Though the three inhibitors had very different 
overall effects on gene expression profiles, -tubulin II was found to be one of the small set 
of genes up-regulated by all three HDACi and its identification as transcriptional marker 
induced by structurally different HDACi in P. falciparum has been proposed as an important 
finding since this marker might be utilized for developing HDACi as “specific” antimalarial 
agents [597]. The ASA compounds 15 and 16, as well as 10, were also the first HDACi to be 
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tested against P. vivax, that is the second most important human infecting malaria parasite 
because, despite not generally responsible of death, is the cause of significant malaria-related 
morbidity and relapses due to parasite stages that can remain dormant in the liver. All three 
hydroxamates were able to inhibit the ex vivo growth of multi-drug resistant P. falciparum 
and P. vivax isolates obtained directly from infected patients [623]. The similar activity profiles 
obtained for 10, 15 and 16 against both P. falciparum (IC50 310, 533, and 266 nM, respectively) 
and P. vivax (IC50 170, 503, and 278 nM, respectively), despite somewhat higher than those 
reported in vitro against laboratory strains, provided the first examples of HDACi targeting 
multiple human-infecting malaria parasite species, which is nowadays thought to be highly 
beneficial for clinical applications. Several series of 2-ASA compounds, such as the one 
containing typical non-steroidal anti-inflammatory (NSAID) components in the CAP region 
(e.g. 17, Table 4.3) were tested over the years for their inhibitory activity against P. 
falciparum, but although many compounds displayed an extremely potent activity against P. 
falciparum (IC50s in the low nanomolar range), it was substantially impossible to get significant 
improvements of parasite selectivity in comparison to 15 (Table 4.3) [624].  
In 2009, Patel et al. screened in a high-throughput viability assay the antimalarial efficacy 
of a library of  2000 HDACi characterized by an acyl hydrazone moiety as CU and with 
chemical diversity in the recognition CAP, the ZBG, and the hydrophobic linker length (4-6 
methylene units). Although many compounds potently inhibited P. falciparum parasite 
growth and recombinant PfHDAC1 activity, only 17 derivatives demonstrated anti-parasitic 
activity in the low nanomolar range coupled with minimum perturbation of mammalian cell 
(human myeloma MM.1S cells) histone acetylation, that was used as an indicator of 
selectivity. Within this series, the selective inhibition of P. falciparum proliferation was highly 
favored by the presence of ortho-substituents (mainly bromine and hydroxyl) in the CAP 
aromatic group, of a hydroxamic acid as metal chelator, and of a linker of five methylene units 
(e.g 18, Table 4.3) [580].  
In the same period, Kozikowski and collaborators reported two series of suberoylamide 
hydroxamates bearing substituted triazolylphenyl and phenylthiazolyl (WR compounds) 
moieties as CAP groups. Among the triazolylphenyl-based HDACi, compound 19, endowed 
with an activity in the low nanomolar range (Table 4.3), resulted one order-fold more potent 
than most of the other congeners and more active than mefloquine and chloroquine against 
the multiple drug-resistant P. falciparum strains C235 and C2A, but in the best case was only 
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 23 fold more selective for C235 over mammalian cells [625]. Interestingly, in a panel of 50 
phenylthiazolyl hydroxamate-based HDACi, were identified three very potent compounds 
(IC50 < 3 nM) with more than 600-fold selectivity toward P. falciparum compared to human 
cells. The most promising HDACi from this set resulted the derivative 20 (WR301801), that 
exhibited IC50 values in the (sub)nanomolar range against several drug-resistant strains (D6, 
W2, C235 and C2A) of P. falciparum (Table 4.3), with a significant inhibition of HDAC activity 
in P. falciparum nuclear extracts (IC50  10 nM), and a strong hyperacetylation of parasite 
histones in situ [620]. In one study, 20 caused a significant suppression of parasitemia but did 
not cure P. berghei-infected mice when administered orally as monotherapy at doses of up 
to 640 mg/kg, while some, but not all, mice were cured when it was combined with sub-
curative doses of CQ (52 mg/kg of 20 plus 64 mg/kg of CQ) [620]. Likewise, oral administration 
of 20 (32 mg/kg/day for 3 days) to P. falciparum-infected Aotus monkeys resulted in parasite 
suppression but not eradication [620]. In another study, 20 improved survival and completely 
and irreversibly suppressed parasitemia in P. berghei-infected mice when given by intra-
peritoneal injection at a dose of 50 mg/kg/day for 4 days, with an experimental follow up 
period of 6 weeks [626]. Despite the optimization of the pharmacokinetic properties of 20 
seems highly desirable since it is rapidly hydrolyzed both in vitro and in vivo to its 
corresponding inactive carboxylic acid, these findings clearly demonstrate the potential of 
HDACi in mono- and/or combination therapy for the treatment of malaria [620, 626].  
In 2010, a series of aryltriazolyl hydroxamate-based HDACi was tested by Oyelere’s team 
for their inhibitory activity against promastigote stages of L. donovani and asexual P. 
falciparum blood-stage parasites [627]. Under the tested conditions, several compounds 
achieved better inhibitory activity (IC50s in the nanomolar range) and selectivity than 10 
against P. falciparum growth (D6 and W2 strains). Despite less active than against P. 
falciparum, some compounds possessed also modest inhibitory potency versus L. donovani, 
with IC50 values from 2- to 4-fold better than those of compound 10 and comparable to 
miltefosine, the standard oral drug for the treatment of visceral leishmaniasis. Notably, the 
anti-parasitic activity was dependent on the length of polymethylene linker and the nature of 
the CAP group. For any given CAP moiety, the activity against both parasites was maximal in 
analogues with 5 or 6 methylene units in the spacer region between the CAP and the ZBG. 
Indeed, compounds 21 and 22 (Table 4.3), characterized by a 3’-biphenyltriazolyl moiety as 
CAP and by a 6 and 5 methylene units linker, respectively, displayed the best activity and 
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selectivity against P. falciparum, with 22 that resulted also the most active against L. donovani 
(IC50  32 M) [627]. Oyelere and collaborators also investigated the antimalarial and 
antileishmanial activity of five tricyclic ketolide-based phenyltriazolyl HDACi [628]. Under the 
tested conditions, the optimal length of the linker between the CAP and the hydroxamic acid 
was of 6 methylene units for the best antimalarial activity that also mirrored the most potent 
PfHDAC1 inhibition (23a), while of 9 methylene units for the best antileishmanial activity that 
did not correlate with the PfHDAC1 inhibition (23b) [628]. More in detail, compound 23a 
showed IC50 values against both CQ-sensitive (D6) and CQ-resistant (W2) P. falciparum strains 
from 7- to 10-fold lower than those of compound 10, resulted up to 10-fold more selective 
over mammalian cells (Vero) compared to it (Table 4.3), and was devoid of antileishmanial 
activity, while compound 23b showed an activity against L. donovani (IC50  5 M) 16-fold 
stronger than 10 (IC50  81 M) together with modest antimalarial effects (Table 4.3) [628]. 
The same group also reported the antimalarial and antileishmanial activities of HDACi 
characterized by nonpeptide macrocyclic skeletons derived from 14- and 15-membered 
macrolides linked to a phenyltriazolyl moiety as large recognition CAP groups. All compounds 
inhibited the proliferation of both CQ-sensitive (D6 clone) and CQ-resistant (W2 clone) strains 
of P. falciparum with IC50 values in the (sub)micromolar range [629]. For both macrolide 
skeletons, the maximum activity and selectivity against P. falciparum was achieved with 6 
methylene units in the linker group separating the triazole ring of the CAP group from the 
active-site zinc binding hydroxamate, accordingly to previous reports [627-628]. The best 
among these compounds resulted the derivative 24 (Table 4.3), that is characterized by a 15-
membered macrolide skeleton, showed the highest anti PfHDAC1 activity (IC50 = 29 nM) and 
exhibited up to 11-fold more potent antiplasmodial activity and up to 14-fold increased 
selectivity over mammalian cells (Vero) in comparison to 10. Interestingly, for both macrolide 
skeletons, compounds with 5 to 7 methylene units at the linker group were devoid of activity 
against the promastigote stage of L. donovani, while maximum activity was obtained for those 
compounds having either 8 or 9 methylene units [629], as in the case of ketolide-based HDACi 
[628], but differently from SAR observed in aryltriazolyl hydroxamates [627]. In particular, 
compound 25 (Table 4.3), that contains a 14-membered macrolide skeleton and a 9 
methylene units linker, was up to 25-fold more active than 10 (IC50  81 μM), displaying the 
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maximum antileishmanial activity with IC50 values of 3.2 and 4.7 μM against the promastigote 
and amastigote stages of the parasite, respectively [629]. 
In 2012, Andrews and coworkers reported the in vitro and in vivo antiplasmodial activities 
of the orally active anticancer HDACi 26 (pracinostat, also indicated as SB939). Compound 26 
potently inhibited the growth of P. falciparum asexual-stage parasites in human erythrocytes 
in vitro (IC50s in the nanomolar range), causing hyperacetylation of parasite histone and non-
histone proteins and showing selectivity indexes over mammalian cells ranging from 4 to  
1250, depending on the different tested cell lines (Table 4.3) [630]. In addition to a promising 
additive effect in vitro in combination with the antimalarial protease inhibitor lopinavir, 26 
offered the first evidence of HDACi as liver-stage antimalarial drug leads. Indeed, 26, as well 
as 10, displayed a potent inhibition of the in vitro growth of exo-erythrocytic-stage P. berghei 
ANKA mouse malaria parasites within HepG2 human hepatocytes (IC50  150 nM) [630]. 
Finally, orally administrated compound 26 was found to be effective in vivo by reducing both 
peripheral parasitemia and total parasite burden at doses of up to 100mg/kg/day in the P. 
berghei ANKA mouse model of malaria. Despite mice were not cured, treatment with 26 
prevented the development of experimental cerebral malaria-like symptoms, and mice did 
not develop hyperparasitemia until 2-3 weeks after the interruption of the treatment.  
Subsequently, a panel of 21 HDACi characterized by a pentyloxyamide connection 
unit/linker moiety and by a substituted benzene ring as CAP were tested by the same group 
in vitro for their effects against different Plasmodium life cycle stages: asexual blood stage of 
P. falciparum (3D7 line); tissue schizontocidal stage of P. berghei (exo-erythrocytic forms 
cultured in HepG2 human liver cells); and late stage (IV and V) P. falciparum gametocytes. All 
compounds displayed activity (IC50 values in the range of 0.09-1.12 μM) against the asexual 
form of P. falciparum, with the potency and selectivity increasing along with the bulkiness of 
the alkyl/alkoxy substituents at the para position of the phenyl ring, as exemplified by the 
most active compound 27a (Table 4.3). Three derivatives revealed nanomolar activity against 
all three life cycle stages (e.g. 27b, Table 4.3), and several compounds showed an improved 
parasite selectivity compared to 11 for at least the asexual and exo-erythrocytic life cycle 
stages (e.g. 27c, Table 4.3) [631]. The same team also reported the antimalarial activity and a 
structure-activity relationship investigation of a series of related alkoxyurea-based HDACi 
[632-633]. Several compounds were active at (sub)micromolar level against the 3D7 line of P. 
falciparum [632], and some of them also displayed early/late stage gametocytocidal activity 
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in the single digit micromolar range (IC50 = 1.68-6.65 µM) [632-633]. The SAR studies revealed 
that the hydroxamic acid as ZBG and a linker of 5 methylene units were crucial for the 
antiplasmodial activity. Indeed, alternative ZBGs such as N-methylhydroxamic acid, o-
hydroxyanilide and o-aminoanilide were inactive, and chain-shortened analogues (less than 5 
methylene units at the linker) exhibited lower potency. Also in this series, bulky alkyl/alkoxy 
substituents at the 4-position of the phenyl CAP group, and its replacement with bulky 
aromatic rings led to the most potent and selective compounds against both asexual and 
gametocyte P. falciparum forms, as exemplified by the 4-tert-butyl derivative 28 and the 1-
naphthyl derivative 29, that anyway both resulted not better than 10 in terms of potency 
while, under the tested conditions, compound 29 was more parasite selective than 10 in its 
asexual stage and late-stage gametocyte killing activity (Table 4.3).  
In 2015, Giannini et al. assessed the potential anti-parasitic (P. falciparum, L. donovani, 
T. cruzi, T. brucei, G. lamblia) efficacy and SAR of a few 10 analogues characterized by the 
substitution with / lactam-carboxamides at the position α of the anilide CU and with 
(trifluoro)methyl groups in the meta position of the phenyl ring CAP, as well as by an 
hydroxamic acid or a thiol function as ZBG [634]. Remarkably, all hydroxamates showed a 
potency comparable with CQ (3-23 versus 6 nM) and slightly better than 10 (3-23 versus 25 
nM) against P. falciparum, the most sensitive parasite, and were highly selective for P. 
falciparum over mammalian L6 cells (SIs = 205-3953), while the thio derivatives, both the free 
and the pro-drug, exhibited poor anti-parasitic activity. It can be pointed out that a 
hydroxamate as ZBG, a -lactam carboxamide in α to the anilide CU, and a methyl or 
trifluoromethyl substituent in the meta phenyl ring position associate with an enhanced anti-
parasitic activity (at least toward P. falciparum and, to a lesser extent, T. cruzi and brucei 
species), though the phenyl modifications are also responsible of an increased cytotoxicity 
and reduced selectivity over mammalian cells [634].  Indeed, in a preliminary test in vivo the 
best results in a P. berghei mouse model of malaria were obtained with the unsubstituted 
phenyl derivative 30, that was the most selective in vitro (Table 4.3) and that inhibited  88% 
of the Plasmodium development versus 99.8% of dihydroartemisinine.  
In 2015, as already above mentioned, Andrews and coworkers reported the in vitro 
activity against P. falciparum (Table 4.3) and T. b. brucei parasites of all four HDACi clinically 
approved for the treatment of cancer [7, 10, 31 (belinostat), and 32 (panobinostat)] up to now 
[613]. All compounds inhibited the growth of asexual-stage P. falciparum parasites with 
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nanomolar potencies (Table 4.3), while only 7 was active at nanomolar level against the 
bloodstream form T. b. brucei (IC50 = 35 nM), despite devoid of any selectivity over 
mammalian cells. The four HDACi also inhibited the deacetylase activity of P. falciparum 
nuclear extracts and of recombinant PfHDAC1 and caused hyperacetylation of (non)histone 
proteins, differentially affecting the acetylation profiles of histones H3 and H4, but no one, 
with the exception of 10 and, to a lesser extent, of 31, displayed some selectivity for malaria 
parasites over mammalian cells (NFF and HEK293) [613].  
4.4.2.4 Thiol-based HDAC Inhibitors 
The thiol-based HDAC6 (class IIb) selective inhibitor 33 [635], when tested against CQ-
sensitive (3D7) and CQ-resistant (Dd2) P. falciparum strains, resulted only poorly active (IC50s 
in the micromolar range) in inhibiting the proliferation of the parasite (Table 4.3), so providing 
a further evidence of the necessity to focus on hydroxamate-based and likely on pan-HDACi 
as potential antimalarial agents [579].  
4.4.2.5 Ortho-Amino-Anilides HDAC Inhibitors 
The same conclusions can be drawn by considering the series of HDACi containing an 
ortho-aminoanilide moiety as ZBG. The prototype of these HDACi is the class-I HDAC selective 
inhibitor 34 (MS275, entinostat) [622, 636-637], that in multiple screening over the years has 
always resulted a modest inhibitor of both PfHDAC1 and parasite proliferation with IC50 values 
of 0.94 μM and  8 μM, respectively [264, 397, 574-575, 579-580].  
Table 4.3: In vitro Antimalarial Activity of Selected Class-I/II HDAC Inhibitors 
Class/ 
Inhibitor 
Structure Nuclear 
extract 
[rPfHDAC1]a 
IC50 (nM) 
P. falciparum 
IC50 (μM) 
Mammalia
n cells  
IC50 (μM) 
SIb 
 5 
(Apicidin)  
 
N
O
HN
O
NH
NH
O
O
O
H
N O
 
NA 
[1±0.1] 
0.200 0.05-0.1 0.2-
0.5 
6 
 
NA 0.063 >15 >238 
 
 
75 
 
7  
(Romidepsin, 
FK228) 
 
0.9±0.8 
[48±39% 
@1M] 
0.09-0.13 0.001-
<0.005 
<1 
Short-Chain Fatty Acids  
8  
(Valproic acid, 
VPA) HO O  
NA >100 1350 NA 
Hydroxamic Acids 
9 
(TSA) 
 N
O
NHOH
O
 
NA  
 [0.6±0.1] 
0.008-0.120 0.2-0.3 2-38 
10  
(SAHA, 
Vorinostat)  
NA  
[59±6] 
0.025-2.2 0.26-20 0-200 
11  
(SBHA) 
 
NA 0.8-2.3 50-300 22-
375 
12 
(MW2796) 
NHOH
O
HOHN
O
 
NA 0.9-1.1 NA NA 
13 
(APHA-7) 
 
NA 1.2-4 >20 5-17 
14 
 
NA 0.048 0.6 12 
15  
(2-ASA-9) 
H
N
O
N
H
O
N
NHOH
O  
NA 0.015-0.039 1.24 30-83 
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16  
(2-ASA-14) 
 
NA 0.013-0.033 0.34 10-26 
17 
 
NA 0.013 0.26 20 
18 Br
N
N
H
NHOH
O O
 
NA 
[37] 
0.015 NA NA 
19  
NHOH
O
5
H
N
O
NN
N
 
NA 0.017-0.035 0.02-0.8 0.6-
22.8 
20  
(WR301801) NHOH
O
5
H
N
O
N
S
H2N  
1-10 
[NA] 
0.0006-0.0016 0.6 400-
1016 
21 
 
NA 0.069 NC >190.
4 
22 
 
NA 0.074-0.107 NC >127 
(>183) 
 
 
23a  
(n=6) 
 
 
NA 
[10±0.5] 
0.144-0.148 >5.2 >36 
(>35) 
23b  
(n=9) 
NA 
[304±17] 
0.93-1.24 >5 >5.4 
(>4) 
24 
 
NA 
[29±0.9] 
0.094-0.226 NC >20.7 
(>47.6
) 
25 
 
NA 
[401±19.7] 
0.76-1.32 NC >3.4 
(>6) 
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26  
(Pracinostat, 
SB939) 
N
N
NHOH
N
O
 
NA 0.08-0.15 0.8->100 4-
>1250 
27 
R N
H
O
O
NHOH
O
5  
a. R = 4-t-Bu-
Ph 
[68.6±1.2% 
@1M] 
0.09 12.47 139 
b. R = 3,4-
CH3-Ph 
[82.6±4.2% 
@1M] 
0.12 3.24 27 
c. R = 4-BuO-
Ph 
[72.1±5% 
@1M] 
0.17 >50 >294 
28 
 
NA 0.16 
(3.45)c 
4.9 31 
(2)c 
29 
 
NA 0.25-0.32 
(2.12-2.25)c 
19.5 36-78 
(9)c 
30 
 
NA 0.019 75.1 >3950 
31  
(Belinostat) 
N
H
S
NHOH
OOO
 
214.7±15.3 
[78.5±4.7% 
@1M] 
0.06-0.13 1.4-2.4 11-40 
32 
(Panobinostat 
) 
HN
N
H NHOH
O  
3.3±0.7 
[100±0% 
@1M] 
0.01-0.03 0.07-0.18 2-18 
33 
H
N SH
O
HN O
O
 
NA 15.2-19.9 NA NA 
34  
(MS275, 
Entinostat) N
O N
H
O
H
N
NH2
O  
NA 
[940±90] 
7.8-8.3 >20 2.5 
a Deacetylase activity tested using either P. falciparum nuclear lysates (no brackets) or recombinant 
PfHDAC1[brackets]; bSI: Selectivity Index - fold difference between mammalian cell and P. falciparum IC50 values 
(IC50 mammalian cells/IC50 P. falciparum); c Relative to gametocytocidal activity; NA: data not available; NC: no 
cytotoxicity at the maximum tested concentration. 
4.4.2.6 Other Amides as HDAC Inhibitors 
Very recently, Ontoria et al., in addition to cast doubts on PfHDAC1 inhibition data 
reported in literature so far, described an innovative screening approach that led to the 
identification of a novel series of P. falciparum growth inhibitors claimed as selective PfHDACi 
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and characterized by a secondary amide as ZBG, an examethylene chain as linker and two 
groups such as an (hetero)aryl substituted imidazole ring and a 2-thiazolylcarboxamide as 
surface contact CAP moieties. Some derivatives in the series showed submicromolar 
inhibition of P. falciparum proliferation (EC50 < 500 nM) with only a modest inhibition of 
human class I HDACs in HeLa cells (IC50 values in the micromolar range), used as an indicator 
of selectivity [638]. Both activity and selectivity were strongly influenced by the nature of the 
(hetero)aryl substituent attached to the imidazole core. Although clear SAR trends were 
difficult to identify, compounds based on phenyl-/ biphenyl-/ benzimidazole- or 
benzotriazole- substituted imidazoles were either weak or poorly selective inhibitors of 
parasite growth. Conversely, analogues bearing indole-, indazole-, isoquinoline- and mainly 
pyrazolylphenyl- (35 and 36) or quinoline-substituted (37) imidazoles turned out to show the 
best activity and selectivity for the parasite (Table 4.4) [638]. Support for the selective 
PfHDACs inhibition as the mechanism of action of these compounds was provided by the 
evidence that compound 35, one the most potent and selective (SI = 37) of the series, induced 
the hyperacetylation of the histone H4K8 in parasite cells at a concentration (EC50 = 350 nM) 
quite close to the potency measured in the parasite growth inhibition assay (EC50 = 450 nM) 
and quite far from the concentration necessary to inhibit recombinant (EC50  5 M) and 
cellular (EC50 = 16.7 M) hHDACs and to promote the same extent of  histone H4 
hyperacetylation in human HeLa cells (EC50  25 M). In summary, the two step screening 
strategy [(i) comparison of parasite growth inhibition in erythrocytes with hHDAC inhibition 
in HeLa cells as preliminary readout of selectivity; (ii) conclusive validation of the parasite 
selectivity of the most promising compounds by measurements of nuclear histone 
hyperacetylation in both human and parasite treated cells] proposed by Ontoria et al. for 
evaluating the parasite selectivity of new potential antimalarial agents seems quite attractive 
because it allows to avoid the problems of the common PfHDAC preparations that are likely 
inactive without endogenous cofactors and are endowed with low in vitro activities just 
because contaminated by co-purified host HDACs coming from the cellular expression 
vectors, and therefore are not reliable for inhibition studies.  
 Table 4.4: In vitro Antimalarial Activity of N-Methyl Carboxamides as HDAC Inhibitors. 
Class/ 
Inhibitor Structure 
Nuclear  
extract 
[rPfHDAC1]a 
IC50 (nM) 
P. falciparum 
EC50 (μM) 
Class I 
hHDACs in 
HeLa cells  
IC50 (μM) 
SIb 
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35 
 
NA 0.45 16.6 37 
36 
 
NA 0.90 20.5 23 
37 
 
NA 0.5 >25 54 
a Deacetylase activity tested using either P. falciparum nuclear lysates (no brackets) or recombinant 
PfHDAC1[brackets]; b SI: Selectivity Index [HeLa class I HDACs IC50 (M) / Pfgrowth EC50 (M)]; NA: data not 
available. 
4.4.3 Antimalarial Sirtuin Inhibitors 
 Despite less studied than class I/II/IV HDACi, a certain number of SIRTi have been tested 
in vitro for anti-proliferative activity against P. falciparum-infected erythrocytes and for 
inhibition of the recombinant PfSir2A protein [264, 397, 574]. Known natural and synthetic 
SIRTi that have been examined over the years for P. falciparum growth inhibition comprise 38 
(IC50  9-13 M) [582-583], 39 (splitomycin, IC50  10 M) [580, 582-583], 40 (surfactin, IC50  
9 M) [582], and 41 (hyperforin, IC50  1.5-2 M) [639-640] (Fig. 4.4). Compound 42 
(nicotinamide), the physiological product of the Sir2-catalyzed NAD+-dependent 
deacetylation reaction, was found to be significantly less active at whole cell level (IC50  9.9 
mM), with a delayed parasite growth inhibitory effect observed (Fig. 4.4) [582-583, 641].  
The depsipeptide 40 and, to a lesser extent, 42 are more potent inhibitors of PfSir2A (IC50 
= 35 and 51 M, respectively) than hSIRT1 (IC50  600 and = 88-250 M, respectively), while 
38 and 39 are less active than them versus PfSir2A (IC50  50 and  400 M, respectively). In 
2009, Chakrabarty et al. applied a click chemistry approach to synthesize lysine-based 
tripeptide analogues designed to target PfSir2A through competition with the peptide binding 
pocket [642]. Despite three of four tested analogues had similar or better potency (IC50s = 23-
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34 M) against PfSir2A compared with 40 and 42, all of them were devoid of selectivity for 
the parasite Sir2 over human SIRT1. The most active compound 43 versus PfSir2A was also 
tested in vitro against P. falciparum-infected erythrocytes where it was as potent as 38 and 
40 in inhibiting the growth of the parasite (IC50 = 9.8 M) [582]. The natural hSIRT1 activator 
resveratrol [308], able to modestly inhibit in vitro the growth of P. falciparum (IC50  60 M), 
was also tested against recombinant PfSir2A, but no enzyme activation or inhibition was 
detected [583].  
Overall, the in vitro activity of the SIRTi tested so far against P. falciparum parasite growth 
is modest, but this is not surprising in the light of the aforementioned experimental evidences 
that seem to indicate PfSir2A and PfSir2B as not essential for the in vitro parasite growth and 
development, and anyway considering the low sequence homology observed between the 
PfSir2 and other eukaryotic Sir2 proteins [527-528]. Moreover, the somewhat low consistency 
between the PfSir2A inhibitory potencies and the in vitro antiproliferative effects promoted 
by some compounds (e.g.  38, 39, 42 and, to a lesser extent, 40) and the pleiotropic nature of 
some of them (e.g. 38 and 42), do not allow to exclude additional mechanisms involved in 
their P. falciparum growth inhibitory activity. For these reasons, it is presently highly desirable 
to identify/develop inhibitors with significantly increased potency against PfSir2 enzymes and 
selectivity over human sirtuins, that could be useful as tools for studying the biology of P. 
falciparum sirtuins and potentially for their pharmacological validation as targets of drugs 
exerting a direct or an indirect (by blocking the parasite evasion from the host innate immune 
surveillance) anti-parasitic activity (see above in text) [527-528].   
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Fig. 4.4: Chemical structures of antimalarial class-III HDAC (SIRT) inhibitors.  
4.4.4 Antimalarial HKMT Inhibitors 
Plasmodium falciparum HKMTs (PfHKMTs) play key role in controlling Plasmodium gene 
expression through epigenetic pathways [560, 643].  PfHKMTs were found to be essential in the 
asexual blood-stages of the parasite, in particular, knockout of PfSET2 was found to reverse the 
silencing of the var gene family, which is centrally involved in the immune evasion mechanism by 
which Plasmodium avoids the host antibody response [529, 643],   and thus may represent good 
drug targets [529, 531]. Despite this potential, production of enzymatically active PfHKMTs has 
proved to be challenging, with only a few successful reports in the literature [531, 590], thus 
hindering the prospect of PfHKMT inhibitor discovery. Indeed, by modifying the amino side chains 
of this scaffold, diaminoquinazoline inhibitors have been reported exhibiting human SETD8 [644-
645] and EZH2 [646] activity. Given this broad HKMT activity, Malmquist et al. [598] suggested 
that ‘repurposing’ the diaminoquinazoline scaffold as inhibitors of the homologous PfHKMTs as a 
potential new antimalarial targets. Two compounds, 44 (BIX-01294) and its derivative 45 (TM2-
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115) (Fig. 4.5), inhibited P. falciparum 3D7 parasites in culture with IC50 values of ∼100 nM, 
values at least 22-fold more potent than their apparent IC50 toward two human cell lines and 
one mouse cell line. These compounds irreversibly arrested parasite growth at all stages of 
the intraerythrocytic life cycle. Decrease in parasite viability (>40%) was seen after a 3-h 
incubation with 1 µM BIX-01294 and resulted in complete parasite killing after a 12-h 
incubation. Additionally, mice with patent Plasmodium berghei ANKA strain infection treated 
with a single dose (40 mg/kg) of TM2-115 had 18-fold reduced parasitemia the following day 
A dose-dependent reduction in histone methylation (H3K4 and, to a lesser extent H3K9) was 
observed in parasites upon treatment (Western analysis), suggesting on-target PfHKMT activity 
[598], and that the broad ranging effects of these compounds is likely due to their target. Highly 
promising effects were also observed for other life cycle stages, with mature gametocyte 
progression to gamete formation inhibited at submicromolar concentrations [599],  and both 
compounds were shown to activate dormant liver forms called hypnozoites [647], which are 
produced by some malaria parasite species including P. vivax and are considered one of the 
less accessible malaria infection reservoirs. This observation raises the intriguing possibility 
that hypnozoite activation may be regulated at the epigenetic level and suggesting that it may 
be possible to target these highly resilient forms with epigenetic drugs. 
A preliminary SAR study on our diaminoquinazoline series revealed that some 
pharmacophoric features might be conserved for both parasite-killing and G9a inhibition, thereby 
suggesting potential similarities between G9a and the yet unidentified PfHKMT target(s) 
responsible for the anti-parasitic activity [648]. As a result, a variety of analogues, based on BIX-
01294 and TM2-115, were designed by substituting the 2 and 4 positions of the quinazoline 
core and these molecules were tested against Plasmodium falciparum (3D7 strain). The 
resulting derivatives were assessed for cytotoxicity against the human HepG2 
hepatocarcinoma cell line as a measure of parasite versus human selectivity. Several 
analogues with IC50 values as low as 18.5 nM and with low mammalian cell toxicity (HepG2) 
were identified [648]. Promisingly, four lead compounds, BIX-01294, TM2-115 and two new 
compounds (46 and 47) (Fig. 4.5) were found to not only be highly potent against Pf3D7, but 
also highly selective for parasite versus host cell killing [599]. All four compounds were found 
to be 110-388-fold more active on Pf3D7 compared to HepG2 cell viability. Both 46 and 47 
revealed a decreased H3K4me3 and H3K9me3 levels and showed similar rapid and 
erythrocytic stage-independent killing phenotype as previously shown for BIX-01294 and 
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TM2-115 [598]. More recently, the same authors reported that an extensive study of the SAR of 
this series against both G9a and P. falciparum. From this series, compound 48 and 49 (Fig. 4.5) 
were employed in analogous phenotypic assays in order to study whether the diaminoquinoline 
chemotype has a comparable target profile to the diaminoquinazolines [649]. Consequently, both 
compounds showed similar erythrocytic stage-independent killing phenotype, suggesting a 
common target profile for the anti-Plasmodium activity with that of BIX-01294. Together, this data 
suggests that while broadly similar, the G9a and potential PfHKMT target(s) binding pockets and/or 
binding modes of the diaminoquinazoline analogues exhibit clear and exploitable differences. 
Thus, there remains significant potential in this series to further develop parasite selective 
analogues. Based on this, we believe this scaffold to have clear potential for development into a 
novel and much needed, new medicine for malaria. 
 
Fig. 4.5: PfHKMT inhibitors 
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5. EPIGENETIC MECHANISMS AS DRUG TARGETS FOR SCHISTOSOMA MANSONI 
The term “epigenetics” envelops a variety of heritable changes in gene expression that 
are linked to structural modifications of the chromatin, without changes to the DNA 
sequence. These include DNA methylation, reversible post-translational modifications of 
histones, histone variants, chromatin remodeling factors and non-coding RNAs. The 
investigation of the role of epigenetic mechanisms in the control of gene transcription in 
schistosomes, and hence in biological processes like development and reproduction, is in its 
early stages. Nevertheless, the complexity of schistosome development and differentiation 
implies a tight control of gene transcription at all stages of the life-cycle and that epigenetic 
mechanisms are likely to play a crucial role in these processes, suggesting that they are viable 
drug targets. In this context, the understanding of developmental and reproductive biology 
of schistosomes is crucial to fight schistosomiasis. Many works have highlighted the 
responsiveness of the developing S. mansoni to the host blood microenvironment and shown 
that the parasite might exploit endocrine and host immune signals to accomplish its 
development [650-654]. The mating status (i.e. paired vs unpaired) has also been shown to 
play an essential role for the maturation of both male and female [655-658]. Other molecular 
studies have highlighted male- or female-biased pathways essential for the development and 
the reproduction of the parasite [659-661]. Global transcriptomic analyses were carried out 
on diverse developmental stages [662-663] and sex-biased expressions were explored in adult 
[663-664] or cercariae [665]. Epigenetic control for gene expression regulation has also been 
investigated and highlighted sex-specific epigenetic processes with chromatin structural 
changes occurring on female-specific microsatellite repeats of the W-chromosome during the 
development of the parasite [666]. Similarly, Picard et al. highlighted that sexual 
differentiation in S. mansoni is accompanied by distinct male and female transcriptional 
landscapes of known players of the host-parasite crosstalk, genetic determinants and 
epigenetic regulators [667]. Therefore, the knowledge so far acquired, or inferred from the 
nature of schistosomes as invertebrate metazoan organisms and from a detailed analysis of 
the epigenetic actors encoded in their genomes, can be exploited to develop novel 
therapeutic strategies. Viewed as potential targets, the most readily “druggable” are the 
enzymes that carry out DNA methylation and histone modifications, and increasingly, micro-
RNAs (miRNAs) among the non-coding RNA categories.  
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5.1 DNA Methylation in Schistosomes  
The presence of functional DNA methylation marks in schistosome genomes is 
controversial. Early work showed no differences in the restriction profiles for adult male or 
female S. mansoni DNA [668]. Moreover, the methyl cytosine-dependent restriction 
endonuclease McrBC failed to digest S. mansoni DNA. However, recently, cytosine 
methylation was found to be a conserved epigenetic feature throughout the phylum 
Platyhelminthes, including Schistosoma haematobium, Schistosoma japonicum, and S. 
mansoni [669]. In addition to cytosine methylation, the arginine methyltransferase PRMT1 
homolog was also identified in S. mansoni and S. japonicum [670-671]. Dnmt 2 has only weak 
DNA methyltransferase activity but has robust methyltransferase activity toward tRNAAsp 
and other tRNAs [51]. However, Dnmt2 does retain some cytosine methyltransferase activity 
[672-673] showed that siRNA knockdown of SmDnmt2 transcripts reduced overall 
methylcytosine levels in the schistosome genome. These authors have further suggested that 
cytosine methylation is conserved throughout the phylum Platyhelminthes [669]. Against this, 
a comprehensive study [674] using whole-genome bisulfite sequencing showed that the S. 
mansoni genome lacked a detectable DNA methylation pattern, even at the 
“hypermethylated” locus identified by [673]. Some clusters of incompletely converted 
cytosines were detected outside this region, but were consistent with bisulfite deamination 
artefacts [675]. However, although these results strongly suggested that the S. mansoni 
genome is in fact unmethylated, the criticism has been levelled that the life-cycle stage 
analyzed, adult male worms, has the lowest level of DNA methylation measured using an 
ELISA method [669]. Notwithstanding this controversy, Dnmt inhibitors were found to 
strongly affect adult worms, particularly in terms of the morphology of the ovaries and in vitro 
egg-laying [673], that indicates Dnmt inhibitors such as 5-azacytidine may provide the basis 
for developing precursors of novel anti-schistosome drugs. 
5.2 Schistosome miRNAs  
Early diagnosis of schistosomiasis is critical to control this disease. However, no reliable 
biomarker exists for early diagnosis of schistosomiasis. Circulating miRNAs, which are present 
in a stable form in the plasma or serum of an infected host, have been considered ideal 
biomarkers for the diagnosis of some cancers. It is possible that such circulating miRNAs could 
also serve as biomarkers for schistosomiasis diagnosis. Because miRNAs act as critical post-
transcriptional regulators in many organisms, studies have been conducted to determine the 
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roles of miRNAs in schistosomes. These miRNAs are likely to play critical roles in schistosome 
development and gene regulation.  
A survey of the available S. mansoni EST sequences [676] concluded that 10.3% (21,107 
sequences) match the genome but have no protein coding potential and are therefore 
possible ncRNAs, suggesting that the parasite may use a range of ncRNAs in transcriptional 
and translational regulation. To the best of our knowledge, miRNAs were first identified in S. 
japonicum [677-678] in two separate studies that demonstrated the existence of a limited 
number of miRNA that are conserved in other organisms and that the miRNA expression 
profiles were highly stage-specific. In a more comprehensive study, researchers used a high-
throughput sequencing technology to characterize small RNAs populations in S. japonicum 
schistosomula, the early stage in the vertebrate host, which identified 16 schistosome-specific 
miRNAs [679-680]. In S. mansoni, the sequencing of a small-RNA cDNA library yielded 211 
novel miRNA candidates of which 11 were further verified by Northern blotting and presented 
data supporting stage-regulated expression patterns for some of the miRNAs [681].  
Thirteen microRNAs exhibit sex-biased expression, 10 of which are more abundant in 
females than in males [682]. Some miRNAs are associated with the morphological formation 
of ovaries in female schistosomes in S. japonicum [683]. These results demonstrate that 
during the life cycle of schistosomes, different microRNAs are likely to participate in 
differentiation/maintenance processes and it is clear that these miRNAs are potential 
therapeutic targets.  
5.3 Schistosome Histone Modifications  
The S. mansoni genome encodes 55 HMEs involved in protein acetylation/deacetylation 
or methylation/demethylation (Table 5.1) [684]. Some of these, including the class I HDACs 
[685] and the sirtuins [686] have been cloned and characterized and preliminary choices of 
targets can be made based on their degree of sequence conservation. Moreover, histone 
modifications have been identified in different life stages of schistosomes, and changes in 
histone modifications appear to be crucial for pathogenesis and thus to be potential 
therapeutic targets. For example, bivalent histone H3 methylation was observed in cercariae, 
demethylation of H3K27 and activation of transcription were observed during the 
transformation into schistosomula (remaining absent in adults), and alterations of H3K9 
methylation and acetylation occurred upstream and downstream of the transcriptional start 
site (TSS) [687]. The modification profiles of four histone modifications (H3K4me3, 
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H3K27me3, H3K27ac, and H4K20me1) were different between the sympatric host and 
allopatric host and these histone marks also differ in cercariae and adult [688]. The promoters 
of the S. mansoni mucingene (SmPoMuc), a key component of the compatibility between the 
schistosome and its snail host, contains the epigenetic marks H3K9Met3 and H3K9Ac, which 
differ significantly between compatible (C) and incompatible (IC) strains and negatively 
regulates the expression of SmPoMuc [689]. The structure of the parasite chromatin 
differentially modifies the transcription of SmPoMuc in the IC strain compared with the C 
strain [690]. These findings suggest that histone alterations maybe important for the initial 
steps in the adaptation of pathogens to new hosts and epidrugs can be used to control 
parasite development. Comparison of H3K27me3 histone modification before (in cercariae) 
and after (in adults) showed that the H3K27me3 enrichment profile in cercariae differs 
between the two sexes both upstream and along the transcription unit, whereas in the adult 
stage, males and females display the same profile after the TSS, while their profile upstream 
the TSS remains different [667]. These results suggest epigenetic regulators play important 
roles in the sex determination and sexual differentiation in schistosomes and represent a 
promising source of therapeutic targets.  
Table 5.1: Identity and characteristics of Schistosoma mansoni histone modifying enzymes [691]. 
HME 
type 
Class Closest human ortholog Size (aa) Substrate 
specificity 
Gene Ida 
HDAC I HDAC1 517* 
 
Smp_005210  
I HDAC3 418* 
 
Smp_093280  
I HDAC8 440* 
 
Smp_091990  
II HDAC4 291 
 
Smp_191310  
II HDAC5 701 
 
Smp_069380  
II HDAC6 1132 
 
Smp_138770  
III Sirtuin) Sirt1 568* H1 – H3 – H4 Smp_138640  
III 
(Sirtuin) 
Sirt2 337* H4K16 Smp_084140 
 
III 
(Sirtuin) 
Sirt5 305* 
 
Smp_055090 
 
III 
(Sirtuin) 
Sirt6 386* H3K9 – H3K56 Smp_134630 
 
III 
(Sirtuin) 
Sirt7 517* 
 
Smp_024670 
HAT GNAT GCN5 (KAT2A) 899* H3K9 – H3K14 – 
H3K18 H2B 
Smp_070190 
 
GNAT HAT1 (KAT1) 435 H4K5 – H4K12 Smp_178700  
MYST Tip60 (KAT5) 463 H2AK5 – H3K14 – 
H4K5 – H4K8 – 
H4K12 – H4K16 
Smp_053140 
 
MYST MYST1 (KAT8) 496 H4K16 Smp_194520 
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MYST MYST2 (KAT7) 400 H4K5 – H4K8 – 
H4K12 – H3 
Smp_171700 
 
MYST MYST3 (KAT6A) 971 H3K14 Smp_131320  
CBP/p300 CBP/SmCBP1 (KAT3A) 2093* H2AK5 – H2BK15 – 
H3K14 – H3K18 – 
H4K5 – H4K8 
Smp_105910 
 
CBP/p300 CBP/SmCBP2 (KAT3A) 1892 H2AK5 – H2BK15 – 
H3K14 – H3K18 – 
H4K5 – H4K8 
Smp_127010 
 
TAFII250 TFIID subunit 1 2241 H3 – H4 Smp_166840 
HMT SET EZH1 1026 H3K27 Smp_078900  
SET MLL3 (KMT2C) 399 H3K4 Smp_070210  
SET MLL3 (KMT2C) 1560 H3K4 Smp_138030  
SET MLL1/4 (KMT2D) 3002 H3K4 Smp_144180  
SET MLL5 (KMT2E) 751 H3K4 Smp_161010  
SET C20orf11/MLL5/Ranbp9 1305 
 
Smp_009980  
SET NSD2/WHSC1 1746 H3K4 – H4K20 Smp_160700  
SET NSD1/2 (KMT3B) 1343 H3K36 – H4K44 Smp_137060  
SET SET8 (KMT5A) 409 H4K20 Smp_055310  
SET SUV 39H2 (KMT1B) 586 H3K9 Smp_027300  
SET SUV4-20H1 (KMT5C) 613 H4K20 Smp_062530  
SET SETD2 1575 H3K36 Smp_133910  
SET SETD1B 1720/1822 H3K4 Smp_140390  
SET SETDB 918/1032 
 
Smp_150850  
SET SETMAR 250 H3K9 Smp_043580  
SET SET/MYND4 782 
 
Smp_000700  
SET SET/MYND4 527 
 
Smp_124950  
SET SET/MYND5 423/429/433 
 
Smp_121610  
DOT1 DOT1L (KMT4) 
 
H3K79 Smp_165000  
PRMT PRMT1 252/359/334 H4R3 Smp_029240  
PRMT PRMT3 1564 
 
Smp_127950  
PRMT PRMT4/CARM1 737 H3R2 – H3R17 – 
H3R26 
Smp_070340 
 
PRMT PRMT5 630 H2A – H4 Smp_171150  
PRMT PRMT7 755 
 
Smp_025550 
HDM KDM1 LSD1A 1043 
 
Smp_150560  
KDM1 LSD1A 916 
 
Smp_160810  
KDM1 LSD1 (KDM1) 1073 H3K4 – H3K9 Smp_162940  
JmjC JMJD1B (KDM3) 273 H3K9 Smp_161410  
JmjC JMJD2C (KDM4C) 1136 H3K9 – H3K36 Smp_132170  
JmjC JMJD4 809 
 
Smp_147870  
JmjC JMJD6 839 
 
Smp_137240  
JmjC JHDM1D (KDM7) 653 H3K36 Smp_127230  
JmjC Jarid (KDM5) 2372 H3K4 Smp_156290  
JmjC jarid (KDM5) 1639 H3K4 Smp_019170  
JmjC UTX (KDM6A) 1137 H3K27 Smp_034000 
5.3.1 Schistosome Histone Acetyltransferase 
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Histone acetyltransferase inhibition also has developmental consequences in 
schistosomes, particularly in egg maturation. The HATs, GCN5, was identified in S. mansoni, 
and specific acetylation at H3K14 was catalyzed by the transcriptional co-activator GCN5 [692-
693]. SmCBP/p300 was also identified in S. mansoni, and it was expressed during all life cycle 
stages, interacted functionally with the nuclear receptor SmFtz-F1 and also potentiated the 
transcriptional activity of this receptor in the CV-1 cell line [694]. 
The schistosome orthologue of the HAT GCN5 has been shown to acetylate H3 and H2A, 
and in particular H3K14 [692] and the CBP/P300 orthologue SmCBP1 primarily acetylates H4 
[694-695]. Knockdown of either or both of these HATs in adult schistosomes has been shown 
to markedly reduce the transcription levels of the major egg shell protein p14 and to damage 
the reproductive system of mature female worms, egg-laying and egg morphology. This result 
suggests that inhibition of Smp14 expression targeting SmGCN5 and/or SmCBP1 represents a 
novel and effective strategy to control S. mansoni egg development and that HATs can be 
used as a drug target against schistosomiasis. Moreover, these effects are reproduced by 
treating adult worm pairs with an HAT inhibitor, PU139 (Fig. 5.1) [696]. After both inhibitor 
treatment and RNAi to knock down transcripts of the HATs, the phenotypic effects on egg 
laying and development were correlated with decreased acetylation of H3 and H4, increased 
methylation at H3K27, a marker of transcriptional repression, on the p14 proximal promoter. 
More recently, the SmEZH2 methyltransferase PRC2 component was targeted with a new 
EZH2 inhibitor GSK343 (Fig. 5.1) and showed a synergistic effect with TSA, significantly 
increasing schistosomula mortality [697]. This paves way to target histone reader genes 
involved in regulation of the epigenetic program in S. mansoni as a starting point to look for 
possible novel schistosomicidal targets. 
 
Fig. 5.1: Example of HAT inhibitors active against Schistosoma mansoni  
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5.3.2 Schistosoma HDACs 
Studies have shown that class-I HDACs (smHDAC1, 3 and 8) are expressed in all stages of 
the Schistosoma lifecycle, with smHDAC8 being the most abundant [685]. Conversely, the 
human orthologue HDAC8 was reported to generally show less abundance than HDAC1 and 
HDAC3 in human cells, except in some tumor cells which show up-regulated levels of HDAC8 
[698]. 
The effects of both HDAC and HAT inhibitors on schistosomes suggest that histone 
acetylation may be a legitimate therapeutic target and initial studies investigating the effect 
of pan-HDAC inhibitors demonstrated their ability to induce schistosome mortality; the exact 
mechanism however is not completely clarified yet [615, 699]. Incubation of schistosomula 
larvae with trichostatin A (TSA) or valproic acid (VPA) caused parasite mortality via an 
apoptotic mechanism. The results indicated that TSA induces a sustained hyperacetylation of 
H4 leading to an increased expression of CASP7, which is responsible of inducing apoptosis 
[699]. Another study demonstrated that TSA arrests the transformation of Schistosoma 
miracidia to intramolluskal sporocysts [615]. These experiments shed light on the potential 
mechanism of HDAC inhibitors-mediated mortality of schistosomes.  
Several studies have thus focused on smHDAC8 as a potential therapeutic target for the 
treatment of schistosomiasis [700-703]. SmHDAC8 was found in in vivo studies to play an 
important role in the homeostasis of the parasite and to be essential for its pathogenicity. 
Mice infected with smHDAC8 knocked-down schistosomules showed, 35 days post 
incubation, a reduced number of recovered adult worms and lower egg burden compared to 
control mice. This indicated the importance of smHDAC8 for the survival and maturation of 
the parasite in its host [702]. 
5.3.3 Antischistosomal HDAC Inhibitors 
To further investigate and confirm the role of smHDAC8 in schistosome biology, several 
investigations were dedicated to the development of smHDAC8 small molecule inhibitors and 
investigate their effect in in vitro studies [700-703]. A structure-based virtual screening 
campaign was successful in finding 25 hydroxamic acid derivatives with an in vitro inhibitory 
potency against smHDAC8. Nine compounds exhibited an activity in the low micromolar range 
[701]. Among the identified inhibitors, J1075 (Fig. 5.2) was found to induce apoptosis and 
mortality in schistosomula larvae [702]. Heimburg et al. recently reported on a new proof of 
concept study, where several benzohydroxamic derivatives were designed as parasite-specific 
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inhibitors. The developed inhibitors were evaluated for their inhibitory activity against 
schistosomal and human HDACs (smHDAC8, hHDAC1, hHDAC6 and hHDAC8). Twenty-seven 
compounds exhibited an inhibitory activity in the nanomolar range in in vitro assays. 
Interestingly, many of the reported compounds showed a notable selectivity for smHDAC8 
over the major human HDAC isoforms (HDAC1 and HDAC6), some of which even exhibited a 
preference for smHDAC8 over human HDAC8 [700]. The obtained crystal structures of 
smHDAC-inhibitor complexes as well as docking studies show that, besides the expected 
coordination of the catalytic zinc-ion by the hydroxamate group, two H-bond interactions are 
formed between the amide linker and the side chains of the protein residues His292 and 
Lys20. This could partly account for the selectivity of the compound over HDAC1 and HDAC6 
(Fig. 5.3). Further phenotypic assays demonstrated that two of the reported compounds 
caused significant dose-dependent reduction of cultured schistosomula larvae [700], as 
opposed to praziquantel which is known to be less effective against larval developing stages 
of the parasite [704]. Moreover, TH65 (Fig. 5.2) caused a noticeable separation of female and 
male worm pairs and an impairment of egg-laying by adult worms [700]. Further hits from 
other chemical series, partially including a thiol group as warheads to chelate the catalytic 
zinc-ion, were also reported to possess in vitro inhibitory activity against schistosomula of S. 
mansoni [703].  
 
Fig. 5.2: Chemical structures of most relevant antischistosomal HDAC  
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Fig. 5.3: (A) X-ray structure of the inhibitor TH31 in complex with SmHDAC8 (PDB ID 5FUE). (B) Docking 
pose of the inhibitor TH65 in SmHDAC8. TH31 and 2 are shown in yellow, protein residues involved in the 
interaction in white, zinc-ion as orange spheres, and H-bond as well as interactions with the metal ion as yellow 
dashed lines.  
5.3.4 Schistosoma Sirtuins 
Sirtuins are NAD+- dependent lysine deacetylases that are involved in a wide variety of 
cellular processes including histone deacetylation, and they have been shown to be 
therapeutic targets in various pathologies including cancer. It has been previously pointed out 
that severalilarities between schistosomes and tumors including the cellular proliferation 
removed from control by the host, a degree of invisibility to the immune response and energy 
metabolism based on the consumption of large amounts of glucose and oxidative glycolysis 
producing lactate as the end-product [684]. It was also pointed out that schistosomes 
undergo a rapid switch from energy production based on oxidative phosphorylation in 
cercariae to glycolysis in schistosomula immediately after skin penetration, and this is 
stimulated by the presence of glucose in the external medium [705]. This metabolic switch is 
analogous to the Warburg effect noted in numerous tumors. Sirtuins link the control of 
metabolism and DNA repair to tumorigenesis and it is probable that schistosome sirtuins fulfill 
similar functions to their human counterparts [706].  
Parasitic class I sirtuins, characterized by the GAGXSXXXGIPDFRS, PS/TXXH, TQNID and 
HG motifs [707] have been extensively and successfully explored as antiparasitic targets. It 
has been reported that these proteins have vital role in parasite survival by catalyzing the 
deacetylation reaction of acetylated lysine residues of nuclear histones and other substrates, 
with NAD+ as a cofactor [708]. To evaluate schistosomal sirtuins and their potential as 
therapeutic drug targets, Lancelot et al. identified and characterized 5 sirtuins encoded in the 
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S. mansoni genome and established their homology relationship to human isoforms. 
Altogether, five sirtuins were found to be encoded in S. mansoni genome, which are 
orthologues of the human sirtuins SIRT1, SIRT2, SIRT5, SIRT6 and SIRT7. The encoded sirtuins 
are expressed at all stages of S. mansoni life cycle; however, there are wide variations in the 
levels of transcripts, particularly in the case of the nuclear sirtuins, Sirt6 and Sirt7, which are 
highly expressed in larval stages, whereas the nucleo-cytosolic sirtuins, Sirt1 and Sirt2 show 
less variation.  
5.3.5 Schistosoma Sirtuin Inhibitors 
With the aim of assessing the potential of schistosomal sirtuins as targets for anti-
parasitic drug development, several reported mammalian SIRTi were tested in in vitro assays 
to investigate their effects on cultured schistosomula and adult worms. Compound sirtinol, 
salermide and the thiobarbiturate derivative MS3 (Fig. 5.4) significantly reduced the viability 
of schistosomula through induction of apoptosis. Moreover, incubation of the 
aforementioned sirtuin inhibitors with adult worms caused separation of female and male 
worms and reduction in egg laying. Interestingly, Salermide also caused a remarkable change 
in the morphology of ovaries and testes [686]. These results suggest that schistosome sirtuins 
could be potential therapeutic targets and validate screening for selective sirtuin inhibitors as 
a strategy for the development of new drugs against schistosomiasis. 
The molecular features of SmSirt2 as well as its use for the development of new targets 
for schistosomiasis were explored in some recent studies [709-710]. The schistosome sirtuins, 
while showing overall conservation of essential catalytic domain residues [686], also show 
significant differences. The solution of crystal structures of schistosome sirtuins bound to 
inhibitors would represent a significant advance for the development of selective inhibitors 
[706]. 
Nevertheless, the use of high-throughput screening of extensive compound libraries 
represents a complementary strategy that has recently been used with success to generate 
inhibitors of human Sirts 1, 2 and 3 that show nanomolar IC50 inhibitory values, although they 
are not selective [711]. It is to be expected that the application of both high-throughput and 
structure-based screening strategies will rapidly lead to the identification of both selective 
and potent sirtuin inhibitors. Indeed, in a recent study, we report the optimization of 
fluorescence-based assays for S. mansoni Sirt2 that allowed a pilot screen with inhibitors 
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showing IC50  values of <50 μM and docking studies rationalizing the binding of hits to the 
target using a homology model of the enzyme [712]. 
 
Fig. 5.4: Chemical structures of most relevant antischistosomal HDAC and sirtuin inhibitors. 
5.3.6 Histone Methylation and Demethylation 
Schistosome genome analysis (Table 5.1) allows to identify 18 lysine methyltransferases 
and 5 PRMT family proteins [691]. A closer look at the specificity of the orthologues of the 
schistosome HMT proteins shows that the parasites possess enzymes that could methylate 
the histone lysine residues involved in transcriptional control: H3K4 (MLL, SETD1B), H3K9 
(Suv39H2, SETDB), H3K27 (EZH1), H3K36 (NSD2/WHSC1, SETD2, NSD1/2, SETMAR), H3K79 
(DOT1L), H4K20 (NSD2/WHSC1, SET8, NSD1/2, Suv420H1), H3R2 (CARM1) and H4R3 (PRMT1, 
PRMT5, PRMT7) [713-714]. Putative orthologues are also present of further lysine 
methyltransferases (Smyd 4 and 5) for which the histone substrates have yet to be defined. 
On the other hand, of the 11 HDM encoded in the S. mansoni genome (Table 5.1), 3 are similar 
to LSD1 and the remaining 8 are JmjC domain-containing proteins. 
In common with the HATs and HDACs, some HMTs have been shown to act on non-
histone proteins. For example, schistosomes present an orthologue of PRMT3, which 
principally methylates the 40S ribosomal protein S2 [715] and the lysine methyltransferase 
SET8 methylates p53 on lysine-382 [716]. 
The latter include a putative orthologue of Utx that has H3K27 demethylase activity, but 
not of JMJD3 that also has this specificity [717]. 
Overall the lower numbers of both HDMs and HMTs in the schistosome genome 
compared to the human genome point to a lower degree of functional redundancy for the 
schistosome enzymes. For example, EZH1 and EZH2 show functional redundancy for the 
methylation of H3K27 [718] and Utx and JMJD3 are both involved in its demethylation. As the 
S. mansoni genome encodes neither EZH2 nor JMJD3, the EZH1 and Utx orthologues are the 
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unique enzymes carrying out these tasks and may therefore represent particularly sensitive 
therapeutic targets [717].. 
Studies using HMT and HDM inhibitors are less common, but some results have shown 
that the chloroacetyl derivative, allantodapsone, a PRMT1 (arginine methyltransferase) 
inhibitor, showed selective inhibition affecting the growth of tumor cells [719]. Recent studies 
performed, knocked down for PRMT3 and KDMs in schistosomula by RNA interference, show 
that these enzymes are important for S. mansoni reproduction.  
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6. DESIGN, SYNTHESIS AND BIOLOGICAL VALIDATION OF URACIL-BASED 
HYDROXAMIDES (HDAC INHIBITORS) AS NEW ANTIMALARIAL AGENTS 
6.1 Research Project 
The emergence and spread of malaria drug resistance presents a worrisome situation 
impacting disease control programs [412, 415]. It is now becoming clear that malaria control 
will require the introduction of new chemotherapies to overcome this situation [720]. One 
promising strategy to identify new antimalarial agents is the “piggyback” approach, which 
focuses on drug targets that have been validated for other diseases, try to apply them to new 
indications such as parasitic diseases [396]. Accumulating evidence indicates that the malaria 
parasite has a unique histone modification signature that plays a fundamental role in gene 
expression and virulence [721]. In the search for promising drugs to combat malaria, 
inhibitors of histone modifying enzymes have started to obtain attention [264]. The factors 
affecting histone modifications are also suggested to have links between mode of action of 
artemisinin and its resistance. Eearlier studies clearly reported that HAT, Sirtuins and HDAC 
inhibitors, including apicidin, curcumin and several hydroxamate derivatives as well as the 
clinically approved HDACi are potent inhibitors of Plasmodium growth [264, 397, 429, 582, 
599, 722-723] Specifically, several HDAC inhibitors have been shown to be highly effective 
blockers of P. falciparum growth, which put the HDAC enzymes into the spotlight of this 
research [264, 397, 574, 579-580, 610, 626, 722, 724] and several of them displaying a 
significant in vitro, ex vivo and, in a few cases, in vivo activity against malarial parasites. Such 
findings underscore the potential for PfHDAC inhibitors to be used for malaria therapy [264, 
397, 633]. 
 HDAC inhibition is expected to affect chromatin structure and the patterns of gene 
expression. The transcriptome explorations of the effects of HDAC inhibition have shown that 
different inhibitors impact differently on the expression of genes highlighting the mechanistic 
complexity of the control of gene expression in the parasite. Despite some progress in recent 
years, there are still a number of challenges in the rational development of HDAC inhibitors 
as antimalarial drug leads. Next generation compounds should retain potent antiplasmodial 
activity and low host cell toxicity, but they also require improved pharmacokinetic properties 
relative to current generation compounds.  
As in other human diseases such as cancer, HDACi bearing a hydroxamic acid warhead as 
zinc-binding group (ZBG) are the best studied anti-parasitic HDACi and have shown promising 
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in vitro activity profiles against P. falciparum and other parasites. From a medicinal chemistry 
point of view, this compound class features fall into a pharmacophoric model widely 
accepted, which consists of a capping group (CAP), able to interact with the rim of the catalytic 
tunnel of the enzyme, a zinc binding group (ZBG), able to complex the Zn2+ ion at the bottom 
of the catalytic cavity, and hydrophobic linker connecting the two parts [264, 574, 722]. In 
this project, we investigated the antimalarial activity of a small library of epi-drugs, including 
the HDAC inhibitors of the class uracil-based hydroxamides (UBHAs, MC1746 and MC1761), 
cinnamyl hydroxamates and related compounds (MC1575, MC2780, MC2059), 2'-
aminoanilides (MS-275 and MC2392), and Sirtuin inhibitors (MC2141, MC1776) (Fig. 6.1), 
against Pf3D7 sensitive strains.  These compounds were chosen because having different 
chemical structures and different selectivity for the various HDAC isoforms. As far as the 
uracil-based hydroxamides are considered, compounds with a phenyl/benzyl ring at the 
uracil-C6 position and bearing 4-5 carbon units as well as methylenecinnamyl moiety as a 
spacer were the most potent inhibitors [725]. Thus, we prepared MC1746 bearing a 2-niphthyl 
group as a CAP, a uracil moiety as a connecting unit, 4 carbon methylene units as hydrophobic 
a spacer, and the hydroxamate function to bind the Zn ion. Whereas, MC1761 was 
characterized by a phenyl group as a CAP, a uracil moiety as a connecting unit, 
methylenecinnamyl moiety as a spacer, and the hydroxamate function to bind the Zn ion, 
crucial for the catalytic activity of the enzyme (Fig. 6.1). it would be nice to metion tha all 
biological tests haven performed by Prof. Khalife’s group at the ‘Institut Pasteur De Lille’, Lille, 
France. 
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Fig. 6.1: A small library of HDAC and Sirtuin inhibitors tested against Pf3D7 sensitive and W2 multidrug 
resistant strains.   
The target-based drugs approach using a series of histone modifying enzymes enable us 
to identify few potent compounds active in vitro on P. falciparum strains with low toxicity. 
More specifically, the antiparasitic activity revealed that MC1746, the only HDACi selective 
towards classes I and IIb of HDACs, as the most potent compound, with IC50 values of 79 nM 
against Pf3D7 sensitive strains (Table 6.1).  
Table 6.1: Percentage of growth inhibition at 10 µM and IC50 values on 3D7 of compounds from the 
primary library. ND: not determined. IC50 values were not determined when the percentage of 
inhibition at 10 µM was lower than 50%. 
Epi-targets Compounds % of 
inhibition at 
10 µM 
IC50 (nM) 
HDACs  MC1746 
class I/IIb HDACi 
97.44 79.38 ± 0.73 
 MC2392 
context-selective class I 
HDACi 
97.09 >1 µM 
 MS-275 
HDAC1-3 inhibitor 
50.91 >1 µM 
 MC1575 
HDAC4-6,8 inhibitor 
89.62 >1 µM 
 MC2780 
HDAC6-selective inhibitor 
100 422.39 ± 19.44 
 MC2059 
pan-HDACi 
98.00 244.03 ± 52.18 
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 MC1761 
HDAC8 inhibitor 
2.82 ND 
    
Sirtuins  MC2141 
Sirt1/2i 
80.52 >1 µM 
 MC1776 
Sirt1/2i 
72.31 >1 µM 
 
In an effort to improve HDAC inhibitory potency against P. falciparum, and however to 
further generate structure-activity relationships on the core UBHA, we decided to prepare 
another small group of compounds (Table 6. 2). During this process, we focused our attention 
on the two portions that, by a HDACi medicinal chemistry point of view, characterize the 
UBHA template: the CAP group and the hydrophobic spacer (HS) by keeping the hydroxamate 
as Zn-binding group (ZBG). For what concerning the CAP group (R, Fig. 6.2), first of all, in 
addition to the phenyl moiety at C6 of the Uracil ring, we also introduced benzyl moiety in 
which both characterized by variety of substituents at meta, or para position of the benzene 
ring of the phenyl/benzyl moiety, including less bulkier aromatic rings (Table 6.2). While 
pursuing our searches on HS (X, Fig. 6.2), we explored the effect of 4 and 5 methylene units 
on the anti-plasmodial activity of such compounds. Selected compounds were then examined 
for their activity against Pf3D7 sensitive and W2 multidrug resistant strains (Table 6.3). 
 
Fig. 6.2: Modifications of the UBHA template 
6.2 Chemistry  
For the synthesis of the UBHA derivatives bearing linear HSs, the properly 6-substituted 
2-thiouracils 20a-j were treated with various sizes of ethyl ω-bromoalkanoates in the 
presence of anhydrous potassium carbonate to afford the ethyl esters 21a-r, which were, in 
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part, hydrolyzed to the corresponding carboxylic acids 22a-r. A subsequent treatment of  22a-
r with (i) ethyl chloroformate and triethylamine, (ii) O-(2-methoxy-2-propyl)-hydroxylamine 
[726], and (iii) Amberlyst 15 ion-exchange resin in methanol  afforded the related 
hydroxamates 1-18 (Scheme 1).  
Among the 6-substituted-2-thioxopyrimidin-4-ones 20a-j,  the synthesis of the not 
commercially available intermediates has been accomplished by condensation of thiourea in 
alkaline medium with the appropriate ethyl β-ketoesters 19a-j, previously prepared by 
reacting potassium monoethylmalonate with chlorides or imidazolides of the corresponding 
acids in the presence of the magnesium/triethylamine system [727]. 
Scheme 1 a  
 
a Reagents and conditions: (a) 1) CDI, CH3CN, 2) KOOCCH2COOEt, (Et)3N, MgCl2, CH3CN, rt then reflux, 3) 
13% HCl; (b) EtONa, thiourea, EtOH, reflux; (c) Br-X-COOEt, K2CO3, DMF, rt; (d) 2N KOH, EtOH, H2O, rt; (e) 1) 
ClCOOEt, (Et)3N, dry THF, 0°C, then NH2OC(CH3)2OCH3, rt, 2) Amberlyst® 15, MeOH, rt; 
Table 6.2. Physical and Chemical Data for Compounds 1-18. 
 
 
comp
d Lab code R X mp, °C 
recryst. 
solventa yield, % 
1  Ph (CH2)4 194-196 b 54 
2  Ph (CH2)5 144-146 c 57 
3 MC1716 3-Cl-Ph (CH2)4 196-198 a 61 
4  3-Cl-Ph (CH2)5 188-192 a 67 
5 MC1714 4-Cl-Ph (CH2)4 198-200 a 52 
6  1-naphthyl (CH2)4 182-184 a 48 
7  1-naphthyl (CH2)5 198-200 a 54 
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8 MC1745 2-naphthyl (CH2)4 188-190 b 51 
9 MC1746 2-naphthyl (CH2)5 144-146 d 57 
10 MC1742 4’-biphenyl (CH2)4 202-204 a 57 
11 MC1738 4’-biphenyl (CH2)5 192-194 a 51 
12  3’-biphenyl (CH2)5 188-190 a 56 
13  3’-biphenyl (CH2)4 198-200 a 52 
14  PhCH2 (CH2)5 179-181 b 57 
15  PhCH2 (CH2)4 104-106 c 49 
16  1-
naphthylCH2 
(CH2)5 172-174 a 51 
17  2-
naphthylCH2 
(CH2)5 160-162 b 52 
18  4’-
biphenylCH2 
(CH2)5 208-210 e 47 
 aa: methanol; b: acetonitrile/methanol; c: acetonitrile; d: benzene; e: ethanol. 
 
6.3 Experimental Section  
Chemistry. Melting points were determined on a Stuart melting point apparatus 
SMP10TM. 1H-NMR spectra were recorded at 400 MHz using a Bruker AC 400 spectrometer; 
chemical shifts are reported in δ (ppm) units relative to the internal reference 
tetramethylsilane (Me4Si). Microwave-assisted reactions were performed with a Biotage 
InitiatorTM (Uppsala, Sweden) high frequency microwave synthesizer working at 2.45 GHz, 
fitted with magnetic stirrer and sample processor; reaction vessels were Biotage microwave 
glass vials sealed with applicable cap; temperature was controlled through the internal IR 
sensor of the microwave apparatus Biotage Isolera One™. All compounds were routinely 
checked by TLC and 1H-NMR. TLC was performed on aluminum-backed silica gel plates (Merck 
DC, Alufolien Kieselgel 60 F254) with spots visualized by UV light or using a KMnO4 alkaline 
solution. All solvents were reagent grade and, when necessary, were purified and dried by 
standard methods. Concentration of solutions after reactions and extractions involved the 
use of a rotary evaporator operating at reduced pressure of ~ 20 Torr. Organic solutions were 
dried over anhydrous sodium sulfate. All chemicals were purchased from Sigma Aldrich s.r.l., 
Milan (Italy) or from TCI Europe N.V., Zwijndrecht (Belgium), and were of the highest purity. 
As a rule, samples prepared for physical and biological studies were dried in high vacuum over 
P2O5 for 20 h at temperatures ranging from 25 to 40 °C, depending on the sample melting 
point. 
General Procedure for the Synthesis of N-Hydroxy-ω-(3,4-dihydro-4-oxo-6-substituted-
2-pyrimidinylthio)alkanamides (1-18). Example 5-((4-([1,1′-Biphenyl]-4-yl)-6-oxo-1,6-
dihydropyrimidin-2-yl)thio)-N-hydroxypentanamide (10, MC1742). To a 0 °C cooled solution 
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of 5-((4-([1,1'-biphenyl]-4-yl)-6-oxo-1,6-dihydropyrimidin-2-yl)thio)pentanoic acid (20j) (0.53 
mmol, 200 mg) in dry tetrahydrofuran (4 mL), ethyl chloroformate (1.3 mmol, 138 mg, 0.12 
mL) and triethylamine (1.38 mmol, 140 mg, 0.19 mL) were added and the mixture was stirred 
for 10 min. The solid was filtered off, and O-(2-methoxy-2-propyl)-hydroxylamine (3.18 mmol, 
0.24 mL) was added to the filtrate. The resulting mixture was stirred at rt for 1 h then was 
evaporated under reduced pressure, and the residue was diluted in MeOH (2.5 mL). 
Amberlyst 15 ion-exchange resin (106 mg) was added to the solution of the O-protected 
hydroxamate, and the mixture was stirred at rt for 1 h. Afterward, the reaction was filtered 
and the filtrate was concentrated in vacuum to give the crude 10, which was purified by 
recrystallization. Recrystallization system: methanol. 1H NMR (DMSO-d6) δ 1.69 (m, 4H, 
CH2CH2CH2CH2S), 2.02 (t, 2H, CH2CO), 3.25 (t, 2H, CH2S), 6.72 (s, 1H, C5-H), 7.39−7.48 (m, 3H, 
benzene rings), 7.73−7.83 (m, 4H, benzene rings), 8.14 (m, 2H, benzene rings), 8.69 (s, 1H, 
NHOH), 10.37 (s, 1H, NHOH), 12.6 (s, 1H, uracil NH). MS (ESI), m/z: 396 [M + H]. 
N-Hydroxy-5-(3,4-dihydro-4-oxo-6-phenyl-2-pyrimidinylthio)pentanamide (1). 1H NMR 
(DMSO-d6) δ 1.65 (m, 4H, CH2CH2CH2S), 1.97 (t, 2H, CH2CO), 3.21 (t, 2H, CH2S), 6.65 (s, 1H, 
C5-H), 7.48 (m, 3H, benzene ring), 8.04 (m, 2H, benzene ring), 8.70 (s, 1H, NHOH), 10.34 (s, 
1H, NHOH), 12.68 (s, 1H, NH uracil ring). 
N-Hydroxy-6-(3,4-dihydro-4-oxo-6-phenyl-2-pyrimidinylthio)hexanamide (2). 1H NMR 
(DMSO-d6) δ 1.38 (m, 2H, CH2CH2CH2S), 1.52 (m, 2H, CH2CH2CO), 1.70 (m, 2H, CH2CH2S), 1.94 
(t, 2H, CH2CO), 3.19 (t, 2H, CH2S), 6.65 (s, 1H, C5-H), 7.47 (m, 3H, benzene ring), 8.03 (m, 2H, 
benzene ring), 8.65 (s, 1H, NHOH), 10.35 (s, 1H, NHOH), 12.65 (s, 1H, NH uracil ring). 
N-Hydroxy-6-(3,4-dihydro-4-oxo-6-benzyl-2-pyrimidinylthio)hexanamide (14). 1H NMR 
(DMSO-d6) δ 1.27 (m, 2H, CH2CH2CH2S), 1.44 (m, 2H, CH2CH2CO), 1.50 (m, 2H, CH2CH2S), 1.92 
(t, 2H, CH2CO), 3.01 (t, 2H, CH2S), 3.72 (s, 2H, PhCH2), 5.92 (s, 1H, C5-H), 7.24 (m, 5H, benzene 
ring), 8.66 (s, 1H, NHOH), 10.33 (s, 1H, NHOH), 12.45 (s, 1H, NH uracil ring). 
N-Hydroxy-5-(3,4-dihydro-4-oxo-6-benzyl-2-pyrimidinylthio)pentanamide (15). 1H 
NMR (DMSO-d6) δ 1.52 (m, 4H, CH2CH2CH2S), 2.03 (t, 2H, CH2CO), 3.03 (t, 2H, CH2S), 3.72 (s, 
2H, PhCH2), 5.91 (s, 1H, C5-H), 7.23 (m, 5H, benzene ring), 8.68 (s, 1H, NHOH), 10.34 (s, 1H, 
NHOH), 12.35 (s, 1H, NH uracil ring). 
General Procedure for the Synthesis of 6-(3,4-Dihydro-4-oxo-6-substituted-2-
pyrimidinylthio)- alkanoic Acids (22a-r). Example: 5-((4-([1,1'-biphenyl]-4-yl)-6-oxo-1,6-
dihydropyrimidin-2-yl)thio)hexanoic acid (22k). A mixture of ethyl 5-((4-([1,1'-biphenyl]-4-
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yl)-6-oxo-1,6-dihydropyrimidin-2-yl)thio)hexanoate (21k) (1.1 mmol), 2 N KOH (8.8 mmol), 
and EtOH (5 mL) was stirred at room temperature for 18 h. The solution was poured into 
water (50 mL) and extracted with ethyl acetate (2 X 20 mL). HCl (2 N) was added to the 
aqueous layer until the pH 5, and the precipitate was filtered and recrystallized to yield the 
title compound 22k as a pure solid. 1H NMR (DMSO-d6) δ 1.32 (m, 2H, CH2CH2CH2S), 1.49 (m, 
2H, CH2CH2CO), 1.61 (m, 2H, CH2CH2S), 1.93 (t, 2H, CH2CO), 3.06 (t, 2H, CH2S), 6.07 (s, 1H, C5-
H, uracil), 7.39−7.48 (m, 3H, benzene rings), 7.73−7.83 (m, 4H, benzene rings), 8.14 (m, 2H, 
benzene rings),12.2 (s, 1H, COOH).  
General Procedure for the Synthesis of Ethyl -(3,4-Dihydro-4-oxo-6-substituted-2-
pyrimidinylthio)alkanoates (21a-n). Example: Ethyl 6-(6-Benzyl-3,4-dihydro-4-
oxopyrimidin-2-ylthio)hexanoate (21n). A mixture of 6-benzyl-4-hydroxy-2-
mercaptopyrimidine (20n) (9.16 mmol, 2.0 g), ethyl 6-bromohexanoate (10 mmol, 1.8 mL), 
and anhydrous potassium carbonate (10 mmol, 1.4 g) in 3 mL of anhydrous DMF was stirred 
at room temperature for 1 h. After treatment with cold water (100 mL), the precipitate which 
formed was filtered and washed to furnish 21n (1.6 g), which was purified by crystallization 
from MeOH. Yield: 49%; mp: 104-106 °C; recrystallization solvent: MeOH; 1H NMR (CDCl3) δ 
1.25 (t, 3H, CH2CH3), 1.40 (m, 2H, CH2CH2CH2CO), 1.63 (m, 4H, CH2CH2CO and CH2CH2S), 2.28 
(t, 2H, CH2CO), 3.13 (t, 2H, CH2S), 3.80 (s, 2H, PhCH2), 4.13 (q, 2H, CH2CH3), 5.96 (s, 1H, H C5), 
7.28 (m, 5H, benzene ring), 12.87 (s, 1H, NH). Anal. C, H, N, S. 
General procedure for the synthesis of derivatives of the 6-substituted 2-thiouracils 
(18a-g). Example: Example: 6-(benzyl)-3,4-dihydro-2-thioxopyrimidin-4(3H)-one (19h). 
Sodium metal (23.70 mmol) was dissolved in 21 mL of absolute ethanol, and thiourea (16.6 
mmol) and 18h (11.80 mmol) were added to the clear solution. The mixture was heated at 
reflux for 12 h. After the completion of reaction the mixture was cooled, the solvent was 
distilled in vacuo at 40-50 °C until dry and the residue was dissolved in water (15 mL) and 
made acidic with 2 N HCl. The resulting precipitate was filtered under reduced pressure, 
washed with diethyl ether, and vacuum dried at 80 °C for 12 h to give title compound 19h as 
a pure white solid which was further purified by crystallization from ethanol. Yield: 68%; mp: 
242-245 °C; recrystallization solvent: ethanol. 1H NMR (DMSO) δ 3.28 5.04 (s, 2H, PhCH2), 5.78 
(s, 1H, C5-H), 7.40 (m, 5H, benzene ring), 12.38 (s, 1H, NH ), 12.43 (s, 1H, NH). 
General procedure for the synthesis of ethyl β-ketoesters (18a-j). Example: ethyl 3-oxo-
4-phenylbutanoate (18h). Triethylamine (48.00 mmol) and magnesium chloride (37.50 
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mmol) were added to a stirred suspension of potassium ethyl malonate (31.50 mmol) in 
acetonitrile (50 mL), and stirring was continued at room temperature for 2 h. Then, a solution 
of phenylacetyl imidazolide [prepared from phenylacetic acid (15.00 mmol) and N,N-
carbonyldiimidazole (CDI, 18.00 mmol)] in acetonitrile (15 mL) was added and the reaction 
mixture was stirred overnight at room temperature. 13% HCl (90 mL) was cautiously added 
while keeping the temperature below 25°C and the resulting clear mixture was stirred for a 
further 15 min. The organic layer was separated from aqueous mixture and evaporated; then 
the residue was treated with ethyl acetate (30 mL). The aqueous layer was extracted with 
ethyl acetate (3 x 30 mL), and the organic phases were combined, washed with saturated 
sodium bicarbonate solution (3 x 30 mL) and brine (3 x 30 mL), dried, and concentrated to 
give 18h as a yellow oil. Yield: 88%. 1H NMR (CDCl3) δ 1.22 (t, 3H, OCH2CH3), 3.50 (m, 2H, 
COCH2CO), 4.13 (q, 2H, OCH2CH3), 4.77 (s, 2H, PhCH2), 7.35 (m, 5H, benzene ring). 
6.4 Biological Evaluation and Results 
6.4.1 Phenotypic screening of epigenetic modulators against 3D7 
In this target-based screening, the antiplasmodial activities of the selected HDAC and 
Sirtuin inhibitors were initially assessed at 10 µM against the P. falciparum 3D7 strain. As 
shown in Table 6.1, 8 compounds inhibited parasite growth between 50 and 100%, and 1 
compound showed an inhibition of parasite growth lower than 5%. The 8 compounds were 
then tested in dose response assays to determine their IC50 values (50% or half maximal 
inhibitory concentration). The most potent compound showing IC50 values of 79.38 was the 
UBHA-based HDACi, MC1746, bearing selectivity for classes I/IIb of HDACs (Table 6.1).  
6.4.2 Antiplasmodial activity of analogues derived from active compounds (focused 
screening) 
In order to optimize the potency of the active compounds primarily tested, further a small 
series of analogues were tested belonging to the HDACi which gave the highest Plasmodium 
growth arrest in the first screen, i.e. MC1746 (focused screening). They were first screened at 
10 µM for their ability to inhibit 3D7 parasite growth. Several compounds showed an 
inhibition of parasite growth greater than 50%; more specifically, among the screened 
compounds, 5 compounds displayed 96-100% inhibition of parasite growth (Table 6.3). For 
the new analogues, IC50 values were then determined as previously described (Table 6.3). 
About the new tested HDACi, several new analogues exhibited IC50 values < 100 nM, 
moreover, three compounds (8, 10 and 11) showed IC50 values lower than the corresponding 
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prototype, in particular 11 displayed the highest antiplasmodial potency with IC50 value of 
4.21 (Table 6.3). Thus, from the results obtained by the two screenings, we selected 11 for 
further experiments. 
Table 6.3: Percentage of growth inhibition at 10 µM and IC50 values on 3D7 of the hit and its 
newly synthesized analogues. ND: not determined. IC50 values were not determined when the 
percentage of inhibition at 10 µM was lower than 50%. 
 
Compounds Structures  
% of inh. 
at 10 µM IC50 (nM) 
1 
 
80.23 88.98 ± 3.12 
2 
 
76.00 98.58 ± 2.11 
3 
MC1716 
 
 
 
 
98.01 
 
 
 
 
88.61 ± 
2.16 
 
 
4 
 
90.30 108.01 ± 5.12 
5 
MC1714 
 
92.05 87.6 ± 5.28 
6 
 
75.24 104.87 ± 5.19 
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7 
 
65.98 110 ± 6.21 
8 
MC1745 
 
97.92 25.17 ± 4.98 
9 
MC1746 
 
 
97.44 79.38 ± 0.73 
10 
MC1738 
 
97.44 50.89 ± 5.01 
11 
MC1742 
 
 
 
 
96.12 
 
 
 
4.21 ± 0.39 
12 
 
78.20 90.39 ± 4.69 
13 
 
83.45 81.97 ± 3.41 
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14 
 
66.65 114.19 ± 5.91 
15 
 
70.00 109.47 ± 4.91 
16 
 
76.07 98.69 ± 5.56 
17 
 
68.04 106.94 ± 6.01 
18 
 
88.95 85.81 ± 4.85 
6.4.3 Antiplasmodial activity against W2, a multiresistant strain 
Several criteria have been proposed for defining hits and leads in the development of 
drugs for diseases such as malaria. To be validated as a hit for antiplasmodial activity, a 
selected compound should be active against multidrug-resistant strains [728]. To this end, the 
growth inhibition of the multidrug-resistant W2 strain [729] has been tested along with the 
sensitive 3D7 strain. Under the experimental conditions used throughout this study, 
chloroquine had an IC50 value of 21.5 nM (± 1.6) and 290 nM (± 6) for 3D7 and W2 strains, 
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respectively, which is consistent with previous reports [598]. As far as MC1742 is considered, 
the IC50 value obtained for W2 (6.6 nM) as close to that obtained for 3D7 (4.2 nM) strain. 
Altogether, these results suggest that MC1742 is a very promising candidate as hit/early lead 
compound for antimalarial treatment.  
6.4.4 Selectivity Index (SI) on primary activated cells (splenic murine cells) and on 
eukaryotic cell line (HFF) 
The high selectivity of a compound for Plasmodium is one of the criterion that has to be 
addressed to exclude potential toxic effects and to validate a compound as a hit (greater than 
10-fold selectivity between the half maximal cytotoxic concentration for mammalian cell line 
and the IC50 value for Plasmodium [728]. To assess the selectivity index (SI) of MC1742, a 
cytotoxicity assay on a murine splenic primary cell line and a human foreskin fibroblast cell 
line (HFF) was performed. As shown in Table 6.4, testing the cytotoxicity of this compound on 
HFF cell line showed SI = 783. The same assay performed on primary murine cells revealed SI 
value of 186, which was less selective in this test. 
Table 6.4: MC1742 selectivity 
   Mammalian cells 
  3D7 Splenic cells HFF 
Epi-target Compd IC50 (nM) IC50 (nM) SI IC50 (nM) SI 
HDAC MC1742 4.21 ± 0.39 785 ± 78 186 3295 ± 247 783 
SI – selectivity index; mammalian cell IC50/P. falciparum IC50.  
4.4.5 Pharmacokinetic analysis 
Based on criteria including P. falciparum IC50 values (<50 nM) on both sensitive and 
multidrug-resistant strains, selectivity indexes on primary murine cells and HFF cell line (> 
100-fold) and the new promising chemical structure, MC1742 was selected for 
pharmacokinetic (PK) studies. A (2-hydroxypropyl)-beta-cyclodextrin (HP-β-CD)-based 
formulation, suitable for both intravenous (i.v.) and per os (p.o.) administration, was selected 
for these PK studies. For MC1742, 2 mice were administered with one single dose (50 mg/kg) 
either intravenously or p.o.. Blood was collected at 3 different time points (15, 60 and 180 
min for i.v and 30, 60 and 180 min p.o). Plasma samples were analysed and concentrations 
are summarized in Table 6.5. MC1742 administered at a 50 mg/kg dose was well tolerated. 
The 15 min i.v. samples showed quite high MC1742 plasma concentrations, but the compound 
concentration decreased rapidly with time. P.o. and i.v. plasma samples at 1 h post 
administration showed MC1742 concentrations between 0.5 and 2.2 µM and after 3 h 
between 43 and 300 nM.  
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Table 6.5: Pharmacokinetic parameters of MC1742 administered intravenously or orally to mice. 
 Administration i.v. Per os 
Compound/Dose Time (min) 
Concentrations (µM) Time 
(min) 
Concentrations (µM) 
Mouse 1 Mouse 2 Mouse 3 Mouse 4 
MC1742 
50 mg/kg 
15 15.2 10.7 30 2.43 0.67 
60 2.16 1.67 60 0.90 0.48 
180 0.044 0.043 180 0.30 0.070 
6.4.6 Effect on histones of treated P. falciparum parasites 
To determine whether MC1742 has an effect on parasite histone acetylation levels, we 
treated parasites with a concentration of 3-fold its IC50 value, collected samples after 5 h 
incubation and performed histone acetylation-specific Western blots on the treated parasites 
samples (Fig. 6.3).  
 
 
Fig. 6.3: Hyper-acetylation, WB; Histone acetylation levels in treated parasites. Asynchronous P. falciparum 
parasites were grown in 3-fold of the IC50 values of MC1742, MC2590 and in DMSO for 5 hours for 
immunoblotting with anti H3 CT and anti-acetyl H4.  
6.4.7 In vivo antimalarial activity in P. berghei infected mice 
In order to comply with “early leads” criteria for malaria treatment, compounds should 
present oral efficacy [728]. From the above PK studies, it appears that the plasma 
concentrations of the selected compounds, when compared to their IC50 values, could provide 
enough exposure to affect parasite growth. To examine the oral efficacy, the Peters 4-day 
suppressive test [730], which indicates the capacity of compounds to reduce or to completely 
inhibit blood parasite growth was carried out. Groups of 6 BALB/c mice were infected 
intraperitoneally (i.p) with 106 P. berghei ANKA parasites and treated as depicted in Fig. 6.4A. 
On day 4 post infection, parasitemia levels in treated groups were compared to vehicle 
control groups. 
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In the group treated orally with MC1742 at 50 mg/kg, none of the mice showed a 
reduction of parasitemia (Fig. 6.4B, Exp. 1). The efficacy of MC1742 was then assessed by a 
combination of oral and i.v route as the PK studies revealed that the concentration of MC1742 
was higher in the plasma samples after 15 and 60 min when administered i.v. (12.95 and 1.91 
µM, respectively) compared to per os (1.55 and 0.69 µM, respectively, Table 6.5). Data 
presented in Fig. 6.4B (Exp. 2) showed that the combined route treatment of mice twice a 
day, one per os and one i.v., still did not have any effect on blood stage infection. 
 
Fig. 6.4: Treatment of BALB/c male mice infected with P. berghei ANKA strain with MC1742 administered 
orally show total parasites clearance at Day 4 of the suppressive Peter’s test. For each compound, 2 independent 
experiments, Exp 1 and Exp 2, were performed. Fifteen BALB/c mice were infected i.p. with 106 RBC infected 
with P. berghei ANKA strain. (A) Six mice were given per os the compound at the appropriate concentration, 
twice a day, 6 mice were given per os DMSO (7%), the vehicle and negative control and 3 mice were given per 
os CQ at 10 mg/kg, the positive control once a day, for 4 days. For MC1742, in Exp 2, mice received also 2 
administrations: one per os and one per iv. On Day 4, parasitemia was determined for each mouse on a blood 
smear (and mouse survival was followed thereafter). Each dot represents one mouse. (B) Parasitemia at Day 4 
for MC1742 (50 mg/kg) and the control-treated groups. The data in panels B, C, D and E are means +/- SEM. 
6.5 Discussion and Conclusion 
The key role played by epigenetic modifications, well known to be involved in 
transcriptional regulation in Plasmodium, provided a strong boost to research efforts on 
epigenetic inhibitors. Nonetheless, the clinical treatment of parasitic infections is quite 
different from that of other diseases, such as cancer, because most morbidity and mortality 
associated with parasitic diseases occur in resource-constrained regions of the world, with 
children, pregnant women, and immune-compromised people being at highest risk. 
Moreover, the coinfection of people in these regions with different infective agents (e.g., HIV) 
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is quite common and needs to be taken into account due to potential drug–drug interactions. 
Consequently, the main features that a HDACi, as any other new antiparasitic drug, should 
have before being considered for clinical use include: (1) high potency and selectivity in vivo 
for parasite over normal host cells, (2) activity against organisms resistant to currently 
employed drug(s), (3) an elevated degree of safety for use also in children and pregnant 
women, (4) low cost, to potentially treat hundreds of millions of deprived people, (5) oral 
bioavailability and effective pharmacokinetic profiles that allow single daily doses, and (6) 
hopefully, pharmacokinetics compatible with those of potential partner drugs to prevent or 
limit the development of drug resistance. 
To progress class I/II HDACi toward clinical trials as potential antiparasitic drugs, a high 
level of potency and selectivity for parasites versus host cells is essential. From a medicinal 
chemistry point of view, there is opportunity to optimize the chemical structures of the 
currently available class I/II HDACi for therapeutic use against parasites by modifying each 
one of the four portions (CAP, CU, linker, and ZBG) of the general pharmacophoric model for 
class I/II HDAC inhibition. The zinc-coordinating residues in HDACs and the tubular cavity 
between the zinc and the surface of HDAC enzymes are relatively well-conserved between 
human and parasite enzymes [264, 578-579], and the linker moiety of HDACi is not able to be 
varied a great deal, being restricted by the size and shape of the active site tunnel. Moreover, 
the length of the linker group has been found to be a major structural determinant for the 
antimalarial and antileishmanial activities of two classes of nonpeptide macrocyclic HDACi 
that displayed the maximal antileishmanial activity in analogues with linkers comprising eight 
or nine methylene units [268, 629], whereas the best antimalarial potency was observed for 
analogues with five or six methylene unit spacers. The CAP group involved in the interaction 
with the rim at the entrance of the catalytic tunnel has more scope for variation and 
exploitation, and it is to be expected that most attempts to improve the activity and/or 
selectivity of the future antiparasitic HDACi will focus on this. 
Therefore, in an attempt to identify HDAC inhibitors with potent and selective 
antimalarial activity, we examined a first series of HDAC inhibitors, including uracil-based 
hydroxamides (UBHAs, MC1746 and MC1761) (Fig. 6.1). Antiparasitic activity revealed 
MC1746, the only HDACi selective towards classes I and IIb of HDACs, as the most potent 
compound, with IC50 value of 79.38 nM against Pf3D7 sensitive strains (Table 6.1). On the 
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other hand, none of the sirtuin inhibitors exhibited appreciable parasite growth inhibition (in 
general IC50 values > 1 µM). 
 To further generate structure-activity relationships on MC1746, another small group of 
analogues (Table 6.2) were synthesized and evaluated their HDAC inhibitory activity against 
P. falciparum. From this series, 4 analogues of MC1742 (MC1716, MC1738, MC1745 and 
MC1746) were found to be active against P. falciparum (Table 6.2). Respect to MC1742, the 
new analogues were different for the C6-uracil substitution [various aryl or aryl methyl 
instead of 4-biphenyl group], or for the length of the spacer between the sulphur atom and 
the hydroxamide [5 instead of 4 methylene groups], or for both. Similar to MC1746, the new 
analogues showed the selectivity for class I/IIb HDACs inhibition. When tested against 3D7, 
several analogues showed a better potency respect to the hit/MC1746, where MC1742 was 
the most potent derivative with IC50 values of 4 and 6 nM against Pf3D7 sensitive and W2 
multidrug resistant strains, respectively.  
From our previous work, in the UBHA general structure, the introduction of 
benzyl/phenyl moiety at the C6 position of the uracil group furnished highly active derivatives, 
depending on either the size of the linear spacer or the methylenecinnamyl regioisomer 
connecting the uracil with the hydroxamate group. Likewise, compounds with a linear, 
polymethylene spacer between the uracil and the hydroxamate showed the highest activity 
with the insertion of 4 to 5 carbon units. By increasing this number to 7 carbon units as well 
as by introducing shorter, linear HSs in the UBHA general formula, a decrease of inhibiting 
activity was recorded. Particularly, the corresponding unsaturated analogues failed in 
inhibiting HDACs. This study also showed that the C6 phenyl substituted analogues performed 
better activity toward P. falciparum compared to the C6 benzyl ones. Indeed, the C6 
benzyl/phenyl substitution with bulkier aromatic rings, in general, led to derivatives with 
better parasite inhibitory activity. In fact, as far as the C6 phenyl substituted analogues are 
considered, the 4′-biphenyl showed the best parasite inhibitory activity followed by 2-
naphthyl whilst the meta and para chloro-substituted phenyl displayed moderate inhibitory 
activity. Interestingly, in all compounds, when we compare the linear HSs of the tested 
compounds, compounds having 4 carbon unit showed a better potency in comparison to 5 
carbon unit compounds, for example, MC1742 vs MC1738 (IC50 = 6.03 vs 50.89) and MC1745 
vs MC1746 (IC50 = 25.17 vs 79.38).  
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In the light of potential role of MC1742 to inhibit HDACs, its role was explored on Histone 
H4 acetylation in P. falciparum. Treated parasites with MC1742 clearly exhibit increased H4 
acetylation, supporting that this compound acts as parasite HADCs inhibitor. The toxicity of 
MC1742 against murine primary cells and human cell line revealed SI values of 186 and 783, 
respectively. These data, together with the PK studies, prompted us to examine MC1742 in a 
rodent model of malaria infection. Mice treated with MC1742 did not show any reduction of 
parasitemia at day 4 post infection and thereafter either after an oral administration or after 
a combination of oral/i.v. injections. In mice treated with chloroquine at 10 mg/kg, no blood 
stage parasites were detected. It is unlikely that the lack of in vivo activity could be linked to 
differences in targeted HDAC enzymes as they are well conserved between P. falciparum and 
P. berghei (60 up to 95% aa identity). The failure of MC1742 to cure mice at doses up to 50 
mg/kg twice a day may be due to a too short exposure of parasites to the compound, even 
after 4-days treatment. Another possibility may be related to the mouse model in which P. 
berghei could be less sensitive in vivo due to genetic redundancy and /or to a tighter control 
of the target expression level. This could be further explored by additional studies using P. 
falciparum-infected humanized SCID mice receiving human erythrocytes [731]. This approach 
could also point out whether metabolism of human versus mouse erythrocytes could affect 
the antiparasitic activity of the compound. However, in the context of hydroxamate-based 
drugs, it is noteworthy that several and convergent studies reported that they showed high 
potencies in vitro when compared to approved drugs, but yet exhibited poor antimalarial 
activities [620, 630, 732].  
In general, MC1742’s lack of in vivo activity was unexpected considering its best ever in 
vitro activity against Pf3D7 sensitive and W2 multidrug resistant strains compared to the 
previously reported HDAC inhibitors (see Table 4.3). 
6.6 Methods  
6.6.1 Determination of in vitro activity against P. falciparum 
Growth inhibition assay performed on P. falciparum 3D7 line using SYBR Green I was 
described in detail in Fréville et al. [733]. Briefly, in vitro cultured P. falciparum 3D7 line 
infected erythrocytes (0.5% parasitemia, 1% haematocrit) were seeded in duplicate wells into 
96-well tissue culture plates containing vehicle control (DMSO, <0.5%), positive control 
(chloroquine, Sigma Aldrich) or test compound and incubated under standard P. falciparum 
culture conditions for 48 h. Cultures were stained for 30 minutes in the dark with SYBR Green 
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I 1X (Invitrogen) diluted in 20 mM Tris pH 8.8, 138 mM NaCl, and fixed with 1% 
paraformaldehyde. Fixed parasited red blood cells (RBC) were stored at 4°C in the dark until 
flow cytometry analysis. Parasite growth was assessed by flow cytometry on a BD FACS 
CantoII (BD Biosciences). Cell pairs were excluded from the analysis using a forward scatter 
(FSC)-width versus FSC-area dot plot. Infected and uninfected erythrocytes were gated on the 
basis of their FSC and side scatter (SSC) signals. Fluorescence analysis (Green fluorescence 
FITC) was performed using BD FACSDiva software (version 6.1.3, BD Biosciences) on a total of 
200,000 acquired events. Fluorescence was observed on a two-parameter dot plot (FTIC-FSC). 
Fluorescence of non-infected RBC was adjusted to plot between 100 and 102.  
For testing the inhibitory effects on P. falciparum, a drug-sensitive (3D7) and drug-
resistant (W2) line were used. For both P. falciparum cell lines growth inhibition was initially 
assessed at 10 µM in two independent assays. Compounds showing more than 50% inhibition 
at 10 µM were then tested in dose response assays to determine 50% growth inhibition (IC50) 
values on Pf3D7. All IC50 values were calculated using log-linear interpolation with mean 
values (±SD) determined over two independent experiments [734]. 
6.6.2 In vivo experiments 
Parasite clearing was examined in an acute infection murine model. To test the anti-
malarial effect in vivo, the Peter’s test was followed using BALB/c male mice infected with P. 
berghei ANKA strain parasites [730]. The compounds were administered per os, twice a day 
for 4 days (D0 to D3). Each experiment comprised 3 groups of mice: a first group of 6 mice 
was given the compound to be tested at the appropriate concentration determined by the PK 
studies, i. e. 50 mg/kg for MC1742; a second group of 6 mice, the negative control (DMSO, 
7%) and the third group of 3 mice, the positive control (CQ at 10 mg/kg, once a day). The 
experiment lasted for 4 days. At Day 0, the mice were all infected i.p. with 106 parasitized red 
blood cells with P. berghei ANKA strain. At Day 4, the parasitemia was determined for each 
mouse on blood smears. Mice parasitemia was followed thereafter for 2 weeks. For each 
compound, the experiment was repeated twice. 
All animal experiments were approved by the animal ethics committee, in accordance 
with the French National Regulations. In this study, infected animals with at least 2 clinical 
signs (respiratory distress, lethargy, piloerection, anemia and body loss weight) were 
euthanized and this time point is denoted as time of death. 
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7. DESIGN, SYNTHESIS AND PRELIMINARY BIOLOGICAL VALIDATION OF 
SCHISTOSOMA MANSONI SIRT2 INHIBITORS 
7.1 Research Project 
Most of the current efforts to identify new drug leads for schistosomiasis and other 
neglected parasitic diseases rely on the screening of random compound libraries directly on 
the parasite maintained in culture (phenotypic screening). The recent publication of the 
genome sequences of a variety of parasites including the three-main species of schistosomes 
that infect humans [735-737] now means that approaches targeting specific gene products or 
pathways can be envisaged. These can include enzymes with activities specific to the parasite, 
or at least not found in the human host [738], metabolic bottlenecks, or molecules that are 
targeted in other pathologies. Nevertheless, the use of high-throughput screening of 
extensive compound libraries represents a complementary strategy that has recently been 
used with success to generate inhibitors of human Sirts 1, 2 and 3 that show nanomolar IC50 
inhibitory values, although they are not selective [711]. It is to be expected that the 
application of both high-throughput and structure-based screening strategies will rapidly lead 
to the identification of both selective and potent sirtuin inhibitors. It has been reported that 
sirtuins have vital role in parasite survival by catalyzing the deacetylation reaction of 
acetylated lysine residues of nuclear histones and other substrates, with NAD+ as a cofactor 
[708]. Altogether, five sirtuins were found to be encoded in S. mansoni genome, which are 
orthologues of the human sirtuins SIRT1, SIRT2, SIRT5, SIRT6 and SIRT7. The encoded sirtuins 
are expressed at all stages of S. mansoni life cycle; suggesting that schistosome sirtuins could 
be potential therapeutic targets and validate screening for selective sirtuin inhibitors as a 
strategy for the development of new drugs against schistosomiasis. 
Previous work showed strong effects of hSirt2 inhibitors on both worm life span and 
reproduction. The molecular features of SmSirt2 as well as its use for the development of new 
targets for schistosomiasis were explored in some recent studies [709-710]. The schistosome 
sirtuins, while showing overall conservation of essential catalytic domain residues [686], also 
show significant differences. The solution of crystal structures of schistosome sirtuins bound 
to inhibitors would represent a significant advance for the development of selective inhibitors 
[706]. Indeed, in a recent study, fluorescence-based assays were optimized for S. mansoni 
Sirt2 that allowed a pilot screen with inhibitors showing IC50  values of <50 μM and docking 
studies rationalizing the binding of hits to the target using a homology model of the enzyme 
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[712]. All these efforts constituent a very good foundation for further development of SmSirt2 
inhibitors. 
GSK published for the first time the outcome from a parallel high throughput screening 
of a pharma compound collection (1.8 million compounds) against three kinetoplastids: 
Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Three corresponding 
kinetoplastid chemical boxes of, 200 compounds each were assembled, encompassing a wide 
variety of potential targets, such as kinases, proteases, and cytochromes as well as potential 
host-pathogen interaction targets. After the setup of the three chemical boxes, they were 
made public with all the relevant data to encourage the search for new potent drugs. These 
chemical boxes prompted us to apply for Schistosoma mansoni based on the basic idea that, 
like T. cruzi, T. brucei and L. donovani, Schistosoma mansoni is a parasite with a complex life 
cycle during which many morphological changes are expected that may be partially 
determined by epigenetic modulators. In our attempt to identify smSIRT2 inhibitors (perhaps 
with the help of our collaborator Prof. Jung), the three chemical boxes were then tested on 
smSirt2 and, from the assays carried out, some compounds are emerged with a discrete 
activity on the target enzyme. We thus decided to work on a particular compound: TCMDC-
143295 (Fig. 7.1), as the starting point for development of novel smSIRT2 inhibitors. TCMDC-
143295 is a pyrimido[4,5-d]pyrimidine with three amino groups, one of which in turn 
substituted, of which an IC50 value of 23.7 ± 9.6 μM was calculated that we considered it to 
be a good starting point for our next optimization work. All biological evaluations have been 
done at Prof. Jung’s lab at the Institute of Pharmacy, Albert-Ludwigs-Universty of Freiburg, 
Germany. 
 
Fig. 7.1: Chemical structure of TCMDC-143295 
Starting from the prototype, we decided to synthesize analogues characterized by a 
simplified structure. Being the starting molecule characterized by a structure that is already 
quite important from the point of view of dimensions, it was thought to embark on a 
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"molecular striptease" pathway that, through progressive de-construction, would allow us to 
identify analogues with the smallest molecular portion that retain or improve the inhibitory 
activity against smSirt2. In particular, the idea was to maintain the pyrimido[4,5-d]pyrimidine 
portion (which could be important for the activity, perhaps mimicking the adenosine portion 
of NAD+) with the two free amine groups. 
Extensive structure-activity relationship (SAR) studies have been applied on the N7-(1-(4-
(4-methoxyphenoxy)phenyl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine 
(TCMDC-143295) to obtain new hit compounds showing potent and selective inhibition of 
smSirt2. In particular, in a first stage of the project, the influence of substituents at the N7 
position of the bispyrimidine ring of TCMDC-143295 has been explored by replacing the 
substituents on the prototype basically by substituents with smaller structures (Table 7.1). In 
general, the newly synthesized analogues in this attempt can be represented by four groups: 
(i) the N7 position of the bispyrimidine is a primary amine, i.e., no substituents (2, MC4222), 
(ii) the N7 position of the bispyrimidine is a secondary amine, i.e., no methyl group at the N7 
position (3-7, MC4262, MC4261, MC4189, MC4234, MC4265); (iii) the N7 position of the 
bispyrimidine is a tertiary amine and is a part of a cyclic structure (8-11, MC4232, MC4235, 
MC4269, MC4236); and (iv) the N7 position of the  bispyrimidine is a tertiary amine, i.e., with 
methyl group at the N7 position, (1, 12-17, MC4223, MC4268, MC4180, MC4210, MC4231, 
MC4211, MC4233). 
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Table 7.1: The newly synthesised dervatives in the first round of optimazation 
 
Sr.
No 
Lab 
code R1 R2 Structure 
1 MC4223 CH3 
 
 
2  MC4222 H H 
 
3  MC4262 H CH3 
 
4  MC4261 H 
 
 
5  MC4189 H 
 
 
6 
 
 
MC4234 
H 
 
7  MC4265 H 
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Sr. 
No 
Lab 
code 
 
Structure 
8 MC4232 1,2,3,4-tetrahydroisoquinoline 
 
 
9 MC4235 2-methylpiperidine 
 
10 MC4269 2-phenylpiperidine 
 
11 MC4236 1-phenylpiperazine 
 
 
S.N
o 
Lab 
code R1 R2 Structure 
12 MC4268 CH3 
 
 
13 MC4180 CH3 
 
 
14 
 MC4210 CH3 
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 Surprisingly, when the final compounds were subjected to enzymatic assays for their 
inhibitory activity of smSIRT2 and hSIRT2 at Prof. Jung's laboratory, we noticed that majority 
of the newly synthesized compounds displayed no activity against both smSIRT2 and hSirt2 
inhibition. Only MC4233 and MC4211 showed some activity against smSIRT2. From this 
attempt, we learnt that smaller substituents or no substituents at N7 position of the 
bispyrimidine yielded analogues devoid of activity. Though the changes made to the 
prototype did not allow derivative with better activity against smSIRT2, on the other hand, 
this attempt highlights the core SARs of the molecule which intern could be useful input for 
the next optimization process. In particular, it was possible to notice that the diphenyl ether 
portion is indispensable for activity against the parasite’s enzyme as well as presence of para 
methoxy in the second phenyl moiety.  
In light of the above observations, in the second part of the project, we decided to keep 
the N7-methyl. Indeed, the alpha carbon at N7 position has been replaced with larger steric 
groups compared the prototype to increase molecular constraint while the portion of 
diphenyl ether, given its importance, remained almost unchanged, though we investigate the 
effect of other heteroatoms instead of oxygen, or increasing the linkage or replacing the 
second phenyl with bulky groups (Table 7.2). Thus, in the second round of modification, we 
decided to keep the methyl group at N7 position of the bispyrimidine (R1 = CH3), except in the 
case of MC4314 (R1 = H), in any way we did modification at four regions of the molecule (Fig. 
7.2): (i) removing the methyl group at N7 position of the bispyrimidine (18, MC4314);  (ii) 
introduction of bulky groups at α-carbon of the N7 position of bispyrimidine (R2), i.e., replacing 
15 MC4231 CH3 
 
16 MC4211 CH3 
 
17 
 
 
MC4233 CH3 
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methyl group by ethyl (19, MC4315), isopropyl (20, MC4313) or phenyl (21, MC4318) group; 
(iii) substitution of the oxygen linkage between the two phenyls (X) by sulfur (22, MC4304) or 
nitrogen (23, MC4316); or increase this linkage by one carbon (24, MC4320); (iv) substitution 
of  the 4-methoxyphenyl part the molecule (R3) by 3,4-dimethoxyphenyl (25, MC4310), 3,5-
dimethoxyphenyl (26, MC4319), 3,4,5-trimethoxyphenyl (27, MC4309), 4-
trifluorommethoxyphenyl (28, MC4311), 3-methoxyphenyl (29, MC4298), 4-benzoxyphenyl 
(30, MC4312), or 4-methoxynaphthalenyl (31, MC4323). 
 
Fig. 7.2: Designed analogues for the second round of optimization 
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Table 7.2: The newly synthesised dervatives in the second round of optimazation 
 
Sr.
N
o 
Cpd R1 R2 X R3 Structures 
1 MC4223 Me Me O 4-MeOPh 
 
18 MC4314 H Me O 4-MeOPh 
19 MC4315 Me Et O 4-MeOPh 
 
20 MC4313 Me i-Pr O 4-MeOPh 
21 MC4318 Me Ph O 4-MeOPh 
22 MC4304 Me Me S 4-MeOPh 
23 MC4316 Me Me N 4-MeOPh 
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7.2 Chemistry 
The final compounds (1, 3-31) were prepared from condensation of the free base 
guanidine and the key pyrimidine intermediates (33, 35a-e, 37a-d, 48a-v) that are 
appropriately substituted at N2 position of the pyrimidine ring according to Scheme 1. While 
24 MC4320 Me Me CH2O 4-MeOPh 
25 MC4310 Me Me O 
3,4-
(MeO)2Ph 
 
 
26 MC4319 Me Me O 
3,5-
(MeO)2Ph 
 
27 MC4309 Me Me O 
3,4,5-
(MeO)3Ph 
 
28 MC4311 Me Me O 4- F3COPh 
29 MC4298 Me Me O 3-MeOPh 
 
30 MC4312 Me Me O 4-BnOPh 
 
31 MC4323 Me Me O 
4-
Methoxyna
phthalen-1-
yl 
Store all compounds at -20 °C and dissolve them in DMSO. 
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compound 2 was prepared by refluxing guanidine and the unsubstituted pyrimidine (33), 
which in turn was prepared from 4-amino-2-bromopyrimidine-5-carbonitrile (32) by treating 
with 7 M methanolic solution of NH3. On the other hand, the displacement reaction between 
32 and the commercially available amines (34a-e and 36a-d) in 2-MeOEtOH in the presence 
of Et3N afforded the intermediates 35a-f and 37a-d, respectively. Similar displacement 
reaction between 32 and 47a-v also gave the intermediates 48a-v. Except compound 47b and 
g, which are commercially available, the other amines (47a,c-f, and h-v) were synthesized 
starting from the appropriately substituted carbonyl compounds (40, 43a-e and 46a-n) by 
treating with a 2 M solution methylamine in anhydrous MeOH in the presence of   Ti(Oi-Pr)4 , 
and a subsequent addition of the reducing agent NaBH4 yielded the aforementioned amine 
intermediates (Scheme 2). While compound 40 and 43a-e are commercially available, 
compounds 46a-n are prepared according to Scheme 2 using three different procedures 
based on the nature of the connection unit (X). Compounds 46a-k, having oxygen/sulfur as 
connecting unit (X = O, S), were synthesized from the appropriate naphthols/phenols (44a-h) 
and para-fluoro substituted ketones (45a-c) in the presence of anhydrous K2CO3 in dry DMF, 
while 1-(4-((4-methoxybenzyl)oxy)phenyl)ethan-1-one (46l), -CH2O- as connecting unit, was 
prepared by refluxing 1-(bromomethyl)-4-methoxybenzene (38) and 1-(4-
hydroxyphenyl)ethan-1-one (39) together with K2CO3 and NaI in dry CH3CN. Finally, the 
reaction of 4-methoxyaniline (41) and 1-(4-bromophenyl)ethan-1-one (42) in the presence of 
K2CO3, Pd2(dba)3 and Xphos in dry toluene yielded 1-(4-((4-
methoxyphenyl)amino)phenyl)ethan-1-one (46m). Table 7.3. depicts the chemical and physical 
data of the final compounds. 
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Scheme 1a 
 
 
a Reagents and conditions: (a) 7M methanolic NH3, TEA, 2-MeOEtOH, 80 °C; (b) TEA, 2-MeOEtOH, 80 °C, 
2.5 h; (c) guanidine, dry 2-MeOEtOH, 150 °C, 4.5 h 
Scheme 2a 
 
 
 
126 
 
R2
HN
R3
47a-v
R
R2
O
F
45a-d
X = O,S,NH,CH2OFor the phenyl (R1= 4-MeO, 4- F3CO, 
4-BnO, 3-MeO, 3,4-(MeO)2, 
3,5-(MeO)2, 3,4.5-(MeO)3)
For the naphthalenyl (R1= 4-MeO)
R2 = Me,Et, i-Pr, Ph
CH3
O
R4
R4 = Ph, MeO, PhO,
(MeO)PhO
43a-e
44a-h
46a-n
d
d
CH3
O
Br
NH2
MeO +
c
CH3
O
HOMeO
+
b
Br
+
a
CHO
O
H3CO
d
X
R1OH/SH
R1
R2
O
38 39 40
41 42
R3= H, Me
 
a Reagents and conditions: (a) K2CO3, dry DMF, 175 °C; (b) K2CO3, NaI, dry CH3CN, 95 °C, 2.5 h; (c) 
K2CO3, Pd2(dba)3, Xphos, dry toluene, 140 °C, 48 h; (d) (i) 2M methylamine, Ti(Oi-Pr)4, dry MeOH, N2, 
5.5 h, rt; (ii) NaBH4, 0 °C-rt. 
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Table 7.3. Physico-chemical data of compounds 1-31 
Sr.
No Cpd Structure MW Mpt (°C) Yield (%) 
1 MC4223 
 
417.47 181-184 60.0 
2  MC4222 
 
 
177.17 
 
>300 
 
68.5 
3  MC4262 
 
 
191.20 
 
>300 
 
70.1 
4  MC4261 
 
 
267.30 
 
>300 
 
75.4 
 
5  MC4189 
 
 
281.32 
 
>300 
 
68.3 
6 
 
 
MC4234 
 
 
 
297.32 
 
 
>300 
 
 
82.7 
7  MC4265 
 
 
350.43 
 
205-208 
 
75.3 
8  MC4232 
 
 
293.33 
 
278-280 
 
70.6 
 
9 
 
MC4235 
 
 
259.32 
 
>300 
 
52.8 
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10  MC4269 
 
 
321.39 
 
188-190 
 
61.1 
11 
 
 
MC4236 
 
 
 
322.38 
 
 
>300 
 
 
62.8 
12 
 
 
MC4268 
 
 
 
371.45 
 
 
>300 
 
 
57.1 
13  MC4180 
 
 
281.323 
 
275-277 
 
65.2 
14 
 
 
MC4210 
 
 
295.350 
 
192-194 
 
76.8 
15  MC4231 
 
 
325.376 
 
184-187 
 
60.1 
 
 
16  MC4211 
 
 
387.45 
 
185-187 
 
41.9 
17 
 
 
MC4233 
 
 
 
 
403.45 
 
 
244-247 
 
 
68.0 
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18 MC4314 
 
403.45 > 300 82.5 
19 MC4315 
 
431.50 186-190 60.7 
20 MC4313 
 
445.53 162-167 64 
21 MC4318 479.54 248-250 58.8 
22 MC4304 
 
433.53 160-163 72.9 
23 MC4316 
 
416.49 146-149 52.1 
24 MC4320 
 
431.50 225-228 78.1 
25 MC4310 
 
447.50 185-188 69.2 
26 MC4319 
 
447.50 233-235 75.6 
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7.3 Experimental Section  
Chemistry: melting points were determined on a Buchi 530 melting point apparatus. 1H-
NMR spectra were recorded at 400 MHz using a Bruker AC 400 spectrometer; chemical shifts 
are reported in δ (ppm) units relative to the internal reference tetramethylsilane (Me4Si). 
Mass spectra were recorded on a API-TOF Mariner by Perspective Biosystem (Stratford, Texas, 
USA), samples were injected by an Harvard pump using a flow rate of 5−10 μL/min, infused in 
the Electrospray system. All compounds were routinely checked by TLC and 1H-NMR. TLC was 
performed on aluminum-backed silica gel plates (Merck DC, Alufolien Kieselgel 60 F254) with 
spots visualized by UV light or using a KMnO4 alkaline solution. All solvents were reagent 
grade and, when necessary, were purified and dried by standard methods. Concentration of 
solutions after reactions and extractions involved the use of a rotary evaporator operating at 
reduced pressure of ~ 20 Torr. Organic solutions were dried over anhydrous sodium sulfate. 
Elemental analysis has been used to determine purity of the described compounds, that is > 
95%. Analytical results are within 0.40% of the theoretical values. All chemicals were 
purchased from Sigma Aldrich s.r.l., Milan (Italy) or from TCI Europe N.V., Zwijndrecht 
(Belgium), and were of the highest purity. As a rule, samples prepared for physical and 
27 MC4309 
 
477.53 172-176 67.1 
28 MC4311 
 
471.44 140-143 58.3 
29 MC4298 
 
417.47 152-154 47.4 
30 MC4312 
 
493.57 129-132 77.8 
31 MC4323 
 
467.53 >300 71.9 
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biological studies were dried in high vacuum over P2O5 for 20h at temperatures ranging from 
25 to 40 °C, depending on the sample melting point. 
General procedure for the synthesis of intermediates 46a-e and h-n. Example:  1-(4-(4-
(benzyloxy)phenoxy)phenyl)ethan-1-one (46m). 
 
A mixture of 4-(benzyloxy)phenol (44c) (1 eq, 2.5 mmol), 1-(4-fluorophenyl)ethan-1-one 
(45a) (1 eq., 2.5 mmol) and  K2CO3 (1.2 eq, 3 mmol) in anhydrous DMF (2.5 mL) was refluxed 
at 175 °C. After 2 h, another 0.2 eq. of 45a and 0.25 eq. of K2CO3 were added and further 6 h 
stirring the reaction was completed and stopped by quenching with 20 mLof NaClss. 
Subsequently, extraction with EtOAc (5 x 20 mL) and washed with NaClss (2 x 5 mL) of NaClss. 
The organic phase thus was dried over Na2SO4, filtered and evaporated. The crude was 
subjected to SiO2 column purification using a mobile phase consisting of EeOAc/PE (1: 7) to 
afford 46m as a white solid. Yield = 70.8% 
General procedure for the synthesis of intermediate: 1-(4-((4-
methoxyphenyl)amino)phenyl)ethan-1-one (46f). 
 
 
A mixture of 4-methoxyaniline (41) (1.2 eq, 3.014 mmol, 5 mL) and 4-(4-
bromophenyl)ethan-1-one (42) (1 eq, 2.5 mmol) in the presence of K2CO3, Pd2(dba)3 and 
Xphos in dry toluene was refluxed at 140 °C and left to stir for 48h. After this time, the reaction 
was stopped and diluted with 20 mL of EtOAc. Then the mixture was filtered using double 
filter paper with subsequent washing with chloroform. The combined organic phase was 
evaporated and the resulting crude was purified Chromatographed using SiO2 with eluent of 
EtOA/Hexane/CHCl3 (15:70:15) to afford 46f as a dark-brown oil. Yield: 66.01% 
General procedure for the synthesis of intermediate: 1-(4-((4-
methoxyphenyl)amino)phenyl)ethan-1-one (46g). 
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A mixture of 4 (methoxy)benzyl bromide (38) (1.2 eq., 3.6 mmol.) and 1-(4-
hydroxyphenyl)ethan-1-one (39) (1 eq, 3 mmol) in anhydrous CH3CN (15 mL) was reacted in 
the presence of  K2CO3 (1.5 eq, 4.5 mmol) and NaI (1.1 eq, 3.3 mmol) at 95 °C. After 5 h, the 
reaction was finished and quenched with 20 mL of water. Following extraction with EtOAc (5 
x 20 mL) and washing with NaClss (2 x 5 mL), the organic layer was dried over Na2SO4, filtered 
and evaporated. The crude was subjected to SiO2 column purification using a mobile phase 
consisting of EeOAc/PE (1:8) to afford 46g as a white solid. Yield = 57.58%. 
General procedure for the synthesis of intermediates 47a, c-f, and h-v. Example:  N-
methyl-1- (4-phenoxyphenyl) ethan-1-amine (47d). 
 
A mixture of 1- (4-phenoxyphenyl) ethan-1-one (43c) (1 eq, 2 mmol), methylamine 2 M 
in methanol (3 eq, 6 mmol) and Ti(Oi-Pr)4 (1.3 eq., 2.6 mmol) in anhydrous methanol (5 ml) 
was reacted under nitrogen and rt for 5 h 30min, subsequently, NaBH4 (1.1eq, 2.2mmol) was 
added at 0 °C and kept the reaction string at rt for another 2 h. Then, the reaction was stopped 
by quenching with distilled H2O (20 mL) and acidified with 1M HCl (12 mL) until a pH of 1-2. 
The resulting suspension was filtered on celite and washed with a mixture of water and EtOAc. 
The filtrate was extracted with 20 ml of EtOAc. Following basification of the aqueous layer to 
pH 10-12 using 10% NaOH (5 mL), it was further extracted with EtOAc (3 x 30 mL). The 
combined EtOAc layer was dried over anhydrous Na2SO4, filtered and evaporated. The 
resulting oily crude was then purified by silica chromatography eluting with a mixture of 
CHCl3: MeOH: NH3 (45: 1: 0.1) to obtain the pure N-methyl-1-(4-phenoxyphenyl)ethan-1-
amine (47d) as an oil. 
 
 
133 
 
General procedure for the synthesis of intermediates 35a-f, 37a-d, 48a-v. Example:  4-
amino-2- (methyl (1-(4-phenoxyphenyl) ethyl)amino)-pyrimidine-5-carbonitrile (48d). 
 
N-methyl-1- (4-phenoxyphenyl) ethan-1-amine (47d) (1.2 eq, 1.2 mmol), 4-amino-2-
bromopyrimidine-5-carbonitrile (32) (1 eq, 1.0 mmol), TEA (1.6 eq, 1.6 mmol) and 2-MeOEtOH 
(2.0 mL, equal to [c] = 0.5 M) were added to a vial and heated at 80 ° C. After 2.5h, the reaction 
was stopped and transferred into round bottom flask and evaporated. To the crude 60 mL of 
EtOAc was added and washed with 0.1 N KHSO4 (2x3 mL) counter extracted with EtOAc. The 
combined organic layer was dried over Na2SO4, filtered and evaporated. The crude was 
purified by silica column eluting with a mixture of CHCl3:n-Hexane (80:20) to give 4-amino-2-
(methyl(1-(4-phenoxyphenyl)ethyl)amino)pyrimidine-5-carbonitrile (48d). 
Synthesis of the intermediate of 2,4-diaminopyrimidine-5-carbonitrile (33) 
 
A mixture of 7 M methanolic solution of NH3 (1.3 eq), 4-amino-2-bromopyrimidine-5-
carbonitrile (32) (1.0 eq), TEA (1.6 eq) and 2-MeOEtOH (2 mL) was refluxed at 80 ° C in a vial 
for 2.5 h. The reaction content was transferred into round bottom flask and evaporated and 
dissolved with 60 mL of EtOAc, followed by washing with 0.1 N KHSO4 (2x3 mL) and counter 
extraction with EtOAc. The combined organic layer was dried over Na2SO4, filtered and 
evaporated to give a pure compound 33.  
General procedure for the synthesis of final compounds (1-30). Example:  Synthesis of 
N7-methyl-N7- (1- (4-phenoxyphenyl) ethyl) pyrimido [4,5-d] pyrimidine-2,4,7-triamine (16) 
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4-Amino-2-(methyl (1-(4-phenoxyphenyl)ethyl) amino) pyrimidine-5-carbonitrile (42d) 
(1eq, 0.829 mmol) was reacted with a 0.73M free base guanidine solution (3.5 eq, 2.901 
mmol) in 2-MeOEtOH anhydrous previously prepared. The reaction is conducted in an oil bath 
at a temperature of 150 ° C. After 4.5 h, the reaction content was transferred into a round 
bottom flask and evaporated. To the crude 10 mL of distilled H2O are added and the extracted 
with EtOAc (5x40 mL). The organic phase was dried over Na2SO4, filtered and evaporated. The 
resulting crude was purified by silica column eluting with a mixture of CHCl3:MeOH:NH3 
(20:1:0.1).After trituration with Et2O and string for 45 minutes, it was filtered to yield a pure 
N7-methyl-N7- (1- (4-phenoxyphenyl) ethyl) pyrimido[4,5-d] pyrimidine-2,4,7-triamine (16) as 
white solid. 1H NMR (400 MHz, DMSO- d6) δ 8.96 (s, 1H, CH pyrimidine), 7.40-7.30 (m, 6H, 
NH2 in pos. 4 pyrimido-pyrimidine and CH aromatic), 7.15-7.11 (m, 1H, CH aromatic), 7.01-
6.97 (m, 4H, CH aromatic), 6.49 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 6.30 (m, 1H, 
CHCH3), 2.84 (s, 3H, N-CH3), 1.53 (d, 3H, CHCH3). MS (ESI) m/z: 378.18 [M]+. 
N7-(1-(4-(4-Methoxyphenoxy)phenyl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-
2,4,7-triamine (1, 4223). 1H NMR (400 MHz, DMSO- d6) δ 8.95 (s, 1H, CH pyrimidine), 7.54 (s, 
2H, NH2 in pos. 4 pyrimido-pyrimidine), 7.27-7.25 (m, 2H, CH aromatic), 7.00-6.94 (m, 4H, CH 
aromatic), 6.90-6.87 (m, 2H, CH aromatic), 6.49 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 
6.28 (m, 1H, CHCH3), 3.74 (s, 3H, OCH3), 2.82 (s, 3H, N-CH3), 1.51 (d, 3H, CHCH3), MS (ESI) m/z: 
417.19 [M]+. 
Pyrimido[4,5-d]pyrimidine-2,4,7-triamine (2, MC4222). 1H NMR (400 MHz, DMSO- d6) δ 
8.86 (s, 1H, CH pyrimidine), 7.31 (s, 2H, NH2 in pos. 4 pyrimido-pyrimidine), 6.71 (s, 2H, NH2 
in pos. 7 pyrimido-pyrimidine), 6.44 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), MS (ESI) m/z: 
177.08 [M]+. 
N7-Methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine (3, MC4262). 1H NMR (400 MHz, 
DMSO- d6) δ 8.85 (s, 1H, C-H pyrimidine), 7.3-7.1 (m, 3H, NH + NH2 in pos. 4 pyrimido-
pyrimidine), 6.45 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 2.8 (s, 3H, NHCH3), MS (ESI) m/z: 
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191.09 [M]+. 
N7-Benzylpyrimido[4,5-d]pyrimidine-2,4,7-triamine (4, MC4261). 1H NMR (400 MHz, 
DMSO- d6) δ 8.85 (s, 1H, CH pyrimidine), 7.8 (sb, 1H, NH) 7.40-7.20 (m, 7H, NH2 in pos. 4 
pyrimido-pyrimidine + CH aromatic), 6.4 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 4.5 (s, 2H, 
CH2), MS (ESI) m/z: 267.12 [M]+. 
N7-(1-Phenylethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine (5, MC4189). 1H NMR (400 
MHz, DMSO- d6) δ 8.85 (s, 1H, CH pyrimidine), 7.81-7.79 (sb, 1H, NH) 7.39-7.37 (m, 2H, NH2 
in pos. 4 pyrimido-pyrimidine), 7.30-7.27 (m, 4H, CH aromatic), 7.19-7.16 (m, 1H, CH 
aromatic), 6.44 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 5.14 (m, 1H, CHCH3), 1.42 (d, 3H, 
CHCH3), MS (ESI) m/z: 281.14 [M]+. 
N7-(4-Methoxybenzyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine (6, MC4234). 1H NMR 
(400 MHz, DMSO-d6) δ 8.86 (s, 1H, CH pyrimidine), 7.67 (sb, 1H, NH) 7.31-7.24 (m, 4H, NH2 in 
pos. 4 pyrimido-pyrimidine + CH aromatic), 6.86-6.84 (m, 2H, CH aromatic), 6.46 (s, 2H, NH2 
in pos. 2 pyrimido-pyrimidine), 4.43-4.41 (m, 2H, CH2), 3.60 (s, 3H, OCH3), MS (ESI) m/z: 297.13 
[M]+. 
N7-(1-Benzylpiperidin-4-yl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine (7, MC4265). 1H 
NMR (400 MHz, DMSO- d6) δ 8.84 (s, 1H, CH pyrimidine), 7.35-7.29 (m, 5H, NH + NH2 in pos. 
4 pyrimido-pyrimidine + CH aromatic), 7.27-7.26 (m, 2H, CH aromatic) 7.25-7.18 (m, 1H, CH 
aromatic), 6.40 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 3.74 (s, 1H, CH piperidine), 3.46 (s, 
2H, CH2-Ph), 2.81-2.79 (m, 2H, CH2 piperidine), 2.01 (t, 2H, CH2 piperidine), 1.84-1.82 (m, 2H, 
CH2 piperidine), 1.54-1.46 (m, 2H, CH2 piperidine), MS (ESI) m/z: 350.20 [M]+. 
7-(3,4-Dihydroisoquinolin-2(1H)-yl)pyrimido[4,5-d]pyrimidine-2,4-diamine (8, 
MC4232). 1H NMR (400 MHz, DMSO- d6) δ 8.97 (s, 1H, CH pyrimidine), 7.43 (s, 2H, NH2 in pos. 
4 pyrimido-pyrimidine), 7.25-7.18 (m, 4H, CH aromatic), 6.51 (s, 2H, NH2 in pos. 2 pyrimido-
pyrimidine), 4.92 (s, 2H, CH2 piperidine), 4.03 (t, 2H, CH2 piperidine), 2.86 (t, 2H, CH2 
piperidine), MS (ESI) m/z: 293.14 [M]+. 
7-(2-Methylpiperidin-1-yl)pyrimido[4,5-d]pyrimidine-2,4-diamine (9, MC4235). 1H 
NMR (400 MHz, DMSO- d6) δ 8.90 (s, 1H, CH pyrimidine), 7.34 (s, 2H, NH2 in pos. 4 pyrimido-
pyrimidine), 6.43 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 5.10 (m, 1H, CH piperidine), 4.69-
4.66 (m, 1H, CH pyrimidine), 2.92-2.85 (m, 1H, CH piperidine), 1.70-1.58 (m, 5H, CH 
piperidine), 1.38-1.24 (m, 1H, CH piperidine), 1.14 (d, 3H, CHCH3), MS (ESI) m/z: 259.15 [M]+. 
 
 
136 
 
7-(2-Phenylpiperidin-1-yl)pyrimido[4,5-d]pyrimidine-2,4-diamine (10, MC4269). 1H 
NMR (400 MHz, DMSO- d6) δ 8.93 (s, 1H, CH pyrimidine), 7.40 (sb, 2H, NH2 in pos. 4 pyrimido-
pyrimidine), 7.35-7.32 (m, 2H, CH aromatic), 7.23-7.18 (m, 3H, CH aromatic), 6.48 (s, 2H, NH2 
in pos. 2 pyrimido-pyrimidine), 6.19 (m, 1H, CH piperidine), 4.84-4.81 (m, 1H, CH piperidine), 
2.84-2.81 (m, 1H, CH piperidine), 2.45-2.41 (m, 1H, CH piperidine), 1.84 (m, 1H, CH piperidine), 
1.63-1.61 (m, 2H, CH2 piperidine), 1.48-1.36 (m, 2H, CH2 piperidine), MS (ESI) m/z: 321.17 
[M]+. 
7-(4-Phenylpiperazin-1-yl)pyrimido[4,5-d]pyrimidine-2,4-diamine (11, MC4236). 1H 
NMR (400 MHz, DMSO- d6) δ 8.96 (s, 1H, CH pyrimidine), 7.43 (s, 2H, NH2 in pos. 4 pyrimido-
pyrimidine), 7.26-7.22 (m, 2H, CH aromatic) 7.01-6.99 (m, 2H, CH aromatic), 6.83-6.79 (m, 1H, 
CH aromatic), 6.52 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 3.95 (m, 4H, CH2 piperazine), 
3.20-3.19 (m, 4H, CH2 piperazine), MS (ESI) m/z: 322.17 [M]+. 
N7-(1-([1,1'-Biphenyl]-4-yl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine 
(12, MC4268). 
1H NMR (400 MHz, DMSO- d6) δ 8.97 (s, 1H, CH pyrimidine), 7.66-7.63 (m, 4H, NH2 in pos. 
4 pyrimido-pyrimidine + CH aromatic), 7.48-7.39 (m, 7H, CH aromatic), 6.51 (s, 2H, NH2 in pos. 
4 pyrimido-pyrimidine), 6.35 (s, 1H, CHCH3), 2.87 (s, 3H, N-CH3), 1.59 (d,3H, CHCH3), MS (ESI) 
m/z: 371.19 [M]+. 
N7-Benzyl-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine (13, MC4180). 1H NMR 
(400 MHz, DMSO- d6) δ 8.94 (s, 1H, CH pyrimidine), 7.33-7.24 (m, 7H, NH2 in pos. 4 pyrimido-
pyrimidine + CH aromatic), 6.49 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 4.90 (s, 2H, CH2), 
3.09 (s, 3H, N-CH3), MS (ESI) m/z: 281.14 [M]+. 
N7-Methyl-N7-(1-phenylethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine (14, 4210). 1H 
NMR (400 MHz, DMSO- d6) δ 8.96 (s, 1H, CH pyrimidine), 7.34-7.28 (m, 7H, NH2 in pos. 4 
pyrimido-pyrimidine and CH aromatic), 6.48 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 6.32-
6.31 (m, 1H, CHCH3), 2.82 (s, 3H, N-CH3), 1.54 (d, 3H, CHCH3), MS (ESI) m/z: 295.15 [M]+. 
N7-(1-(4-Methoxyphenyl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine 
(15, MC4231). 1H NMR (400 MHz, DMSO- d6) δ 8.95 (s, 1H, CH pyrimidine), 7.40-7.39 (s broad, 
2H, NH2 in pos. 4 pyrimido-pyrimidine), 7.22-7.20 (m, 2H, CH aromatic), 6.90-6.88 (m, 2H, CH 
aromatic), 6.48 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 6.26 (s, 1H, CHCH3), 3.73 (s, 3H, 
OCH3) 2.78 (s, 3H, N-CH3), 1.49 (d, 3H, CHCH3), MS (ESI) m/z: 325.17 [M]+. 
N7-(4-(4-Methoxyphenoxy)benzyl)-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-
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triamine (17, MC4233). 1H NMR (400 MHz, DMSO- d6) δ 8.94 (s, 1H, CH pyrimidine), 7.54-
7.23 (m, 4H, NH2 in pos. 4 pyrimido-pyrimidine + CH aromatic), 6.99-6.86 (m, 6H, CH aromatic), 
6.50 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 4.85 (s, 2H, CH2), 3.74 (s, 3H, OCH3), 3.08 (s, 
3H, N-CH3), MS (ESI) m/z: 403.18 [M]+. 
N7-(1-(4-(4-Methoxyphenoxy)phenyl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine 
(18, MC4314). 1H NMR (400 MHz, DMSO-d6) δ 8.85 (s, 1H, CH pyrimidine), 7.78-7.768 (m, 1H, 
NH), 7.36-733 (d, 4H, CH aromatic), 6.98-6.85, (m, 4H, aromatic CH), 6.85-6.83 (d, 2H, NH2 in 
pos. 4 pyrimido-pyrimidine), 6.45 (s, 2H, NH2 in pos. 2 pyrimido-pyrimidine), 5.13 (m, 1H, 
CHCH3), 3.91 (s, 3H, OCH3) 1.42 (s, 3H, CHCH3), MS (ESI) m/z: 403.18 [M]+. 
N7-(1-(4-(4-Methoxyphenoxy)phenyl)propyl)-N7-methylpyrimido[4,5-d]pyrimidine-
2,4,7-triamine (19, MC4315). 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 1H, CH pyrimidine), 
7.38-7.30 (d, 4H, CH arom.), 7.00-6.94 (m, 4H, aromatic CH), 6.89-6.86 (d, 2H, NH2 in pos. 4 
pyrimido-pyrimidine), 6.48 (sb, 2H, NH2 in pos. 2 pyrimidopyrimidine), 6.01 (d, 1H, CHCH2CH3), 
3.74 (s, 3H, OCH3), 2.82-2.79 (m, 3H, N-CH3), 2.07-1.89 (m, 2H, CH2CH3), 0.86 (m, 3H, CH2CH3), 
MS (ESI) m/z: 431.21 [M]+. 
N7-(1-(4-(4-Methoxyphenoxy)phenyl)-2-methylpropyl)-N7-methylpyrimido[4,5-
d]pyrimidine-2,4,7-triamine (20, MC4313). 1H NMR (400 MHz, DMSO-d6) δ 8.95-8.91 (d, 1H, 
CH pyrimidine), 7.42-7.36 (m, 4H, CH arom.), 7.00-6.93 (m, 4H, aromatic CH), 6.87-6.85 (d, 2H, 
NH2 in position 4 pyrimido-pyrimidine), 6.46 (sb, 2H, NH2 in pos. 2-pyrimidopyrimidine), 5.84-
5.81 (d, 1H, CH-iPr), 3.74 (s, 3H, OCH3), 2.89-2.81 (d, 3H, N-CH3), 2.51-2.50 (m, 1H CH-iPr), 
0.89-0.83 (m, 6H, CH3-iPr), MS (ESI) m/z: 445.22 [M]+. 
N7-((4-(4-Methoxyphenoxy)phenyl)(phenyl)methyl)-N7-methylpyrimido[4,5-
d]pyrimidine-2,4,7-triamine (21, MC4318). 1H NMR (400 MHz, DMSO-d6) δ 8.97 (s, 1H, CH 
pyrimidine), 7.43-7-23 (m, 6H, NH2 in pos. 4 pyrimidopyrimidine, CH aromatic), 7.18-7.13 (m, 
4H, CH aromatic), 7.04-6.90 (m, 6H, CH aromatic, CH-Ph), 6.52 (sb, 2H, NH2 in pos. 2 
pyrimidopyrimidine), 3.93 (s, 3H, OCH3), 2.89 (s, 3H, N-CH3), MS (ESI) m/z: 479.21 [M]+. 
N7-(1-(4-((4-Methoxyphenyl)thio)phenyl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-
2,4,7-triamine (22, MC4304). 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 1H, CH pyrimidine), 7.54 
(sb, 2H, NH2 in position 4 pyrimido-pyrimidine) 7.27-7.25 (m, 2H, CH aromatic), 7.00-6.94 (m, 
4H, aromatic CH), 6.90-6.87 (m, 2H, CH aromatic), 6.49 (sb, 2H, NH2 in position 2 pyrimido-
pyrimidine), 6.28 (m, 1H, CHCH3), 3.74 (s, 3H, OCH3), 2.82 (s, 3H, NCH3), 1.51 (s, 3H, CHCH3), 
MS (ESI) m/z: 433.17 [M]+. 
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N7-(1-(4-((4-Methoxyphenyl)amino)phenyl)ethyl)-N7-methylpyrimido[4,5-
d]pyrimidine-2,4,7-triamine (23, MC4316). 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 1H, CH 
pyrimidine), 7.83 (s, 1H, Ph-NH-Ph), 7.38-7.37 (sb, 2H, NH2 in pos. 4-pyrimidopyrimidine), 7.1-
7.08 (d, 2H, CH aromatic), 7.03-7.01 (d, 2H, CH aromatic, 6.89-6.83 (m, 4H, CH aromatic), 6.46 
(sb, 2H, NH2 in pos. 2 pyrimidopyrimidine), 6.23 (m, 1H, CHCH3), 3.70 (s, 3H, OCH3), 2.79 (s, 
3H, N-CH3) 1.47-1.46 (d, 3H, CHCH3), MS (ESI) m/z: 416.21 [M]+. 
N7-(1-(4-((4-Methoxybenzyl)oxy)phenyl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-
2,4,7-triamine (24, MC4320). 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 1H, CH pyrimidine), 
7.37-7.35 (d, 4H, CH aromatic), 7.21-7.20 (sb, 2H, NH2 in pos. 4-pyrimidopyrimidine), 6.96-
6.92 (t, 4H, CH arom.), 6.47 (sb, 2H, NH2 in pos. 2-pyrimidopyrimidine), 6.26 (m, 1H, CHCH3), 
4.99 (s, 2H, O-CH2-Ph) 3.76 (s, 3H, OCH₃), 2.79 (s, 3H, N-CH₃), 1.50-1.49 (d, 3H, CHCH₃), MS 
(ESI) m/z: 431.21 [M]+. 
N7-(1-(4-(3,4-Dimethoxyphenoxy)phenyl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-
2,4,7-triamine (25, MC4310). 1H NMR (400 MHz, DMSO-d6) δ 8.96 (s, 1H, CH pyrimidine), 7.39 
(sb, 2H, NH2 in pos. 4 pyrimidopyrimidine), 7.27-7.25 (sb, 2H, NH2 in position 2 pyrimido-
pyrimidine), 6.95-6.89 (m, 3H, CH aromatic), 6.74-6.73 (m, 1H, CH arom.), 6.53-6.48 (m, 3H, 
CH arom.), 6.29 (s, 1H, CHCH3), 3.74-3.72 (d, 6H, OCH3), 2.82 (s, 3H, N-CH3), 1.52-1.50 (d, 3H, 
CHCH3), MS (ESI) m/z: 447.20 [M]+. 
N7-(1-(4-(3,5-Dimethoxyphenoxy)phenyl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-
2,4,7-triamine (26, MC4319). 1H NMR (400 MHz, DMSO-d6) δ 8.96 (s, 1H, CH pyrimidine), 7.39 
(sb, 2H, NH2 in pos. 4 pyrimidopyrimidine) 7.31-7.29 (m, 2H, CH aromatic), 7.00-6.98 (m, 2H, 
CH aromatic), 6.48 (sb, 2H, NH2 in position 2 pyrimido-pyrimidine), 6.79-6.83 (m, 1H, CH 
arom.), 6.59-6.61 (m, 2H, CH arom.), 6.31 (s, 1H, CHCH3), 3.74-3.72 (d, 6H, OCH3), 2.82 (s, 3H, 
N-CH3), 1.52-1.50 (d, 3H, CHCH3),  MS (ESI) m/z: 447.20 [M]+. 
N7-Methyl-N7-(1-(4-(3,4,5-trimethoxyphenoxy)phenyl)ethyl)pyrimido[4,5-
d]pyrimidine-2,4,7-triamine (27, MC4309). 1H NMR (400 MHz, DMSO-d6) δ 8.96 (s, 1H, CH 
pyrimidine), 7.40 (sb, 2H, NH2 in pos. 4 pyrimidopyrimidine), 7.29-7.27 (d, 2H, CH aromatic), 
6.96-6.94 (m, 2H, CH aromatic), 6.48 (sb, 2H, NH2 in pos. 2 pyrimidopyrimidine), 6.39 (s, 2H, 
CH aromatic), 6.30 (m, 1H, CHCH3), 3.71 (s, 6H, m-OCH3), 3.63 (s, 3H, p-OCH3), 2.82 (s, 3H, N-
CH3), 1.52-1.51 (d, 3H, CHCH3), MS (ESI) m/z: 477.21 [M]+. 
N7-Methyl-N7-(1-(4-(4-(trifluoromethoxy)phenoxy)phenyl)ethyl)pyrimido[4,5-
d]pyrimidine-2,4,7-triamine (28, MC4311). 1H NMR (400 MHz, DMSO-d6) δ 8.96 (s, 1H, CH 
 
 
139 
 
pyrimidine), 7.38-7.32 (m, 6H, NH2 in position 4 pyrimidopyrimidine, CH arom.), 7.10-7.03 (m, 
4H, CH arom.), 6.49 (sb, 2H, NH2 in pos. Pyrimidopyrimidine), 6.31 (sb, 1H, CHCH3), 2.85 (s, 
3H, N-CH3), 1.54-1.53 (m, 3H, CHCH3), MS (ESI) m/z: 471.16 [M]+. 
N7-(1-(4-(3-Methoxyphenoxy)phenyl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-
2,4,7-triamine (29, MC4298). 1H NMR (400 MHz, DMSO-d6) δ 8.94 (s, 1H, CH pyrimidine), 7.54 
(s, 2H, NH2 in position 4 pyrimido-pyrimidine) 7.27-7.25 (m, 2H, CH aromatic), 7.00-6.94 (m, 
4H, aromatic CH), 6.90-6.87 (m, 2H, CH aromatic), 6.49 (s, 2H, NH2 in position 2 pyrimido-
pyrimidine), 6.28 (m, 1H, CHCH3), 3.74 (s, 3H, OCH3), 2.82 (s, 3H, N-CH3), 1.51 (d, 3H, CHCH3), 
MS (ESI) m/z: 417.19 [M]+. 
N7-(1-(4-(4-(Benzyloxy)phenoxy)phenyl)ethyl)-N7-methylpyrimido[4,5-d]pyrimidine-
2,4,7-triamine (30, MC4312). 1H NMR (400 MHz, DMSO-d6) δ 8.96 (s, 1H, CH pyrimidine), 
7.47-7.38 (m, 5H, CH aromatic), 7.35-7.34 (d, 2H, NH2 in position 4 pyrimido-pyrimidine), 7.28-
7.25 (d, 2H, CH2 aromatic), 7.04-6.97 (m, 4H, aromatic CH), 6.90-6.88 (m, 2H, CH aromatic), 
6.48 (sb, 2H, NH2 in position 2 pyrimidopyrimidine), 6.28 (s, 1H, CHCH3), 5.08 (s, 2H, OCH2-
Ph), 2.81 (s, 3H, NCH3), 1.52-1.51 (d, 3H, CHCH3), MS (ESI) m/z: 493.22 [M]+. 
N7-(1-(4-((4-Methoxynaphthalen-1-yl)oxy)phenyl)ethyl)-N7-methylpyrimido[4,5-
d]pyrimidine-2,4,7-triamine (31, MC4323). 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 1H, CH 
pyrimidine) 8.21-8.19 (t, 1H, aromatic CH), 7.91-7.88 (t, 1H, aromatic CH), 7.587-53 (m, 2H, 
CH aromatic), 7.38 (sb, 2H, NH2 in position 4 pyrimidopyrimidine), 7.30-7.24 (t, 2H, CH arom.), 
7.09-7.07 (d, 1H, CH arom.), 6.96-6.89 (m, 3H, aromatic CH), 6.46 (sb, 2H, NH2 in pos. 2 
pyrimido-pyrimidine), 6.28 (m, 1H, CHCH3), 3.98 (s, 3H, OCH3), 2.82 (s, 3H, N-CH3), 1.51-1.49 
(d, 3H, CHCH3), MS (ESI) m/z: 467.21 [M]+. 
7.4 Biological evaluation, results and discussion 
The inhibitory effects of the newly synthesized compounds on smSirt2 and hSirt2 
deacetylase activity were tested through continuous fluorescence assay. The residual smSirt2 
and hSirt2 activity in presence of 25 µM of the candidate inhibitors was evaluated (Table 7.4).  
Table 7.4: Enzymatic inhibition of selected compounds derived from the prototype at 25 µM 
 Lab code Structure 
% inh. 
smSIRT2 at 
25 µM 
% inh. 
hSIRT2 at 25 
µM 
1 MC4223 
 
62.6% 
± 
1.1% 
IC50 =23.7 ± 
9.6 µM 
21.9% 
± 
0.6% 
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2  MC4222 
 
-14.1% 
± 
4.7% 
-16.4% 
± 
3.7% 
5  MC4189 
 
0.9% 
± 
7.2% 
-0.8% 
± 
4.4% 
6 
 
 
MC4234 
 
 
-13.7% 
± 
1.8% 
 
-18.35% 
± 
5.1% 
7 MC4265 
 
-7.9%  
 23.2 %  
 
8 
 
MC4232 
 
-4.4% 
± 
0.7% 
-5.2% 
± 
5.7% 
9  MC4235 
 
-6.6% 
± 
3.5% 
-3.9% 
± 
8.1% 
11 
 
 
MC4236 
 
 
-8.8% 
± 
8.7% 
 
-10.9% 
± 
5.6% 
12 
 
 
MC4268 
 
 
24.8%  
 
 
9.3% 
13  MC4180 
 
-0.5% 
± 
2.4% 
1.8% 
± 
3.7% 
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14  MC4210 
 
-1.1% 
± 
6.8% 
-4.4% 
± 
5.5% 
15 
 
 
MC4231 
 
 
3.2% 
± 
1.4 
 
-11.1% 
± 
4.6% 
16  MC4211 
 
27.6% 
± 
2.8% 
5.0% 
± 
4.5% 
 
 
17 
 
 
MC4233 
 
 
14.0 % 
± 
3.3% 
 
4.2% 
± 
0.1% 
18 MC4314 
 
37.5% 
 
 
21.0% 
19 MC4315 
 
 IC50 = 12.8 ± 
0.8 µM* 
 
 
49.6% 
20 MC4313 
 
37.9%  
 
 
57.4% 
21 MC4318 
 
IC50 = 2.34 ± 
0.2 µM* 
 
 
 63.4%  
 
22 MC4304 
 
IC50 =14.9 ± 
0.9 µM* 
 
 
45.9%  
 
23 MC4316 
 
52.9% 
 
 
 40.8% 
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24 MC4320 
 
 18.4% 
 
 
30.6% 
25 MC4310 
 
IC50 = 44.7± 
4.4 µM* 
 
 
35.3% 
 
26 MC4319 
 
IC50 = 12.5 ± 
1.1 µM* 
 
 
7.4% 
 
27 MC4309 
 
52.2%  
 
 
29.2% 
 
28 MC4311 
 
20.3% 
 
 
37.5% 
29 MC4298 
 
 IC50 = 23.1± 
1.4 µM* 
 
 
33.8% 
 
30 MC4312 
 
40.3% 
 
 
70.4% 
31 MC4323 
 46.2%  
 
 
61.7% 
Intermediate compounds tested along the final one 
 
48g 
 
MC4238 
 
2.0% 
± 
2.6% 
-18.1% 
± 
7.6% 
 
47c 
 
MC4239 
 
-9.9% 
± 
1.1% 
4.9% 
± 
0.6% 
In the first part of this project, extensive structure-activity relationship (SAR) studies have 
been applied on the N7-(1-(4-(4-methoxyphenoxy)phenyl)ethyl)-N7-methylpyrimido[4,5-
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d]pyrimidine-2,4,7-triamine (TCMDC-143295) to obtain new hit compounds showing potent 
and selective inhibition of smSirt2; in particular, the influence of substituents at the N7 
position of the bispyrimidine ring of TCMDC-143295 has been investigated by replacing the 
substituents on the prototype basically by substituents with smaller structures. 
Unfortunately, none of the newly synthesized compounds showed better smSirt2 inhibitory 
activity compared to the prototype. Together with these final compounds, we tested also the 
pyrimidine intermediate, MC4238, and the amine intermediate, MC4239; but neither of them 
did not show any smSirt2 inhibitory activity. In general, the tested compounds, except for 
three compounds MC4233, MC4211 and MC4268 which showed modest smSirt2 inhibitory 
activities, showed either very poor or no activity against both smSirt2 and hSirt2. Noticeably, 
replacing the substituent at the N7 position of the bispyrimidine ring of TCMDC-143295 
basically by substituents with smaller structures strongly decreased or totally abolished both 
smSirt2 and hSirt2 inhibitory activity. More accurately, no substituents at the N7 position of 
bispyrimidine (MC4222), or no methyl group at the N7 position of bispyrimidine (MC4189, 
MC4261, MC4234, MC4262, MC4265, MC4314), or the N7 position of bispyrimidine is a 
tertiary amine and is a part of a cyclic structure (MC4236, MC4269, MC4235, MC4232), 
resulted in significant reduction or total loss of activity toward smSirt2. In the light of these 
data, one methyl group and another larger substituent, N7 position of pyrimido[4,5-
d]pyrimidine appear to be essential for the maintenance of inhibitory activity against 
smSIRT2. 
In the second round of modification, we decided to keep the methyl group at the N7 
position of bispyrimidine ring, however, introduction of bulky groups at α-carbon of the N7 
position of bispyrimidine, i.e., replacing methyl group by ethyl (MC4315), isopropyl (MC4313) 
or phenyl (MC4318) group; led to compounds with better smSirt2 inhibitory activity (MC4315 
and MC4318) or slightly lower smSirt2 inhibitory activity (MC4313) compared to the 
prototype. In this regard, substitution of the methyl group with ethyl or phenyl group gave 
analogues with improved potency. Nevertheless, this improved potency came as the expense 
of poor selectivity over the hSirt2. Compared to the prototype, analogues with bulky group at   
α-carbon of the N7 position of bispyrimidine ring showed also improved hSirt2 inhibitory 
activity. 
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On the other hand, substitution of the oxygen linkage between the two phenyls by sulfur 
afforded compound (MC4304) with improved potency toward both smSirt2 and hSirt2 activity 
while replacing it with nitrogen gave compound (MC4316) with comparable potency but low 
selectivity over hSirt2 compared to the prototype. Likewise, increasing this linkage by one 
carbon resulted in analogue (MC4320) characterized by weak smSirt2 activity but comparable 
hSirt2 activity in comparison to the prototype. 
Furthermore, several modifications have been made on the etheric phenyl such as 
shifting the methoxy group from para to meta gave compound MC4298, having the same 
potency against smSirt2 but higher potency toward hSirt2 compared to the prototype. The 
introduction of additional methoxy groups, for example, 3,4-dimethoxyphenyl instead of 4-
methoxyphenyl resulted in derivative MC4310 that showed low potency and selectivity over 
hSirt2 in comparison to the prototype, whereas replacement of the 4-methoxyphenyl by 
3,4,5-trimethoxyphenyl led to compound MC4309 with similar potency and selectivity 
compared to the prototype. Interestingly, the substitution of 4-methoxyphenyl by 3,5-
dimethoxyphenyl produced analogue MC4319 which is characterized with good potency and 
the best selectivity over hSirt2 in comparison to the prototype. This is one of the most 
promising compound from the series with modest smSirt2 activity (IC50 = 12.5 µM) and almost 
devoid of activity against hSirt2 (7.4% inh. @ 25 µM). Finally, replacement of 4-
methoxyphenyl by 4-trifluorommethoxyphenyl resulted in a 3-fold loss of potency against 
smSirt2 and selectivity over hSirt2 (MC4311), whilst replacement of 4-methoxyphenyl by 4-
benzoxyphenyl (MC4312) or 4-methoxynaphthalenyl (MC4323) led to modest reduction of 
potency against smSirt2 but more than 3-fold active toward hSirt2 in comparison to the 
prototype. Fig. 7.3 represents the IC50 curves of selected compounds. 
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Fig. 7.3: The IC50 curves of selected compounds. 
7.5 Conclusion and perspectives  
Sirtuins are crucial regulators of cellular processes, two of which, energy metabolism and 
the DNA repair response, determine their potential importance as therapeutic targets. In the 
case of parasitic diseases, it is evident that the inhibition of sirtuins is sufficient to cause 
detrimental effects to the parasite and that species selectivity and/or enhanced bioavailability 
to the parasitic organism is most important. The differences in the catalytic domains of 
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schistosome sirtuins compared with their human counterparts are likely to be sufficient to 
allow the development of selective inhibitors, but this requires verification by molecular 
modeling and, where possible, x-ray crystallographic studies. However, high-throughput 
screening of recombinant enzymes can also allow the detection of inhibitors with novel 
scaffolds and warheads that are selective. Using the later approach, a fluorescent-based 
enzyme assay was developed by our collaborators and this led to the identification of novel 
compounds targeting smSirt2. From the screening series disclosed here we select one 
compound/hit, TCMDC-143295, as initial structural feature and represents a novel smSirt2 
inhibition template that provides the possibility to develop potent and selective inhibitors for 
the therapy of schistosomiasis. Consequently, extensive structure-activity relationship (SAR) 
studies have been applied on TCMDC-143295 (MC4223) to obtain new hit compounds 
showing potent and selective inhibition of smSirt2; in particular, the influence of substituents 
at the N7 position of the bispyrimidine ring of TCMDC-143295 has been investigated. 
Unfortunately, in the first round of SAR optimization, none of the newly synthesized 
compounds showed better smSirt2 inhibitory activity compared to the prototype. In light of 
the above observations, in the second part of the project, we decided to keep the N7-methyl. 
Indeed, the alpha carbon at N7 position has been replaced with larger steric groups compared 
prototype to increase molecular constraint while the portion of diphenyl ether, given its 
importance, remained almost unchanged. Enzymatic assays of the tested compounds showed 
that several compounds exhibit a relatively better potency and selectivity toward smSirt2, 
indicating that the inhibition of some of these new analogues could be some potential leads 
for further SAR optimizations. Central to this optimization was the inclusion of a methyl or 
bulky groups at the alpha carbon of N7 position of bispyrimidine ring and dimethoxy group at 
the phenyl moiety as well as replacement of the ether with thioether linkage.  
Thus, while we recognize that both potency toward smSirt2 and selectivity over hSirt2 
still needs optimization, there are strong indications that the high selectivity by MC4319 with 
respect to hSirt2 and good potency by MC4304 and MC4318 that we have already obtained 
are more important for potential further SAR optimization of new derivatives with better 
potency toward smSirt2 and selectivity over hSirt2.  
A best strategy could be to synthesize new derivatives based on the above observations, 
specifically, further exploring the different SAR approaches, perhaps by combination, that had 
already led to better potency toward smSirt2 and selectivity over hSirt2, in particular, it would 
 
 
147 
 
be a good of intervening on the other portion of the molecule without, for now, touching the 
pyrimido[4,5-d]pyrimidine nucleus. The above results suggest that the ether linkage between 
the two phenyls is flexible and it could be replaced with sulphones, sulphoxides, amides or 
methylene groups in obtaining derivatives with target biological profile. It would be also nice 
to see the effects of methylthio instead of methoxy on the ethereal phenyl. Further goal of 
future projects will be to investigate the importance of carbon chiral alpha at N7. Indeed, it is 
thought to be possible to functionalize the N2 of pyrimido[4,5-d]pyrimidine by using 
condensation reactions with appropriately substituted guanidine (Fig. 7.4). 
 
 
Fig. 7.4: Suggested possible future modifications for further SAR optimization on MC4223/TCMDC-143295 
7.6 Methods 
Coupled Enzymatic Deacetylation Assay: the deacetylase activity of smSirt2 was assayed 
using a described coupled enzymatic reaction, preciously optimized for assay of hSirt2.[739-
740] This assay is based on fluorescence measurements and uses a synthetic substrate, Z-
Acetyl-Lysine-Amino-methylcumarin (ZMAL), that mimics the peptide containing an 
acetylated lysine residue. smSIRT2 will deacylated ZMAL, thus leading to the liberation of the 
lysine amino-terminal group (ZML), which is recognized only in the deacylated state, by 
trypsin. Trypsin mediates the lysis of amide bonds, leading therefore to the release of Amino-
methylcumarin (AMC), which is fluorescent (Fig. 7.5). As negative control, sample without the 
inhibitor was used (in this case smSIRT2 will deacylated lysine and trypsin will split the peptide 
bond), while nicotinamide (which acts as SIRT4 inhibitor) was employed as a positive control, 
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finally only enzyme in DMSO was used as a blank control in order to identify hypothetical 
contamination. Briefly, smSirt2 (60 ng/μL), NAD+ (500 µM), ZMAL (10.5 µM), the potential 
inhibitor (dissolved in DMSO at various concentrations), and the FdL-developer (Trypsin 
1mg/mL and nicotinamide 8 mM). The assay employed 384 wells (Greiner Bio-One) with a 
reaction volume of 20 μl per well and all tests were performed at least in duplicate. The 
concentration of both smSIRT2 and NAD+ was prepared by dissolving in a buffer of 50mM 
TRIS, 137mM NaCl, 2.7mM KCl, 1mM MgCl2, 0.5mM DTT, 0.015% Triton X-100, pH 8.0. while 
ZMAL was prepared from 12.6 mM DMSO solutions which were diluted with the same buffer 
until the concentration became 10.5 μM. On the other hand, the FdL-developer (stop 
solution) was composed of 50mM TRIS, 100mM NaCl, 6.7% (v / v) DMSO, 1mg / mL trypsin, 
8mM nicotinamide, pH 8.0. 
Thus, ZMAL, smSIRT2, NAD+ and a hypothetical inhibitor dissolved in DMSO at various 
concentrations were incubated at 37 °C for 1h. In the presence of its cofactor, NAD+, smSIRT2 
is able to deacetylase ZMAL to the formation of AMC, but in the presence of smSIRT2 inhibitor, 
this activity is blocked or become less depending on the power of the smSIRT2 inhibitory 
activity. Then, a solution containing/buffer trypsin and nicotinamide, was added and the 
plates were incubated at 37 °C for another 20 min. The action of trypsin leads to the formation 
of AMC and Z-lysine, where AMC is the source of fluorescence signal in the assay. Then the 
fluorescence intensity was measured in a microplate reader (BMG 
Polarstar, λex 365 nm, λem 465 nm). The amount of inhibition was determined with respect to 
the mixture with only DMSO. IC50 values were determined with Graphpad Prism software 
using a non-linear regression to fit the dose–response curve. 
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Fig. 7.5: Graphic representation of the deacetylation of the substrate ZMAL during the assay 
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8. DESIGN AND SYNTHESIS OF TRANYLCYPROMINE-BASED LSD1 INHIBITORS 
POTENTIALLY ACTIVE AGAINST SCHISTOSOMA MANSONI 
8.1 Research Project 
The role of epigenetic mechanisms in the control of gene transcription in schistosomes, 
and hence in bio-logical processes like development and reproduction, has gained a 
momentum in epigenetics.  Epi-drugs, including LSD1 inhibitors, were characterized and 
studied in recent years as potential new drug targets, with the strategy of testing known anti-
cancer drugs to kill schistosomes [264, 686, 699, 702-703, 708-709, 741]. Here, we prosed a 
new series of LSD1 inhibitors based on the trans 2-phenylcyclopropylamine (trans-2-PCPA), 
which is a useful lead to develop several highly potent small-molecules active toward various 
cancer cell lines, as a potentially active against S. mansoni parasites. The rationale of the 
approach is based on the fact that the parasite shares some of the characteristics of malignant 
cells, such as high levels of metabolic activity and of cell division, an effective host immune 
evasion, and an intense oxidative metabolism [684]. In addition, in silico analyses [742] have 
pointed to a large number of S. mansoni histone binding partners potentially involved in the 
regulation of gene expression, DNA replication, cell death, cellular growth and proliferation 
[742], thus suggesting that drug-induced histone modifications could affect these cellular 
processes in the parasite.  Insights into schistosome epigenetic mechanisms has been gained 
from studies aimed at developing such strategies, including for example the characterization 
of the actions of inhibitors of histone modifying enzymes (HMEs), or from transcript 
knockdown studies.  For example, during the previous EC-funded project (SEtTReND) 
transcript knockdown by RNA interference was used to identify three HMEs, SmHDAC8, 
SmLSD1 and SmPRMT3 as valid targets in Schistosoma mansoni and three of them were found 
to be essential to the survival and/or development of the parasite within its mammalian host. 
Studies on these three HMEs have been continued during another EC-funded project (A-
ParaDDisE) in which our group involved in.  
The results from both SEtTReND and A-ParaDDisE prompted us, as part of the FP7 A-
ParaDDise Project, to prepare a small group of LSD1 inhibitors (1-9, 11, 15, 19-24, Table 8.1) 
potentially active against S. mansoni. The resulting compounds have been tested against 
Schistosoma at Prof. Fantappié’s lab (in Brazil). Interestingly, preliminary data indicate that 
most of the tested compounds were relatively toxic to the juvenile stage of schistosomula 
(the ideal target to control schistosomiasis because no eggs are involved in this stage) and to 
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a lesser extent to adult worms. Among these tested compounds, MC3935, an analogue of the 
2-phenylcyclopropylamine (Fig. 8.1), was found to be extremely toxic to both schistosomula 
and adults. A subsequent treatment of S. mansoni with MC3935 led to induced tegumental 
and muscle abnormalities as well as the presence of apoptotic and necrotic vesicles and 
granules. Induction of apoptosis cause the death of the parasite after treatment and extensive 
alterations to reproductive systems were also observed in adult schistosomes treated with 
these inhibitors. These inhibitors resulted in hypermethylation of histone 3 at lysine 4 (H3K4), 
which is the specific target of this enzyme, that showed the aforementioned alterations in the 
parasites are in fact as a result of inhibition of LSD1. RNASeq analysis of adult worms treated 
with the LSD1 inhibitor showed that 2709 and 938 genes were differentially expressed in 
males and females, respectively. While, 270 genes were differentially expressed in 
schistosomula treated with the inhibitor. Downregulated genes in male worms included those 
involved in drug pumps and cytoskeleton formation, whereas in female’s transmembrane 
transporter genes were downregulated. Notch signaling pathway genes were upregulated in 
female worms and schistosomula. 
 
  
Fig. 8.1: Effect of MC3935 on the tegument of S. mansoni after treatment with 25 µM for 
48h. 
These compounds deserved further investigation, more specifically, MC3935 is an 
interested compound with magnificent antischistosomal activities that needs further 
medicinal chemistry exploration.  Hence, we decided to synthesized a small group of 
compounds by chemical modifications of MC3935 in order to improve its potency and 
selectivity over human LSD1 activity. As result, during my stay in Prof. Ganesan′s lab at the 
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University of East Angelia, Norwich, I prepared small series of MC3935 analogues (10, 12-14, 
16-18, 25 and 26, Table 8.1).  In this regard, the new analogues were designed by two 
modification approaches on MC3935: (i) moving the ethynyl from para to meta position(GS4), 
or substituting the ethynyl group with other alkynyl (GS3 and GS5-7) or alkyl (GS1 and GS2) 
groups; and (ii) moving the amido (CONH) from para to meta and varying the aroyl groups 
(GS8 and GS9) (Fig. 8.2). 
 
Fig. 8.2: Structure of MC3935 and its proposed potential analogues 
8.2 Chemistry  
The trans-2-(3/4-ntrophenyl)cyclopropylcarboxylic acids (28a,b) were prepared by 
treating the commercially available trans-2-phenylcyclopropylcarboxylic acid (27) with 69.5% 
HNO3. To a suspension of trans-2- (3/4-nitrophenyl) cyclopropylcarboxylic acid in anhydrous 
toluene was added TEA, DPPA, tert-butanol and di-tert-butyl dicarbonate and refluxed under 
nitrogen to afford trans-tert-butyl-2- (3/4-nitrophenyl) cyclopropylcarbamates (29a,b) [743]. 
The key intermediate trans-tert-butyl-2- (3/4-aminophenyl) cyclopropylcarbamates (30a,b) 
were prepared by hydrogenation of trans-tert-butyl-2- (3/4-nitrophenyl) 
cyclopropylcarbamate in MeOH in the presence of 10% Pd/C under nitrogen condition 
(Scheme 3). Subsequently, the synthesis of the final compounds 1-26 was carried out 
following two routes. According to Scheme 1, the appropriate acids, prepared as Scheme 4 
and 5 (35a-c, 39a-c) or commercially available (40-44), were activated by benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) or 1-(3-dimethylaminopropyl)-
3-ethylcarbodiimide (EDC), in the presence triethylamine and condensated with tert-butyl N-
[2-(4-aminophenyl)cyclopropyl]carbamate 30a to afford their corresponding carbamates 
45a-j. The final compounds 1-11 were smoothly obtained by removing Boc protection with 
hydrochloric acid in dioxane. On the other hand, the final compounds 12-26 were prepared 
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according to Scheme 2. Where, the key intermediates 30a,b were treated with the 
appropriate arolyl/benzyl chlorides, which were prepared as scheme 6 (49a-c) or 
commercially available (50-59), in the presence of TEA and dry DCM to give the intermediates, 
trans tert-butyl 2-(4-aroyl/benzyl)aminophenyl)cyclopropyl carbamates (60a-o).1 Finally, 
cleavage of the Boc group by the addition of 4 N hydrochloric acid in dioxane/tetrahydrofuran 
yielded the final compounds, trans tert-butyl 2-(4-
aroyl/benzyl)aminophenyl)cyclopropylamine hydrochlorides (12-26) [744]. The arolyl 
chloride intermediates (49a-c) were synthesized starting from methyl-4- iodobenzoate (46), 
which was treated with the appropriate alkynes in the presence of   PdCl2(PPh3)2 and CuI in 
dry DMF/THF to provide the corresponding substituted para-alkyne-benzoates (47a-c) [745-
746]. The resulting esters were dissolved in MeOH, treated with aqueous 2 N LiOH and heated 
under reflux to give the carboxylic acids (48a-c). Further the appropriate carboxylic acid was 
heated under reflux with excess thionyl chloride to furnish the arolyl chlorides (49a-c). Table 
8.1 depicts the physico-chemical data of the final compounds 1-26. 
Scheme 1a 
 
a Reagents and conditions: (a) PyBop, Et3N, dry DMF, N2 atmosphere, overnight, rt; (b) 4 N HCl 
in dioxane, anhydrous THF, 24-48 h, 0 °C-rt. 
Scheme 2a 
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a Reagents and conditions: (a) Et3N, anhydrous DCM, 2-4 h, 0 °C-rt; (b) 4 N HCl in dioxane, 
anhydrous THF, 24-48 h, 0 °C-rt. 
Table 8.1. Physico-chemical data of compounds 1-26 
Sr. 
No 
Lab 
Code R Structure M.W. 
M.P. 
(°C) 
Yield 
(%) 
1 MC3371 
  
523.03 195-197 77 
2 MC3384 
N N
HN
O
O
H3C
 
 
572.53 190-192 79 
3 MC3473 
 
 
523.03 186-189 78 
4 MC3413  
 
411.89 177-179 62 
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5 MC3288 
  
411.89 192-194 61 
6 MC3382 
  
461.95 202-204 63 
7 MC3937  
 
264.75 >250 75 
8 MC3934  
 
314.81 >250 80 
9 MC3935 
 
 
312.79
3 >250 86 
10 GS4 
 
N
H
O
NH3 Cl
 
312.80 >250 70 
11 MC3205 
  
465.98 
218-
220 
 
70 
Cm
pd 
Lab 
Code R1  M.W. 
M.P. 
(°C) Yield 
12 GS5 
 
 
388.90 >250 69 
13 GS6 
 
 
352.86 >250 72 
 
 
156 
 
14 GS7 
 
 
326.82 >250 78 
15 MC2584 
  
288.78 210-212 83 
16 GS1 
 
 
302.80 >250 86 
17 GS2 
 
 
330.86 >250 79 
18 GS3 
 
 
313.79 >250 65 
19 MC2652 
 
 
364.87 >250 85 
20 MC2653 
  
338.84 >250 81 
21 MC2634 
  
338.84 >250 76 
22 MC2646  
 
352.86 238-240 84 
23 MC2645 
  
352.86 240-242 78 
24 MC2639 
  
302.80 180-182 73 
25 GS8 
 
 
326.82 >250 75 
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26 GS9 
 
 
352.86 >250 60 
 
8.3 Experimental Section  
Chemistry. Melting points were determined on a Buchi 530 melting point apparatus. 1H-
NMR spectra were recorded at 400 MHz using a Bruker AC 400 spectrometer; chemical shifts 
are reported in δ (ppm) units relative to the internal reference tetramethylsilane (Me4Si). 
Mass spectra were recorded on a API-TOF Mariner by Perspective Biosystem (Stratford, Texas, 
USA), samples were injected by an Harvard pump using a flow rate of 5−10 μL/min, infused in 
the Electrospray system. All compounds were routinely checked by TLC and 1H-NMR. TLC was 
performed on aluminum-backed silica gel plates (Merck DC, Alufolien Kieselgel 60 F254) with 
spots visualized by UV light or using a KMnO4 alkaline solution. All solvents were reagent 
grade and, when necessary, were purified and dried by standard methods. Concentration of 
solutions after reactions and extractions involved the use of a rotary evaporator operating at 
reduced pressure of ~ 20 Torr. Organic solutions were dried over anhydrous sodium sulfate. 
Elemental analysis has been used to determine purity of the described compounds, that is > 
95%. Analytical results are within 0.40% of the theoretical values. All chemicals were 
purchased from Sigma Aldrich s.r.l., Milan (Italy) or from TCI Europe N.V., Zwijndrecht 
(Belgium), and were of the highest purity. As a rule, samples prepared for physical and 
biological studies were dried in high vacuum over P2O5 for 20h at temperatures ranging from 
25 to 40 °C, depending on the sample melting point. 
General Procedure for the synthesis of 2- (3/4-nitrophenyl) cyclopropylcarboxylic acids 
(28a,b, Scheme 3). Example: trans 2-(4-nitrophenyl)cyclopropylcarboxylic acid (28a). The 
commercially available trans -2-phenylcyclopropylcarboxylic 27 (1 eq) was treated with 69.5% 
nitric acid solution (15 eq) and left to stir at rt for 7 h. After completion of the reaction, it was 
filtered and washed with water to give the trans 2-(4-Nitrophenyl)cyclopropylcarboxylic and 
trans 2-(3-Nitrophenyl)cyclopropylcarboxylic (4:1). Crystallization of the resulting solid from 
benzene affords the pure trans 2-(4-nitrophenyl)cyclopropylcarboxylic 28a as a white solid. 
1H NMR (DMSO, 400 MHz): δ 1.44–1.48 (m, 1H, CHH cyclopropane), 1.51-1.56 (m, 1H, CHH 
cyclopropane), 1.96–2.00 (m, 1H, CHCOOH cyclopropane), 2.54–2.59 (m, 1H, PhCH 
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cyclopropane), 7.44–7.46 (d, 2H, benzene protons), 8.11–8.13 (d, 2H, benzene protons), 12.47 
(bs, 1H, COOH). 
General Procedure for the Synthesis of trans tert-Butyl 2-(3/4-Nitrophenyl)cyclopropyl 
Carbamates (29ab, Scheme 3): example trans tert-butyl 2-(4-nitrophenyl)cyclopropyl 
carbamate (29a). A solution of trans 2-(4-Nitrophenyl)cyclopropylcarboxylic 28a (12.5 mmol, 
2.56 g) in dry toluene (75 mL), triethylamine (16.25 mmol, 2.26 mL), diphenylphosphoryl azide 
(15 mmol; 3.23 mL) and tert-butanol (24 mmol, 5 mL) was stirred at 90 °C under N2 
atmosphere for 18 h. Afterwards, di-tert-butyldicarbonate (18.75 mmol, 4.1 g) was added, 
and the reaction was continued at 90 °C for further 2 h. The solvent was removed under 
vacuum and dissolved with a 100 mL EtOAc and extracted with 50 Ml of H2O and 50 mL of 
saturated NaHCO3. After drying with Na2SO4 and evaporation, the resulting residue was 
purified on flash chromatography by silica gel eluting with ethyl acetatet/n-hexane to give 
pure trans tert-butyl 2-(4-nitrophenyl)cyclopropyl carbamate 29a as a white solid. 1H NMR 
(CDCl3, 400 MHz, δ; ppm) δ 1.10–1.15 (m, 1H, CHH cyclopropane), 1.19-1.23 (m, 1H, CHH 
cyclopropane), 1.39 (s, 9H, C(CH3)3), 2.40-2.45 (m, 1H, CHNH cyclopropane), 2.62-2.67,(m, 1H, 
PhCH cyclopropane), 4.96 (bs, 1H, NHCO), 7.29-7.31 (d, 2H, benzene protons), 7.84-7.86 (d, 
2H, benzene protons). 
General procedure for the synthesis of trans tert-Butyl 2-(3/4-amophenyl)cyclopropyl 
Carbamate (30a,b, Scheme 3): example trans tert-Butyl 2-(4-Amminophenyl)cyclopropyl 
Carbamate (30a). To a solution trans tert-butyl 2-(4-nitrophenyl)cyclopropyl carbamate 29a 
(6.72 mmol, 1.87 g) in methanol (100 mL), 10% Pd/C (100 mg) was added at nitrogen 
atmosphere. The reaction mixture was stirred under hydrogen gas at room temperature for 
4 h. After completion, the reaction mixture was filtered off through a Celite bed, and the 
filtrate was concentrated. The crude was subjected to flash column chromatography using 
ethyl acetate/hexane as eluting system to provide the trans tert-butyl 2-(4-
amminophenyl)cyclopropyl carbamate 30a as an oil. 1H NMR (CDCl3, 400 MHz, δ; ppm) 
δ 0.98–1.01 (m, 1H, CHH cyclopropane), 1.17-1.21 (m, 1H, CHH cyclopropane), 1.38 (s, 9H, 
C(CH3)3), 1.85-1.90 (m, 1H, CHNH cyclopropane), 2.55-2.57 (m, 1H, PhCH cyclopropane), 3.49 
(bs, 2H, –NH2), 4.73 (bs, 1H, NHCO), 6.52-6.54 (d, 2H, benzene protons), 6.88-8.90 (d, 2H, 
benzene protons). 
Scheme 3 
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Reagents and conditions: (a) 69.5% HNO3, rt; (b) (i) Et3N, DPPA, tert-BuOH, anhydrous toluene, 
N2 atmosphere, 16 h, 90 °C; (ii) di-tert-butyl dicarbonate, 2 h, 90 °C; (c) H2, 10% Pd/C, anhydrous 
MeOH, 5 h, rt. 
General procedures for preparation of tert-butyl 3/4-morpholino/(4-methylpiperazin-
1-yl)-3/4-nitrobenzoate (32a-c) Scheme 4. Example: tert-Butyl 4-(4-methylpiperazin-1-yl)-3-
nitrobenzoate (32b. A suspension of 2.0 g (7.8 mmol) tert butyl 4-chloro-3-nitro-benzoate 31, 
3.22 g (23.3 mmol) of dry K2CO3) and 2.58 mL (23.3 mmol) of N-methylpiperazine was stirred 
in 10 mL of dry DMF at 90 °C for 5 h in a sealed tube. Then, the reaction mixture was quenched 
with water and extracted with EtOAc. The combined organic phases were washed with brine, 
dried over Na2SO4, concentrated and the residue was purified on silica gel (eluent: EtOAc) and 
recrystallized from toluene to obtain 2.3 g (92%) of intermediate 32b as a yellow solid. 1H 
NMR (CDCl3, 400 MHz) δ, 1.61 (s, 9H, -COOC(CH3)3), 2.38 (s, 3H, -NCH3), 3.20 (t, 4H, -
PhN(CH2)2), 2.58 (t, 4H, -CH3N(CH2)2), 7.07-7.10 (d, 1H, aromatic proton), 8.03-8.06 (d, 1H, 
aromatic proton), 8.37 (s, 1H, aromatic proton); MS (EI) m/z: 321.17 [M]+; m.p. 138- 140°C.  
tert-butyl 3/4-amino-3/4-morpholino/(4-methylpiperazin-1-yl)benzoate (33a-c) 
Scheme 4. Example: tert-Butyl 3-amino-4-(4-methylpiperazin-1-yl)benzoate (33b). A 
suspension of 0.80 g (2.5 mmol) of the tert-butyl nitrobenzoate 32b in 30 mL MeOH and 0.13 
g (0.12 mmol) of 10% palladium on carbon were placed in a Parr apparatus and was 
hydrogenated at 50 psi and 25 °C for 5 h. The palladium was then filtered off and the MeOH 
was evaporated to afford an oily residue that was first purified on silica gel (eluent: 
CHCl3/MeOH, 10:1, v:v) and then recrystallized from cyclohexane to provide 0.29 g (65%) of 
the tert-butyl 4-amino-benzoate 33b as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 1.58 (s, 
9Η,-COOC(CH3)3), 2.38 (s, 3H, -N(CH3)),  2.61 (t, 4H, -CH3N(CH2)2), 2.98 (t, 4H, -PhN(CH2)2), 3.96 
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(s, 2H, Ph(NH2)), 6.99-7.00 (d, 1H, aromatic proton), 7.36 (d, 1H, aromatic proton), 7.41-7.43 
(dd, 1H, aromatic proton),; MS (EI) m/z: 291.19 [M]+; m.p. 114-116°C. 
tert-butyl 3/4-(benzyloxycarbonylamino)-3/4-morpholino/(4-methylpiperazin-1-
yl)benzoate (34a-c) Scheme 4. Example: tert-Butyl 3-(benzyloxycarbonylamino)-4-(4-
methylpiperazin-1-yl)benzoate (34b). 
Benzyl chloroformate (2.1 mmol, 0.3 mL) was slowly added at 0 °C to a solution of 0.50 g 
(1.72 mmol) of tert-butyl 4-amino-3-(4-methylpiperazin-1-yl)benzoate (33b) 1in 10 mL of THF 
and 0.29 mL (2.1 mmol) of TEA. After stirring at RT for 1.5 h the solution was then quenched 
with water (20 mL) and extracted with CH2Cl2 (3 x 20 mL). The organic phases were washed 
with brine, dried over Na2SO4 and concentrated to afford a residue that was purified on silica 
gel (eluent EtOAc/CHCl3, 1:1, v:v) providing 0.53 g (65%) of the tert-butyl benzoate 34b. 1H 
NMR (CDCl3, 400 MHz) δ 1.60 (s, 9Η, -COOC(CH3)3), 2.20 (s, 3H, -N(CH3)),  2.61 (t, 4H, 
CH3N(CH2)2), 2.92 (t, 4H, -PhN(CH2)2), 5.28 (s, 2H, -COOCH2Ph), 7.15-7.17 (d, 1H, aromatic 
proton), 7.37-7.47 (m, 5H, -CH2Ph), 7.69-7.71 (m, 2H, aromatic proton), 8.69 (br s, 1H, -
PhNHCOO),; MS (EI) m/z: 425.23 [M]+. 
3/4-(benzyloxycarbonylamino)-3/4-morpholino/(4-methylpiperazin-1-yl)benzoic acid 
(35a-c) Scheme 4. Example: 3-(benzyloxycarbonylamino)-4-(4-methylpiperazin-1-yl)benzoic 
acid (35b). A solution of 0.20 g (0.47 mmol) of tert-butyl benzoate 34b, and 0.72 mL (9.4 
mmol) of TFA in 5 mL of dry CH2Cl2 was stirred at RT overnight. The solvent was then removed 
and the resulting solid was first triturated with 10 mL Et2O and then crystallized from 
acetonitrile to give 0.13 g (76%) of the benzoic acid 35b as a colorless solid. 1H NMR (DMSO-
d6, 400 MHz) δ 2.86 (s, 3H, -N(CH3)), 3.08 (t, 4H, CH3N(CH2)2), 3.20 (t, 4H, -PhN(CH2)2), 5.22 (s, 
2H, -COOCH2Ph), 7.22-7.25 (d, 1H, aromatic proton), 7.36-7.38 (d, 2H, aromatic protons),  
7.40-7.46 (m, 3H, aromatic protons), 7.66-7.68 (d, 1H, aromatic proton), 8.36 (s, 1H, aromatic 
proton),  9.85 (br s, 1H, -PhNHCOO),12.84 (br s, 1H, -COOH); MS (EI) m/z: 369.17 [M]+; m.p. 
205-207°C. 
Scheme 4a 
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a Reagents and conditions: (a) morpholine or 4-methylpiperazine, K2CO3, DMF,90 °C. 5 h; (b) 10% 
Pd-C, MeOH, Parr apparatus, 50 psi, 25 °C, 5h; (c) Benzyl chloroformate, TEA, THF, RT 1.5 h; (d) TFA, 
CH2Cl2, RT, overnight.  
General procedure for the synthesis of the tert-butyl 1H-pyrrole and -1H-indole–2- and 
-3-carboxylates (37-c, Scheme 5). Example: tert-butyl 1H-pyrrole-3-carboxylate (37a). A 
mixture of 1H-pyrrole-3-carboxylic acid 36a (1.0 mmol, 0.11 g) and N,N-dimethylformamide 
di-tert-butyl acetal (3.96 mmol, 0.80 g, 0.95 mL) in anhydrous benzene (15 mL) was stirred at 
80 ºC for 1 h. Afterwards, the solvent was evaporated and the residue obtained was purified 
by column chromatography (SiO2 eluting with ethyl acetate/petroleum ether 1:9) to provide 
the pure 37a. 1H NMR (CDCl3, 400 MHz, δ; ppm) δ 1.63 (s, 9H, (CH3)3), 6.78 (s, 1H, pyrrole 
proton), 7.12 (s, 1H, pyrrole proton), 7.46 (s, 1H, pyrrole proton), 11.3 (bs, 1H, NH pyrrole). 
MS (EI) m/z: 167.09 [M]+. 
General procedure for the synthesis of the 1-benzyl 2- and 3-tertbutyl 1H-pyrrole- and 
1H-indole-1,2- and -1,3-dicarboxylates 38a-c (Scheme 5). Example: 1-benzyl 3-tert-butyl 1H-
pyrrole-1,3- dicarboxylate (38a). Tert-butyl 1H-pyrrole-3-carboxylate 37a (0.63 mmol, 0.14 g) 
in dry THF (2 mL) was added to a solution of NaH (0.94 mmol, 0.04 g) in dry THF (3 mL) at 0 
°C, and the mixture was stirred at room temperature for 30 min, followed by the addition of 
benzyl chloroformate (0.94 mmol, 0.13 mL), and the reaction was stirred for 1 h further. The 
reaction was then quenched with water (20 mL) and extracted with chloroform (3 × 30 mL). 
The organic layers were washed with saturated sodium chloride solution (2 × 15 mL), dried 
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with anhydrous sodium sulfate and concentrated. The residue was purified by 
chromatographic column on silica gel eluting with ethyl acetate/n-hexane 1:10 to afford the 
pure 38a. 1H NMR (CDCl3, 400 MHz, δ; ppm) δ 1.63 (s, 9H, (CH3)3), 5.27 (s, 2H, CH2), 6.48 (s, 
1H, pyrrole proton), 7.02 (s, 1H, pyrrole proton), 7.33- 7.36 (m, 3H, benzene protons), 7.54-
7.56 (m, 2H, benzene protons), 8.03 (s, 1H, pyrrole proton. MS (EI) m/z: 401.13 [M]+. 
General procedure for the synthesis of the 1- (benzyloxycarbonyl)-1H-pyrrole- and -1H-
indole-2- and -3- carboxylic acids 39a-c (Scheme 5). Example: 1- (benzyloxycarbonyl)-1H-
pyrrole-3-carboxylic acid (39a). 1-Benzyl 3-tert-butyl 1H-pyrrole-1,3-dicarboxylate 38a (0.64 
mmol, 0.22 g) was added to a solution of trifluoroacetic acid (0.77 mmol, 0.05 mL) in dry 
dichloromethane (3 mL). The resulting mixture was stirred for 5 h at room temperature. The 
reaction was then quenched with water (30 mL) and extracted with ethyl acetate (3 × 30 mL). 
The organic layers were washed with saturated sodium chloride solution (2 × 15 mL), dried 
with anhydrous sodium sulfate and concentrated in vacuo. The precipitated colorless solid 
was filtered, washed with petroleum ether and dried to afford the pure 39a. 1H NMR (DMSO-
d6, 400 MHz, δ; ppm) δ 5.45 (s, 2H, CH2), 6.78 (s, 1H, pyrrole proton), 7.12 (s, 1H, pyrrole 
proton), 7.43.7.46 (m, 3H, benzene protons), 7.64-7.66 (m, 2H, benzene protons), 8.33 (s, 1H, 
pyrrole proton), 12.09 (bs, 1H, COOH); MS (EI) m/z: 245.07 [M]+. 
Scheme 5a 
N
H
Ar COOH
N
H
Ar COOt-Bu
N
Ar COOt-Bu
OO
N
Ar COOH
OO
b
37a,b (Ar = none);
37c (Ar = fused Ph)
38a,b (Ar = none); 
38c (Ar = fused Ph)
39a,b (Ar = none); 
39c (Ar = fused Ph)
a
c
36a,b (Ar = none);
36c (Ar = fused Ph)
 
 
 
163 
 
a Reagents and conditions: (a) N,N-dimethylformamide di-tert-butyl acetal, toluene, 1 h, 80 °C; 
(b) 60% NaH, dry THF, benzyl chloroformate, 1 h, rt; (c) trifluoroacetic acid, dry DCM, 5 h, rt. 
General procedure for Sonogashira reaction in liquid phase compounds 47a-c (Scheme 
6): example methyl- 4-cyclopropylethynyl-benzoate (47b). Methyl-4-iodobenzoate 46 (2.50 
mmol; 655 mg), triethylamine (25 mmol; 3.5 mL), CuI (5 mol %), PdCl2(PPh3)2 (5 mol %), and 
ethynylcyclopropane (3.25 mmol) were dissolved in dry DMF (10 mL). After the mixture was 
stirred at 70 °C overnight, it was quenched with EtOAc and filtrated on Celite. The EtOAc 
solution was washed with water and brine, and the organic layer was dried over MgSO4 and 
evaporated. The residue was purified by flash chromatography (ethyl acetate/hexane) to give 
methyl- 4-cyclopropylethynyl-benzoate 47b as a white solid. 1H NMR (400 MHz, CDCl3): δ 
0.75-0.77 (m, 2H, CH2 cyclopropyl), 0.82-0.85 (m, 2H, CH2 cyclopropyl), 1.38-1.42 (m, 1H CH 
cyclopropyl), 3.83 (s, 3H, CH3), 7.33-7.36 (d, 2H, benzene protons), 7.85-7.88 (d, 2H, benzene 
protons). 
General Procedure for the Preparation of 4-(Alkynyl)benzoic acids 48a-c (Scheme 6): 
example 4-(phenylethynyl)benzoic acid (48a). Methyl 4-(phenylethynyl)benzoate 47a (2.27 
mmol, 1 eq) was dissolved in a 60 mL of methanol/water (3:1), 2 N LiHO (6.81 mmol, 3 eq) 
was added thereto, and the mixture was stirred at room temperature for 5 min, and heated 
under reflux for overnight. The reaction mixture was allowed to cool to room temperature, 
and the solvent was evaporated under reduced pressure. The residue was suspended in 
water, and the suspension was acidified with 1 N HCl solution (pH = 2-4), and stirred at room 
temperature for 30 min. The obtained suspension was filtered, washed with water, and dried 
to obtain 4-(phenylethynyl)benzoic acid 48a as a white solid. 1H NMR (400 MHz, CDCl3): δ 
7.45-7.47 (m, 3H, benzene protons), 7.59-7.61 (m, 2H, benzene protons), 7.66-7.69 (d, 2H, 
benzene protons), 7.96-7.99 (d, 2H, benzene protons), 13.19 (bs, 1H, OH). 
General Procedure for the preparation of aroyl chlorides 49a-c (Scheme 6): example 4-
propynebenzoyl chloride (49c). A mixture of 4-phenylethynyl benzoic acid 48c (3 mmol) in 
excess of SOCl2 with two drops of N,N-dimethylformamide was refluxed at 85 °C for 3 h with 
nitrogen purge before the SOCl2 was distilled off and purified by flash chromatography with 
DCM to afford 4-propynebenzoyl chloride 49c as a low melting yellowish-solid. 1H NMR (400 
MHz, CDCl3): δ 2.03 (s, 3H, CH3), 7.41-7.43 (d, 2H, benzene protons), 7.95-7.98 (d, 2H, benzene 
protons). 
Scheme 6a 
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a Reagents and conditions: (a) alkyne, 5% PdCl2(PPh3)2, 5% CuI, Et3N, dry THF/DMF, 
overnight, rt-70 °C; (b) 2 N LiOH, MeOH:H2O, (3:1) overnight, rt; (c) SOCl2, 3 h reflux. 
General procedures for the preparation of carbamates (45a-j) according to Method 1 
(Scheme 1). Example: tert-Butyl ((1R,2S)-2-(4-((R)-2-(((Benzyloxy)carbonyl)amino)-3-
phenylpropanamido)phenyl) cyclopropyl)carbamate 45j. Triethylamine (0.89 mmol, 0.12 
mL) and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.89 mmol, 0.39 g) 
were added to a solution of N-benzyloxycarbonyl-D-phenylalanine 44 (0.74 mmol, 0.22 g) and 
N-hydroxybenzotriazole (0.89 mmol, 0.12 g) in dry dichloromethane (5 mL), and the mixture 
was stirred over a period of 1h. After this time, the compound 30a [tert-butyl ((1R,2S)-2-(4-
aminophenyl)cyclopropyl)carbamate, 0.81 mmol, 0.2 g] was added, and the stirring was 
continued for 1 h. The reaction was poured into water (50 mL) and extracted with 
dichloromethane (3 × 10 mL). The organic layers were washed with saturated sodium chloride 
solution (3 × 10 mL), dried with anhydrous sodium sulfate and concentrated. The residue was 
purified by chromatographic column on silica gel eluting with ethyl acetate/n-hexane 1/2 to 
afford the pure 45j as a colorless solid. 1H NMR (CDCl3, 400 MHz, δ; ppm) δ 0.87-0.89 (m, 1H, 
CHH cyclopropane), 1.05-1.07 (m, 1H, CHH cyclopropane), 1.47 (s, 9H, C(CH3)3), 1.99-2.01 (m, 
1H, PhCH), 2.67-2.69 (m, 1H, CHNH), 3.08-3.13 (m, 2H, PhCH2CH), 4.54-4.56 (m, 1H, 
PhCH2CH), 4.89 (bs, 1H, NHCOOC(CH3)3), 5.10 (s, 2H, PhCH2OCONH), 5.60 (bs, 1H, NHCOOBn), 
7.03-7.05 (d, 2H, benzene protons), 7.21-7.34 (m, 12H, benzene protons), 7.77 (bs, 1H, 
PhNHCOCH); MS (EI) m/z: 529.26 [M]+. 
General Procedure for the Synthesis of trans tert-butyl 2-(3/4-
aroyl/benzyl)aminophenyl)cyclopropyl carbamates  60a-o (Method 2, Scheme 2). Example: 
trans tert-butyl (2-(4-(4-propylbenzamido)phenyl)cyclopropyl)carbamate (60f). 
Triethylamine (0.846 mmol; 0.120 mL; 1.5 equiv) and 4-propyl-benzoyl chloride 52 
(0.677 mmol; 0.130 mL; 1.2 equiv) were added dropwise to a cooled (0 °C) solution of trans 
tert-butyl 2-(4-aminophenyl)cyclopropylcarbamate 30a (0.564 mmol; 140 mg; 1.0 equiv) in 
dry dichloromethane (5 mL). The mixture was stirred at room temperature for 2.3 h, 
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afterwards the reaction was quenched with saturated NaHCO3 (30 mL) and extracted with 
EtOAc (3 × 30 mL), washed with saturated NaHCO3 and Na2CO3 solution and dried with 
sodium sulfate. The solvent was removed under vacuum and the residue purified by flash 
chromatography on silica gel 60 eluting with ethyl acetate:hexane system to provide 
pure trans tert-butyl (2-(4-(4-propylbenzamido)phenyl)cyclopropyl)carbamate 60f as white 
solid. 1H NMR (CDCl3, 400 MHz): δ 0.86–0.90 (t, 3H, CH2CH2CH3), 1.05–1.09 (m, 1H, CHH 
cyclopropane), 1.18 (s, 1H, CHH cyclopropane), 1.39 (s, 9H,  COO(CH3)3), 1.57–1.63 (m, 2H, 
CH2CH2CH3), 1.94–1.99 (m, 1H,  CHNHCOO(CH3)3 cyclopropane), 2.56–2.60 (t, 2H, 
CH2CH2CH3), 2.62–2.64 (m, 1H, PhCH cyclopropane), 4.78 (bs,1H,  NHCOO(CH3)3), 7.06–7.08 
(d, 2H, benzene protons), 7.20–7.22 (d, 2H, benzene protons), 7.45–7.47 (d, 2H, benzene 
protons), 7.68 (bs, 1H, NHCOPh), 7.70–7.72 (d, 2H, benzene protons). MS (EI) m/z: 395.23 
[M]+. 
General Procedure for the preparation of the final compounds 1-26 (Scheme 1 and 2): 
example trans 2-(4-(4-cyanobenzamido)phenyl)cyclopropylamine hydrochloride (18, GS3). 
trans tert-Butyl (2-(4-(4-cyanobenzamido)phenyl)cyclopropyl)carbamate 60g (95.5 mg, 
0.253 mmol; 1.0 equiv) was dissolved in dry tetrahydrofuran (6 mL) and the solution was 
stirred at 0 °C. Then 4 N HCl in 1,4-dioxane (4.1 mL; 16.45 mmol; 65 equiv) was added 
dropwise and the mixture was allowed to warm at room temperature. After 48 h, when 
conversion was complete, the suspension was filtered and washed with dry THF and then with 
dry Et2O to afford 18 as a hydrochloride salt. 1H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 1.17–
1.22 (m, 1H, CHH cyclopropane), 1.36–1.34 (m, 1H, CHH cyclopropane), 2.32–2.34 (m, 1H, 
CHNH2), 2.77–2.82 (m, 1H, PhCH), 7.15–7.17 (d, 2H, benzene protons), 7.70–7.72 (d, 2H, 
benzene protons), 8.01–8.03 (d, 2H, benzene protons), 8.10–8.12 (d, 2H, benzene protons), 
8.46 (bs, 3H, NH3+), 10.51 (bs, 1H, CONH). 
Benzyl N-[5-[[4-[trans-2-aminocyclopropyl]phenyl]carbamoyl]-2-morpholinophenyl] 
carbamate hydrochloride (1, MC3371). Yield: 77%. 1H NMR (DMSO-d6, 400 MHz) δ 1.21 (m, 
1H, -CHH cyclopropane), 1.38 (m, 1H, -CHH cyclopropane), 2.33 (m, 1H, -CHNH2),  2.89 (t, 4H, 
-N(CH2)2), 3.88 (m, 4H, -O(CH2)2), 5.27 (s, 2H, -NHCOOCH2Ph), 7.15-7.18 (d, 2H, aromatic 
protons), 7.32-7.46 (m,5H, aromatic protons), 7.71-7.73 (d, 2H, aromatic protons), 7.79-7.86 
(m, 2H, aromatic protons), 8.03-8.05 (d, 1H, aromatic proton), 8.58 (br s, 3H, -NH3 +)8.75 (br 
s, 1H, -NHCOOCH2Ph), 10.30 (br s, 1H, -PhCONH), 11.13 (br s, 1H, -NH+); MS (ESI) m/z: 487 
([M+H]+). 
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Benzyl N-[5-[[4-[trans-2-aminocyclopropyl]phenyl]carbamoyl]-2-(4-methylpiperazin-1- 
yl)phenyl]carbamate dihydrochloride (2, MC3384). 1H NMR (DMSO-d6, 400 MHz) δ 1.20 
(m, 1H, CHH cyclopropane), 1.39 (m, 1H, -CHH cyclopropane, 2.34 (m, 1H, -CHNH2),), 2.83 (t, 
4H, -CH3N(CH2)2), 3.15 (m, 4H, -PhN(CH2) 2), 3.33 (s, 3H, -NCH3), 5.23 (s, 2H, -NHCOOCH2Ph),  
7.15-7.18 (d, 2H, aromatic protons), 7.30-7.48 (m, 5H, aromatic protons), 7.70-7.72 (d, 2H, 
aromatic protons), 7.79-7.86 (m, 2H, aromatic protons), 8.01-8.03 (d, 1H, aromatic proton), 
8.56 (br s, 3H, -NH3 +), 8.74 (br s, 1H, -NHCOOCH2Ph), 10.27 (br s, 1H, -PhCONH), 11.12 (br s, 
1H, -NH+); MS (ESI) m/z: 500 ([M+H]+). 
Benzyl N-[4-[[4-[trans-2-aminocyclopropyl]phenyl]carbamoyl]-2-morpholinophenyl] 
carbamate hydrochloride (3, MC3473). Yield: 78%. 1H NMR (DMSO-d6, 400 MHz) δ1.22 
(m, 1H, -CHH cyclopropane), 1.38 (m, 1H, -CHH cyclopropane), 2.33 (m, 1H, -CHNH2), 2.88 (t, 
4H, -N(CH2)2), 3.79 (m, 4H, -O(CH2)2), 5.22 (s, 2H, -NHCOOCH2Ph), 7.14-7.16 (d, 1H, aromatic 
proton), 7.31-7.46 (m, 6H, aromatic protons), 7.69-7.71 (d, 1H, aromatic proton), 7.74-7.83 
(m, 3H, aromatic protons), 7.94-8.02 (m, 2H, aromatic protons), 8.47 (br s, 3H, -NH3 +),  8.61 
(br s, 1H, - NHCOOCH2Ph), 10.15 (br s, 1H, -PhCONH); MS (EI) m/z: 486.23 [M]+. 
trans benzyl 3-((4-(2-aminocyclopropyl)phenyl)carbamoyl)-1Hpyrrole-1-carboxylate 
hydrochloride (4, MC3413). Mp, 177-179 °C (acetonitrile/methanol); yield, 62%. 1H NMR 
(DMSO-d6, 400 MHz, δ; ppm) δ 1.33-1.35 (m, 2H, CH2 cyclopropane), 2.27 (m, 1H, CHNH2HCl), 
2.77-2.78 (m, 1H, PhCH), 5.46 (s, 2H, CH2), 6.79 (s, 1H, pyrrole proton), 7.11-7.13 (d, 2H 
benzene protons), 7.41-7.47 (m, 4H, benzene and pyrrole protons), 7.52-7.54 (d, 2H, benzene 
protons), 7.64-7.66 (d, 2H, benzene protons), 8.33 (bs, 3H, NH3+), 9.91 (bs, 1H, CONH) ppm; 
13C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 17.2, 25.6, 34.3, 66.3, 102.4, 109.8, 115.0, 118.9, 
121.0 (2C), 125.2 (2C), 127.0 (2C), 127.8, 128.7 (2C), 134.6, 136.4, 137.9, 150.1, 164.9 ppm; 
MS (EI) m/z: 375.16 [M]+ 
trans benzyl 2-((4-(2-aminocyclopropyl)phenyl)carbamoyl)-1Hpyrrole-1-carboxylate 
hydrochloride (5, MC3288). Mp, 192-194 °C (methanol); yield, 61%. 1H NMR (DMSO-d6, 400 
MHz, δ; ppm) δ 1.33-1.35 (m, 2H, CH2 cyclopropane), 2.28 (m, 1H, CHNH2HCl), 2.76-2.78 (m, 
1H, PhCH), 5.57 (s, 2H, CH2), 6.79 (s, 1H, pyrrole proton), 6.91 (s, 1H, pyrrole proton), 7.11-
7.13 (d, 2H benzene protons), 7.39-7.43 (m, 4H, benzene and pyrrole protons), 7.52-7.54 (d, 
2H, benzene protons), 7.64-7.66 (d, 2H, benzene protons), 8.31 (bs, 3H, NH3+), 10.01 (bs, 1H, 
CONH) ppm; 13C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 17.2, 25.6, 34.3, 66.1, 109.0, 110.8, 
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121.0 (2C), 124.0, 124.7, 125.2 (2C) 127.1 (2C), 127.7, 128.6 (2C), 134.5, 136.1, 137.6, 150.3, 
162.7 ppm; MS (EI) m/z: 375.18 [M]+. 
trans benzyl 2-((4-(2-aminocyclopropyl)phenyl)carbamoyl)-1Hindole-1-carboxylate 
hydrochloride (6, MC3382). Mp, 202-204 °C (methanol); yield, 63%. 1H NMR (DMSO-d6, 400 
MHz, δ; ppm) δ 1.31-1.33 (m, 2H, CH2 cyclopropane), 2.26 (m, 1H, CHNH2HCl), 2.74-2.75 (m, 
1H, PhCH), 5.44 (s, 2H, CH2), 7.28-7.31 (m, 2H, benzene and indole protons), 7.31-7.43 (m, 4H 
benzene and indole protons), 7.47-7.52 (d, 2H, benzene protons), 7.59-7.61 (d, 2H, benzene 
protons), 7.69-7.71 (d, 2H, benzene protons), 7.94-7.96 (d, 1H, benzene proton), 8.14 (s, 1H, 
indole proton), 8.30 (bs, 3H, NH3+), 9.99 (bs, 1H, CONH) ppm; 13C NMR (DMSO-d6, 100 MHz, 
δ; ppm) δ 17.2, 25.6, 34.3, 66.3, 114.4, 115.8, 119.9, 121.2 (2C), 123.9, 124.1, 125.6 (2C), 127.0 
(2C), 127.5, 127.9, 128.9 (2C), 134.1, 136.0, 136.9, 137.9, 144.1, 150.0, 162.3 ppm; MS (EI) 
m/z: 425.17 [M]+. 
trans 2-(4-(3-Ethynylbenzamido)phenyl)cyclopropylamine hydrochloride (10, GS4): 1H 
NMR (DMSO-d6, 400 MHz, δ; ppm) δ 1.16–1.21 (m, 1H, CHH cyclopropane), 1.34–1.40 (m, 1H, 
CHH cyclopropane), 2.28–2.32 (m, 1H, CHNH2), 2.76–2.79 (m, 1H, PhCH), 4.33 (s, 1H, CH 
acetylene), 7.14–7.16 (d, 2H, benzene protons), 7.53–7.57 (t, 1H, benzene protons), 7.68–
7.72 (t, 3H, benzene protons), 7.96–7.98 (d, 1H, benzene protons), 8.05 (s, 1H, benzene 
protons), 8.42 (bs, 3H, NH3+), 10.33 (bs, 1H, CONH). 
Benzyl ((R)-1-((4-((1S,2R)-2-aminocyclopropyl)phenyl)amino)-1-oxo-3-phenylpropan-
2-yl)carbamate Hydrochloride (11, MC3205). 1H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 1.12-
1.17 (m, 1H, CHH cyclopropane), 1.36-1.40 (m, 1H, CHH cyclopropane), 2.27-2.32 (m, 1H, 
CHNH2), 2.74-2.78 (m, 1H, PhCH), 2.83-2.88 (m, 1H, PhCHHCH), 2.99-3.04 (m, 1H, PhCHHCH), 
4.38-4.42 (t, 1H, PhCH2CHCONH), 4.96 (s, 2H, PhCH2OCONH), 7.09-7.33 (m, 12H, benzene 
protons and NHCOOBn), 7.53-7.55 (d, 2H, benzene protons), 7.70-7.72 (d, 1H, benzene 
proton), 8.47 (bs, 1H, NH3+), 10.19 (bs, 1H, CONH); MS (EI) m/z: 465.18 [M]+. 
trans 2-(4-(4-Phenylethynylbenzamido)phenyl)cyclopropylamine hydrochloride (12, 
GS5): 1H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 1.18–1.21 (m, 1H, CHH cyclopropane), 1.35–
1.40 (m, 1H, CHH cyclopropane), 2.29–2.33 (m, 1H, CHNH2), 2.78–2.81 (m, 1H, PhCH), 15–7.17 
(d, 2H, benzene protons), 7.46–7.47 (m, 3H, benzene protons), 7.60–7.62 (m, 2H, benzene 
protons), 7.71–7.74 (m, 4H, benzene protons), 8.01–8.03 (d, 2H, benzene protons), 8.38 (bs, 
3H, NH3+), 10.34 (bs, 1H, CONH). 
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 trans 2-(4-(4-Cyclopropylethynylbenzamido)phenyl)cyclopropylamine hydrochloride 
(13, GS6): 1H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 0.78 (s, 2H, CH2 cyclopropane acetylene), 
0.92–0,93 (d, 2H, CH2 cyclopropane acetylene), 1.16–1.20 (m, 1H, CHH cyclopropane), 1.35–
1.39 (m, 1H, CHH cyclopropane), 1.55–1.62 (m, 1H, CH cyclopropane acetylene), 2.29–2.33 
(m, 1H, CHNH), 2.78–2.80 (m, 1H, PhCH), 7.13–7.15 (d, 2H, benzene protons), 7.49–7.51 (d, 
2H, benzene protons), 7.69–7.71 (d, 2H, benzene protons), 7.90–7.92 (d, 2H, benzene 
protons), 8.38 (bs, 3H, NH3+), 10.26 (bs, 1H, CONH). 
trans 2-(4-(4-Propynylbenzamido)phenyl)cyclopropylamine hydrochloride (14, GS7): 1H 
NMR (DMSO-d6, 400 MHz, δ; ppm) δ 1.16-1.21 (m, 1H, CHH cyclopropane), 1.34-1.38 (m, H, 
CHH cyclopropane), 2.09 (s, 3H, CH3), 2.31–2.33 (m, 1H, CHNH), 2.77–2.79 (m, 1H, PhCH), 
7.13–7.15 (d, 2H, benzene protons), 7.52–7.54 (d, 2H, benzene protons), 7.69–7.72 (d, 2H, 
benzene protons), 7.91–7.93 (d, 2H, benzene protons), 8.40 (bs, 3H, NH3+), 10.27 (bs, 1H, 
CONH). 
trans 2-(4-(4-Methylbenzamido)phenyl)cyclopropylamine hydrochloride (16, GS1): 1H 
NMR (DMSO-d6, 400 MHz, δ; ppm) δ 1.16–1.22 (m, 1H, CHH cyclopropane), 1.34–1.39 (m, 1H, 
CHH cyclopropane), 2.28–2.33 (m, 1H, CHNH2), 2.39 (s, 3H, CH3), 2.77–2.80 (m, 1H, PhCH), 
7.13–7.15 (d, 2H, benzene protons), 7.32–7.34 (d, 2H, benzene protons), 7.70–7.72 (d, 2H, 
benzene protons), 7.86–7.88 (d, 2H, benzene protons), 8.42 (bs, 3H, NH3+), 10.15 (bs, 1H, 
CONH). 
trans 2-(4-(4-Propylbenzamido)phenyl)cyclopropylamine hydrochloride (17, GS2): 1H 
NMR (DMSO-d6, 400 MHz, δ; ppm) δ 0.88–0.92 (t, 3H, CH2CH2CH3), 1.16–1.21 (m, 1H, CHH 
cyclopropane), 1.33–1.38 (m, 1H, CHH cyclopropane), 1.57–1.67 (m, 2H, CH2CH2CH3), 2.27–
2.32 (m, 1H, CHNH2), 2.61–2.65 (t, 2H, CH2CH2CH3), 2.76–2.80 (m, 1H, PhCH), 7.12–7.14 (d, 
2H, benzene protons), 7.33–7.35 (d, 2H, benzene protons), 7.69–7.71 (d, 2H, benzene 
protons), 7.86–7.88 (d, 2H, benzene protons), 8.38 (bs, 3H, NH3+), 10.15 (bs, 1H, CONH). 
trans 2-(3-(4-Propynylbenzamido)phenyl)cyclopropylamine hydrochloride (25, GS8): 1H 
NMR (DMSO-d6, 400 MHz, δ; ppm) δ 1.14-1.19 (m, 1H, CHH cyclopropane), 1.26-1.31 (m, H, 
CHH cyclopropane), 2.09 (s, 3H, CH3), 2.43–2.47 (m, 1H, CHNH), 2.79–2.81 (m, 1H, PhCH), 
7.07–7.08 (d, 1H, benzene protons), 7.21–7.29 (m, 2H, benzene protons), 7.33–7.35 (m, 1H, 
benzene protons), 7.52–7.55 (d, 2H, benzene protons), 8.02–8.04 (d, 2H, benzene protons), 
8.39 (bs, 3H, NH3+), 10.21 (bs, 1H, CONH). 
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 trans 2-(3-(4-Cyclopropylethynylbenzamido)phenyl)cyclopropylamine hydrochloride 
(26, GS9): 1H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 0.79-80 (d, 2H, CH2 cyclopropane 
acetylene), 0.94–0,96 (m, 2H, CH2 cyclopropane acetylene), 1.15–1.19 (m, 1H, CHH 
cyclopropane), 1.28–1.31 (m, 1H, CHH cyclopropane), 1.58–1.63 (m, 1H, CH cyclopropane 
acetylene), 2.44–2.47 (m, 1H, CHNH), 2.81–2.82 (m, 1H, PhCH), 7.08–7.09 (d, 1H, benzene 
protons), 7.22–7.30 (m, 2H, benzene protons), 7.34–7.35 (d, 1H, benzene protons), 7.51–7.53 
(d, 2H, benzene protons), 8.02–8.04 (d, 2H, benzene protons), 8.38 (bs, 3H, NH3+), 10.21 (bs, 
1H, CONH). 
8.4 Conclusion and perspectives  
At this stage of the analysis of the results obtained with different LSD1 inhibitors in 
schistosomes, it is too early to draw hard and fast conclusions, as we are still waiting for 
biological results from Prof. Fantappié. However, some of the tested LSD1 inhibitors, including 
MC3935, have striking effects on the morphology of adults and schistosomula. Indeed, these 
effects are correlated with the downregulation of genes involved in egg shell formation and 
transmembrane transporters. Besides, effects on signaling pathways and genes involved in 
cell differentiation and cell fate determination are affected. This suggests that LSD1 inhibitors 
affect parasite development pathways. Taking into account the preliminary effect of MC3935 
on S. mansoni, it has been demonstrated, as expected, that histone demethylase inhibitors 
are essential and attractive targets for development of new antischistosomal agents. 
Indeed, several patents described LSD1 inhibitors, predominantly N-alkylated 
compounds, have been reported with excellent potency and selectivity against LSD1 over 
MAOs. In fact, the first two of the N-alkylated compounds, GSK2879552 and ORY-1001, have 
already been advanced to clinical trials for the treatment of cancer and neurodegenerative 
diseases. Hence, it would be wise to further explore the effect of N-alkylation of MC3935 and 
related derivatives on their activity against S. mansoni (Fig. 8.3).  
 
Fig. 8.3: Suggested further modifications on MC3935 and other analogues. 
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